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ABSTRACT 
 
An accumulation of epidemiological studies along with several lines of experimental research 
highlight sustained elevated resting heart rate as a significant predictor of cardiovascular 
morbidity and mortality. However, resting heart rate as a simple and inexpensive clinical 
parameter often remains overlooked by physicians. We therefore sought to raise awareness 
concerning the detrimental role of elevated resting heart rate in cardiovascular disease. Using 
three separate large prospective cohort studies, we examined the clinical importance of 
accelerated resting heart rate as a robust predictor of adverse cardiovascular prognosis. The 
current data supports the contention that a raised resting heart rate amplifies the risk of 
having several cardio-metabolic risk factors including type 2 diabetes mellitus, the metabolic 
syndrome, and increased pulse wave velocity. Resting tachycardia also appeared to increase 
the risk of cardiovascular mortality in otherwise healthy individuals, as well as negatively 
predicting outcome in patients already at-risk for the condition. Notably, we observed a 
strong synergistic effect between inflammatory activity and concurrent elevated resting heart 
rate among those who experienced a cardiovascular event. Overall, these findings underline 
the relevance of a high resting heart rate in the pathogenesis of atherosclerosis and in the 
clinical manifestations of cardiovascular mortality. 
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ABBREVIATIONS AND ACRONYMS 
 
CVD = cardiovascular disease 
RHR = resting heart rate 
ANS = autonomic nervous system 
HRV = heart rate variability 
HRR = heart rate recovery 
BMI = body mass index 
MetS = metabolic syndrome 
CAD = coronary artery disease 
CRP = C-reactive protein 
MI = myocardial infarction 
CHD = coronary heart disease 
IHD = ischaemic heart disease 
GBCS = Guangzhou Biobank Cohort Study 
EPIC = European Prospective Investigation into Cancer and Nutrition  
LURIC = LUdwigshafen RIsk and Cardiovascular Health 
GHHARE = Guangzhou Health and Happiness Association for Respectable Elders 
PWV = pulse wave velocity 
ACS = acute coronary syndrome   
SCD = sudden cardiac death  
IL-6 = interleukin-6 
OR/HR = odds/hazard ratio 
IDI = integrated discrimination improvement 
NRI = net reclassification improvement 
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CHAPTER ONE 
 
1.0. INTRODUCTION 
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1.1. CARDIOVASCULAR AGEING 
 
“.... A light heart lives long.” Love’s Labour’s Lost, V.ii.1895 William Shakespeare (1564-
1616) 
 
Undoubtedly, over the past few decades the world population has been progressively ageing, 
a trend which is likely to persist into the foreseeable future 
1
. Despite this global increase in 
life expectancy, there has been a comparable growth in adverse health outcomes. Notably, 
with ageing of the population, cardiovascular disease (CVD) presents a significant health 
threat, and is considered the most common cause of morbidity and mortality among persons 
aged 65 and older. CVD accounts for 40% of the overall mortality rate, with 80% of deaths 
due to CVD occurring in those over 65 years 
2
. Thus, given the substantial burden of CVD 
among the aged, ensuring identification of modifiable risk factors for attenuating the risk of 
CVD is an important dimension of preventive medicine. With increased longevity however, 
established risk factors for CVD such as smoking, obesity, and total cholesterol 
concentrations tend to lose their prognostic ability with advancing age 
3-5
, which in turn, has 
led researchers and clinicians to explore more potent constituents. To this end, an 
accumulation of epidemiological data supports the notion that sustained elevated resting heart 
rate (RHR) increases the risk of CVD morbidity and mortality. On the other hand, the 
predictive utility of this simple, easily-measured clinical parameter is often neglected by 
physicians. The following represents an effort to address the misconceptions which many 
clinicians seem to have regarding the detrimental role of high RHR in promoting CVD. 
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1.2. RESTING HEART RATE 
 
It is well recognized that the autonomic nervous system (ANS) predominantly controls RHR 
as well as other essential life functions 
6, 7
. The ANS consists of two key divisions, the 
sympathetic and parasympathetic limbs, both of which act in synergy or in opposition of each 
other to mediate essential physiological responses in real time 
7
. Typically, accelerated 
sympathetic tone results in a faster RHR via stimulation of circulating epinephrine as well as 
neural release of norepinephrine 
8, 9
. Conversely, a raised parasympathetic tone slows RHR as 
a consequence of acetylcholine release from efferent vagus nerve discharge 
6, 9
. Indeed, the 
interplay between sympathetic and parasympathetic control of the heart creates a complex 
variability in heart rhythm that characterizes a healthy system 
10
. For this reason, researchers 
and physicians have focussed on the application of readily available tools based on RHR for 
determining the link between dysfunctional ANS and subsequent adverse prognosis 
6
. 
Moreover, epidemiologists have exploited such markers as RHR, heart rate variability 
(HRV), and heart rate recovery (HRR) as a means of exploring the relation between 
perturbed ANS function with morbidity and mortality at a population and environmental level 
(Figure 1.1). Evidently, many determinants of ANS function have been described, though as 
a non-invasive and inexpensive parameter, RHR is undoubtedly one of the most 
straightforward to obtain in the clinic. 
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Figure 1.1. Schematic diagram showing the physiological effects of 
the sympathetic and parasympathetic pathways. Illustration highlights 
the accentuated antagonistic effects of the sympathetic and 
parasympathetic limbs on the sinus node to increase or decrease, 
respectively, the RR-interval (the distance between two successive R 
waves, representing the time between successive heart beats), heart 
rate variability, and heart rate recovery. These characteristics of 
autonomic nervous activity can be quantified via short-term 
electrocardiogram, Holter monitoring, or stress testing and are used to 
provide prognostic information in patients at risk for cardiovascular 
disease. Adapted from Lahiri et al. 
6
 with permission. 
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1.3. RESTING HEART RATE AND LIFE EXPECTANCY 
 
From the smallest shrew or bumble-bee bat, to the largest blue whale 
11
, there is an 
extraordinary amount of variation in heart size and physiology. Indeed, the size of a 
mammalian heart can differ by more than seven orders of magnitude, ranging from 
approximately 12 mg to 600 kg 
11
. In small animals such as a shrew, the heart can beat as 
high as 800-1,200 beats/minute (bpm), pumping 1-5 millilitres/minute, while in larger 
animals like the blue whale, RHR can be as low as 2-6 bpm while producing a cardiac output 
of 2,000-5,000 litres/minute 
11
. Likewise, there is considerable disparity in maximum life 
expectancy among mammals (Figure 1.2). Those with a slower RHR tend to have a longer 
lifespan in contrast to those with a higher RHR who correspondingly have a shorter life 
expectancy 
9, 12, 13
. Despite some inevitable variations among mammals, the total number of 
heart beats in a lifetime seems remarkably constant at approximately 1.1 x 10
9
 (~1.1 billion) 
11, 12
. In this regard, it appears mammals have a finite number of heart beats, whereby those 
who expend their overall “quota” at a faster rate ultimately have a shorter life 12. However, 
one may speculate that given humans, on average, have a RHR of 60-100 bpm, our lifespan 
should be similar to that of a giraffe or tiger 
13
, or close to 28 years 
11
. One noticeable 
exception is that the human heart can produce almost 3.03 x 10
9
 (~3 billion) beats in a 
lifetime 
11
. Evidently, it would appear modern humans have broken the trend by extending 
the biological boundaries, thus achieving life expectancies of around 80 years 
13, 14
. A 
question which has therefore sparked much public interest is whether humans differ 
physiologically or biologically compared with other mammals in some way that enhances 
longevity? In short, the most plausible answer is probably not. Perhaps the most reasonable 
explanation how humans have extended their lifespan potential is largely attributable to 
recent cultural advancements including scientific, technological and evidence-based medical 
developments 
15
. Indeed, throughout the majority of human history, average life expectancy 
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was rarely seen to go beyond 40 years 
12, 15
. Albeit, acquired knowledge in science, 
technology, and medicine in the last 1-2 centuries has significantly improved disease control 
and prevention, raising the average life expectancy. Nonetheless, as the risk of death due to 
conventional diseases such as infection and malnutrition becomes increasingly smaller, it 
seems reasonable to speculate that the likelihood of succumbing to other noxious influences 
(i.e., CVD) will be greatly augmented with advancing age. Clearly, as the rise in life 
expectancy persists, it appears humans are entering an era where cardiovascular health 
represents a critical determinant of optimal longevity 
12
. 
 
1.4. RESTING HEART RATE AND PHYSICAL FITNESS 
 
The association between poor physical fitness and greater risk of adverse health outcomes is 
well described in the literature 
16-19
. Notably, RHR and physical fitness appear to be inversely 
related. Individuals with poor cardio-respiratory fitness tend to have a faster RHR, and 
reciprocally, those who appear physically fit are more likely to possess a lower overall RHR 
20
. However, the matter of whether RHR, and likewise, physical fitness, are strong predictors 
of poor health outcomes independent of one another has remained controversial. In particular, 
a limitation of most studies is the use of self-reported physical activity as a determinant of 
fitness. Indeed, self-reported measures of physical activity along with objectively measured 
physical fitness demonstrate only a poor-to-moderate correlation 
21
. Nonetheless, two 
separate studies derived from a cohort of 1,960 healthy men residing in Oslo 
22, 23
 
demonstrated both RHR and physical fitness appeared to be strong, graded, predictors of 
mortality from cardiovascular causes, independent of one another, suggesting both variables 
may contain important information towards risk of adverse health outcomes. Though clearly, 
further studies are required to test this notion. 
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Figure 1.2. Relation between resting heart rate (beats/minute [A] 
and total beats/lifetime [B]) and life expectancy in 15 mammal 
species. Adapted from Levine 
13
, with permission. 
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1.5. ASSOCIATION OF RESTING HEART RATE WITH CARDIOVASCULAR 
RISK FACTORS 
 
1.5.1. Obesity 
Several large epidemiological studies have consistently shown that a number of cardio-
metabolic risk factors are associated with increased morbidity; a relationship which may be 
explained, in part, by the deleterious effect of increased RHR. The predictive utility of RHR 
for the development of adverse glucose and lipid metabolism was assessed after 20 years 
follow-up in a general population, located in south-western Japan. Shigetoh and colleagues 
24
 
reported that baseline RHR (≥80 bpm) independently predicted the development of obesity 
even after adjusting for a range of potential confounders. From the Hypertension and 
Ambulatory Recording Venetia Study (HARVEST) 
25
, both baseline clinic RHR and change 
in clinic RHR during follow-up were recorded among 701 persons screened for stage 1 
hypertension who were subsequently followed for 7 years. In that study, both baseline clinic 
RHR (hazard ratio [HR], 95% confidence interval [95% CI] = 1.30, 1.10-1.50) and clinic 
RHR change during follow-up (HR, 95% CI = 1.17, 1.06-1.28) were found to be independent 
predictors of weight gain at study end. 
 
1.5.2. Type 2 diabetes mellitus 
In the Shanghai Women’s Health Study 26, the relation between RHR and type 2 diabetes 
mellitus was examined. Around 47,571 Chinese women with no prior history of diabetes or 
other non-communicable diseases were included in this population-based cohort 
investigation. The incidence of diabetes was obtained via biennial in-person interviews 
26
. 
During an average follow-up of 4.9 years, the incidence rates of diabetes per 1,000 person 
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years were 2.91, 3.31, 3.71, 4.16 and 5.34 according to RHR categories of ≤68, 69-72, 73-76, 
77-80 and ≥80 bpm, respectively 26. Shigetoh et al. 24 also demonstrated that a higher RHR 
may predispose to the development of type 2 diabetes mellitus. In fact, those with a RHR ≥80 
bpm were considered to be over five-fold at greater odds of developing diabetes 
24
. Likewise, 
in the San Antonio Heart Study 
27
, a population-based cohort of 3,301 Mexican Americans 
and 1,857 non-Hispanic whites, volunteers who were defined as hyperdynamic (i.e., RHR 
and pulse pressure in the upper-most quartile of their respective distributions) had an odds 
ratio (OR) of 3.97 for the prediction of future type 2 diabetes mellitus. In the Chicago Heart 
Association Detection Project in Industry 
28
, a 12 bpm increment in RHR was associated with 
a 10% increase in the odds of having diabetes, though following full adjustment, this 
relationship attenuated to non-significance. In the same study however, a raised RHR was a 
robust predictor (OR 1.21, 95% CI = 1.03-1.41) of diabetes mortality among adults aged 
between 35-49 years even after correcting for body mass index (BMI) and post-load glucose 
at baseline 
28
. 
 
1.5.3. Hypertension 
It has been shown that hypertensive patients, in general, tend to have a faster RHR compared 
to their normotensive counterparts 
29, 30
. Data from the HARVEST study group indicated that 
baseline clinic RHR as well as altered RHR within the first 6 months of follow-up were 
important predictors for the development of sustained hypertension 
31
. Indeed, the adjusted 
risk doubled (95% CI = 1.4-2.9) among patients whose RHR remained persistently elevated 
throughout the investigation 
31
. Earlier studies have also noted the relation between sustained 
tachycardia and hypertension. Notably, findings from the four Chicago epidemiologic 
surveys 
32
 are of particular relevance. Across all four cohorts encompassing an overall sample 
size of greater than 35,000 men and women between the ages of 25-64 years, RHR emerged 
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as one of the strongest correlates of blood pressure 
32
. Similar findings were reported in the 
Gubbio Study which consisted of 2,809 men and women from Italy. The findings in that 
investigation showed pulse rate to be significantly, albeit, modestly correlated with systolic (r 
= 0.20 [men], r = 0.19 [women]) and diastolic (r = 0.15 [men], r = 0.14 [women]) blood 
pressure following adjustment 
33
. However, a number of prospective investigations have 
failed to find consistent results on the association between RHR and blood pressure 
27, 34-37
. In 
this respect, some lost statistical significance after correcting for baseline blood pressure, 
while others had not considered adjusting for important confounders such as physical 
activity, or fitness. On the other hand, in a cohort of more than 8,000 Japanese men residing 
in Hawaii, bivariate and multivariate analyses of more than 50 variables revealed RHR was 
independently associated with changes in blood pressure 
38
. In that study, multiple regression 
analyses of the first examination indicated that RHR was related cross-sectionally to levels of 
systolic (cumulative r
2
 = 0.13) and diastolic (cumulative r
2
 = 0.15) blood pressure, 
respectively 
38
. Albeit, longitudinal changes in blood pressure between the first and third 
examinations found RHR to be associated with diastolic (cumulative r
2
 = 0.28) blood 
pressure only 
38
. In line with this data, the multi-centre longitudinal Coronary Artery Risk 
Development in Young Adults (CARDIA) study 
39
 found RHR to be an independent 
predictor of subsequent diastolic blood pressure regardless of initial blood pressure and other 
possible confounders among white and black men, as well as white women (0.7 mm Hg 
increase per 10 bpm increments). Thus, on the background of this information, it seems a 
raised RHR may be considered a risk factor for sustained elevated diastolic blood pressure 
39
. 
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1.5.4. The metabolic syndrome 
Some epidemiological evidence supports the notion that elevated RHR is associated with 
several conventional risk factors known to amplify the CVD profile including obesity, 
diabetes, and hypertension 
40
. To this end, we may speculate that a raised RHR is 
consequently related with the clustering of these risk factors, better known as the metabolic 
syndrome (MetS). A handful of studies have recently described the association between a 
faster RHR and the MetS. One such study was the Pressioni Arteriosi Monitorate E Loro 
Associazioni (PAMELA) project 
41
, a cross-sectional and longitudinal survey designed to 
examine variations in blood pressure at home, and in the office among more than 3,000 
individuals representative of the general population living in Italy. Compared to healthy 
controls in that study, participants identified as having the MetS displayed significantly 
greater office, home, and 24-h ambulatory RHR values. Inuoe and colleagues 
42
 also 
examined the association of RHR and risk of developing the MetS in a large cohort of 6,281 
Japanese individuals who participated in a health evaluation program. Over the 5 year follow-
up period, men with a higher baseline RHR were more likely to experience the MetS. The OR 
for developing the MetS for men in the upper-most quartile for RHR was 1.73 (95% CI = 
1.28-2.32) 
42
. In another large sample consisting of 7,706 apparently healthy men and women 
who attended a general health screening program, a raised RHR was significantly associated 
with the presence of the MetS 
43
. In that study, the adjusted OR increased progressively from 
1.0 (reference figure) in the lowest RHR quintile (<60 bpm in men and <64 bpm in women) 
to 4.2 (95% CI = 3.0-5.9) and 3.6 (95% CI = 2.2-6.1), for men and women in the highest 
quintile (≥80 bpm in men and ≥82 bpm in women), respectively 43. Moreover, in the Bypass 
Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) randomized clinical trial 
44
, regression analyses revealed that RHR was significantly higher in patients with the MetS 
compared to those without (regression coefficient; 2.9, P =0.002). From the same study, in 
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patients with type 2 diabetes or coronary artery disease (CAD), sustained elevated RHR was 
associated with an increasing number of components for the MetS, proposing that the risk of 
an elevated RHR for the development of the MetS extends beyond only those who seem 
apparently healthy. 
 
1.5.5. Inflammation 
Moving forward, inflammation is proposed to play an important role in the patho-
physiological progression of atherosclerosis 
45-49
. Yet, despite this bulk of evidence, we still 
lack an understanding with regards to the mechanisms responsible for modulating the 
inflammatory response during atheroprogression. With respect to RHR, only two 
investigations have shown an association with increased inflammation 
50, 51
. In the 
Copenhagen Holter Study 
50
 the relation between RHR and HRV with subclinical 
inflammation was examined among 775 apparently healthy men and women. In that study, 
both RHR and HRV were significantly associated with increased inflammation. In the 
second, Rogowski et al. 
51
 explored the possibility that a raised RHR was related to an 
elevated microinflammatory response. In this investigation, concentrations of absolute 
leukocytes, C-reactive protein (CRP) as well as fibrinogen were analysed in a cohort of 4,553 
subjects belonging to the Tel Aviv Medical Center Inflammation Survey (TAMCIS). In this 
relatively large survey, following adjustment, those in the fifth quintile of RHR (≥79 bpm) 
had significantly greater concentrations for each of the previously mentioned inflammatory 
markers compared to those in the first quintile (≤58 bpm); 4.74 and 4.23 x 109/L (leukocytes), 
1.61 and 1.12 mg/L (CRP) and 8.11 versus 7.38 µmol/L, respectively 
51
. Although the 
number of investigations evaluating the relationship between RHR and inflammation are few 
and far between, the findings from these two studies represent an attractive avenue for which 
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targeting RHR and inflammation via therapeutic manipulation may ultimately reduce the 
burden of CVD. 
 
1.6. HIGH RESTING HEART RATE AS A PREDICTOR OF CARDIOVASCULAR 
MORTALITY 
 
The integral relation between RHR and CVD has been reported as far back as the 1940s 
52
. 
Since then, a number of studies have found an association between a raised RHR and CVD 
mortality including the Chicago People Gas Company Study 
53
, and the Framingham Heart 
Study 
54
. These investigations are mentioned in passing because they are some of the earliest 
to document an association between rapid RHR and CVD death. Thereafter, it is not 
surprising that several other large epidemiological studies have shown sustained elevated 
RHR to be an important predictor of CVD mortality. These include the first National Health 
and Nutrition Examination Survey (NHANES 1) Epidemiological Follow-up Study 
(NNHEFS) 
55
, the Framingham Study 
56
, the British Regional Heart Study 
57
, the Secondary 
Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) 
58
, the Cardiovascular Study in the 
Elderly 
3
, as well as a few other prospective cohort studies 
59-61
. 
 More recently, there has been renewed interest in the awareness of resting tachycardia 
and its implications towards CVD mortality. During an 8 year follow-up of 3,527 Israeli 
industrial employees, the adjusted relative risk (RR) for death due to CVD was 2.02 (95% CI 
= 1.1-4.0) among workers with a RHR >90 bpm compared to those with a RHR <70 bpm 
62
. 
In the Malattie Cardiovascolari Aterosclerotiche, Istituto Superiore di Sanità (MATISS) 
Project, Seccareccia et al. 
63
 sought to verify the independent role of elevated RHR for 
predicting CVD mortality. Among 2,533 low-risk men, the adjusted HR for CVD mortality 
increased 1.63 (95% CI = 1.26-2.10) for each RHR category 
63
. Likewise, in two separate 
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Japanese cohorts, RHR was found to be an important predictor of mortality. Over a 16.5 year 
follow-up period involving 8,800 subjects who participated in the National Survey on 
Circulatory Disorders 
64
, the RR in the upper-most quartile of RHR for CVD death in middle-
aged men was 2.55 (95% CI = 1.22-5.31). Further, the role of RHR on CVD mortality did not 
materially change even after removing those who died within 5 years of study entry, thereby 
dismissing the hypothesis that RHR is simply an indicator of underlying chronic disease. 
Second, in the Ohasama Study, Hozawa and co-workers 
65
 examined the prognostic value of 
self-measured RHR at home for the risk of 10 year CVD mortality in 1,780 Japanese 
individuals. In that study, a 5 bpm increment in self-measured RHR during the morning was 
associated with a 17% increase in the risk of CVD death, and remained significant following 
adjustment for blood pressure. In the Paris Prospective Study I 
66
, a total of 5,713 
asymptomatic middle-aged working men were followed prospectively for a total of 23 years. 
During this period, a RHR of more than 75 bpm was related to an increased risk (RR 3.92, 
95% CI = 1.91-8.00) of sudden death due to myocardial infarction (MI). In the Coronary 
Artery Surgery Study (CASS), 24,913 patients with suspected or proven CAD were studied 
for a median follow-up duration of 14.7 years 
67
. Patients whose RHR was ≥83 bpm at 
baseline presented with a greater risk (HR 1.31, 95% CI = 1.15-1.48) of CVD mortality, even 
after correcting for multiple clinical parameters. In line with this finding, the morBidity-
mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary artery disease 
and left ventricULar dysfunction (BEAUTIFUL) Study 
68
 evaluated RHR as a prognostic risk 
factor of cardiovascular outcomes. After adjusting for baseline characteristics, those with a 
RHR ≥70 bpm had a greater risk of death due to CVD by around 34%. Accordingly, for 
every increase of 5 bpm in RHR, the risk of CVD mortality increased by 8% 
68
. In the 
National FINRISK Study 
69
, the effect of RHR towards CVD mortality was determined 
among 10,519 men and 11,334 women. In men, each 15 bpm increase in RHR was associated 
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with an adjusted HR of 1.24 (95% CI = 1.11-1.40). For the women, a similar association was 
observed on the background of every 15 bpm increment in RHR (HR 1.32, 95% CI = 1.08-
1.60). This relationship persisted even after removal of those with comorbidities and events 
occurring within the first 2 years of observation 
69
. Two separate investigations from the 
Copenhagen City Heart Study (CCHS) examined the usefulness of RHR as a predictor of 
CVD mortality 
70, 71
. In the first study, heavy, moderate, and former smokers had significantly 
greater risk (RR [95% CI] 1.13 [1.08-1.18], 1.15 [1.09-1.21] and 1.11 [1.05-1.17] 
respectively, per 10 bpm increase in RHR) of CVD death compared to never-smokers 
70
. 
Second, Jensen and colleagues 
71
 assessed whether a raised RHR was a robust predictor of 
CVD mortality independent of inflammation. In that study, after adjusting for both CRP and 
fibrinogen, as well as other conventional risk factors, a 10 bpm increase in RHR was 
associated with increased (HR 1.14, 95% CI = 1.07-1.22) risk of CVD mortality. 
Despite these observations, not all studies examining the relationship between RHR 
and CVD mortality achieved significance. In an earlier examination of the Paris Prospective 
Study I, adjusting for multiple confounders, Filipovsky et al. 
72
 failed to find an association 
between RHR and all-CVD mortality in middle-aged employees after 17 years of follow-up. 
In a large Finnish prospective study comprising 10,717 men and women between the ages of 
30-59 years, elevated RHR was not shown to be related (RR 1.00, 95% CI = 0.79-1.26 in 
men with RHR ≥84 bpm and RR 1.05, 95% CI = 0.75-1.49 in women with RHR ≥94 bpm) to 
the risk of mortality from CVD 
73
. In particular, the initial association between higher RHR 
and CVD risk was subsequently explained by high blood pressure 
73
. In the Three-City (3C) 
Study 
74
, a French multi-centre investigation involving 7,147 community-dwelling older 
volunteers followed longitudinally for 6 years, RHR was significantly associated with overall 
and non-CVD mortality, though conversely, not with risk of death from CVD causes. In that 
study, however, it should be noted there was an 87% (95% CI = 0.98-3.6) increase in the risk 
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of CVD mortality in those with a RHR >79 bpm, while the non-significance observed was 
marginal (P = 0.06). More recently, the incremental prognostic value of RHR was assessed in 
a subgroup of 5,320 subjects from the Diabetes Cardiovascular Risk Evaluation Targets and 
Essential Data for Commitment of Treatment (DETECT) cohort study 
75
. Here, it was 
concluded that a raised RHR provided minimal and non-significant prognostic value when 
added to a number of conventional risk factors as determined by the C-statistic (0.001, P 
=0.979). However, due to the known limitations of the C-statistic to discriminate between the 
additions of prognostic variables which usually result in small improvements, researchers and 
clinicians should continue to seek more appropriate methods for evaluating the prognostic 
utility of RHR in risk stratification. 
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Table 1.1. Studies of the association between resting heart rate and cardiovascular mortality 
Reference Study population Country Follow-up Heart rate Impact on cardiovascular mortality
¶
 
Dyer et al. 
53
 1,233  men aged 40-
59 years 
USA 15 years RHR quintiles Independent risk factor for sudden 
death due to CHD. 
Kannel et al. 
54
 5,070 subjects 
between 35-64 years 
free of CVD 
USA >30 years Antecedent RHR 
measured biennially 
CVD mortality rates increased 
progressively in relation to antecedent 
RHR in both sexes at all ages. 
Gillum et al. 
55
 14,407 individuals 25-
74 years of age 
USA 6-13 years RHR >84 bpm Risk of death from CVD was elevated 
in white men; incident CHD increased 
in white women, risk of death from 
CVD was also increased in black men 
and women. 
Filipovsky et al. 
72
  4,907 working men 
between the ages of 
42-53 years  
France 17 years Baseline RHR NS. 
Gillman et al. 
56
 4,530 hypertensive 
subjects aged 35-74 
USA 36 years 40 bpm increments in 
RHR 
1.68 times higher risk of CVD 
mortality in men and 1.70 for women.  
Shaper et al. 
57
 7,735 men  aged 40-
59 years without pre-
existing IHD 
UK 8 years RHR ≥90 bpm versus 
<60 bpm 
3.3 times greater risk for IHD 
mortality and 5.2 times increased risk 
of sudden cardiac death. 
Disegni et al. 
58
 1,044 patients (aged 
50-79) hospitalized 
for acute MI 
Israel 1 year RHR ≥90 bpm on 
admission 
Independent predictor of in-hospital 
and 1 year post-discharge mortality.  
Aronow et al. 
59
 1,311 men and women 
(60-100 years) with 
known heart disease 
and sinus rhythm 
USA 4 years Increment of 5 bpm 
measured from 24 h 
ambulatory 
electrocardiograms 
1.14 higher chance of developing a 
new coronary event.  
Palatini et al. 
3
  1,938 white men and 
women 65 years or 
older 
Italy 12 years RHR quintiles (>80 
bpm versus <64 bpm) 
1.38 times greater risk of CVD death 
for elderly men in the top quintile of 
RHR. 
Benetos et al. 
60
 19,386 subjects aged 
40-69 years 
France 21 years RHR categories (<60, 
60-80, 81-100, and 
>100 bpm) 
Relative risk of 2.18 for men in the 
highest RHR category according to 
CVD mortality. 
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Table 1.1. Continued 
Reference Study population Country Follow-up Heart rate Impact on cardiovascular mortality
¶
 
Greenland et al. 
61
  33,781 black and 
white men and women 
aged between 18-74 
years 
USA 22 years Increment of 12 bpm 
in RHR  
RHR independently predicted risk of 
fatal coronary disease as well as all-
CVD mortality in younger men and 
middle-aged men and women.  
Reunanen et al. 
73
 10,717 men and 
women 30-59 years of 
age 
Finland 23 years RHR deciles NS. 
Kristal-Boneh et al. 
62
   3,527 male employees 
mean age 43 years at 
study entry 
Israel 8 years RHR >90 bpm versus 
<70 bpm 
Relative risk 2.02 for death due to 
CVD among workers with a RHR >90 
bpm. 
Seccareccia et al. 
63
 2,533 men aged 40-69 
years 
Italy 4-13 years Five RHR categories 
(<60, 60-69, 70-79, 
80-89, and ≥90 bpm) 
1.63 increased risk of CVD mortality 
per increment in RHR category. 
Okamura et al. 
64
 8,800 men and women 
≥30 years 
Japan 16.5 years RHR quartiles 2.55 greater risk of CVD death for 
middle-aged men in the highest 
quartile. 
Hozawa et al. 
65
 1,780 individuals ≥40 
years of age 
Japan 10 years Increment of 5 bpm 
in RHR  
17% increase in the risk of CVD 
mortality.  
Jouven et al. 
66
 5,713 working men 
(between the ages of 
42 and 53 years) 
France 23 years RHR >75 bpm 3.92 increase in relative risk of sudden 
death from MI. 
Diaz et al. 
67
 24,913 patients, mean 
age 53.2 years with 
suspected or proven 
CAD  
Canada 14.7 years RHR ≥83 bpm 1.31 increased risk for CVD mortality. 
Fox et al. 
68
 5,438 men and women 
aged 55 years or older 
with stable CAD and 
left ventricular 
dysfunction 
International 
multi-centre 
trial 
2 years RHR >70 bpm versus 
<70 bpm and 
increments of 5 bpm  
34% greater risk of CVD death for 
RHR >70 bpm and 8% increase in risk 
per 5 bpm increments.  
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Table 1.1. Continued 
Reference Study population Country Follow-up Heart rate Impact on cardiovascular mortality
¶
 
Cooney et al. 
69
  21,853 men and 
women, mean age of 
43.2 years 
Finland 6-27 years RHR as 15 bpm 
increments 
1.24 and 1.32 greater risk of CVD 
mortality in men and women, 
respectively.  
Legeai et al. 
74
 7,147 men and women 
≥65 years 
France 6 years RHR quintiles NS. 
Jensen et al. 
70
  43,293 men and 
women aged 20 years 
or older at study entry 
Denmark 33 years 10 bpm increments in 
RHR 
1.13, 1.15, and 1.11 increased risk of 
CVD mortality for heavy, moderate, 
and former smokers, respectively. 
Leistner et al. 
75
  5,320 men and 
women, mean age 
55.9 years free of 
CAD at study entry 
Germany 5 years RHR quartiles NS. 
Jensen et al. 
71
 6,518 men and women 
aged 20 years or older 
at baseline 
Denmark 18 years 10 bpm increments in 
RHR 
1.14 times greater risk of CVD 
mortality  
¶
Data reported from fully adjusted analyses. 
 RHR = resting heart rate, CHD = coronary heart disease, CVD = cardiovascular disease, bpm = beats per minute, NS = non-
significant, IHD = ischaemic heart disease, MI = myocardial infarction, CAD = coronary artery disease.  
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1.7. SUMMARY AND AIMS OF THESIS 
 
In light of the preceding evidence, however, RHR as an easily measured and inexpensive 
parameter, as well as potential risk factor for CVD appears to be overlooked in the clinical 
setting. Moreover, information regarding the association between RHR and adverse CVD 
prognosis beyond western populations or apparently healthy individuals is still lacking. Thus, 
the following studies aimed to explore the association between sustained elevated RHR with 
CVD morbidity and mortality. Specifically, we attempted to examine these associations via 
several large epidemiological cohorts including the Guangzhou Biobank Cohort Study 
(GBCS), consisting of an older Asian population; the European Prospective Investigation into 
Cancer and Nutrition (EPIC) Norfolk Study, where the relation between RHR and mortality 
was assessed in apparently healthy middle-aged British men and women; the LUdwigshafen 
RIsk and Cardiovascular Health (LURIC) Study, which included a population of German 
patients already at-risk for CVD. 
 
The principle objectives of the current thesis therefore were to:  
    
1) Evaluate the association of a raised RHR with a number of cardio-metabolic risk factors 
in older Chinese participants. 
2) Assess whether a high RHR independently increases the risk of death due to CVD among 
generally healthy men and women, and separately, in those who are already at 
intermediate-to-high-risk for CVD.  
3) Explore whether elevated RHR appears to increase the risk of CVD by amplifying the 
inflammatory process. 
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CHAPTER TWO 
 
2.0. INDEPENDENT AND COMBINED ASSOCIATIONS OF ABDOMINAL 
OBESITY AND SEATED RESTING HEART RATE WITH TYPE 2 DIABETES 
MELLITUS AMONG OLDER CHINESE: THE GUANGZHOU BIOBANK COHORT 
STUDY 
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2.1. ABSTRACT 
 
Central obesity and poor physical fitness predict the development of type 2 diabetes mellitus 
and cardiovascular mortality among Caucasian populations. We studied the independent and 
combined impact of abdominal obesity and seated resting heart rate used as an indicator of 
physical fitness, on the presence of type 2 diabetes mellitus among 30,519 older residents of 
Guangzhou, Southern China. Participants were stratified into four groups, based on the Asian 
criteria for abdominal obesity (≥90/≥80 cm in men/women) and the 75% cut-off point for 
seated resting heart rate (≥83 bpm). The association with type 2 diabetes mellitus was 
assessed using multivariable logistic regression. A total of 3,777 (12.7%) volunteers were 
diagnosed with type 2 diabetes mellitus, which was independently associated with seated 
resting heart rate and in particular, increasing levels of abdominal obesity (P < 0.001). An 
odds ratio of 3.93 (95% CI = 3.48, 4.43) was identified for type 2 diabetes mellitus in 
participants who were obese with a seated resting heart rate ≥83 bpm after adjusting for 
potential confounders. Higher seated resting heart rate, a marker of poor physical fitness, 
independently doubles the risk of type 2 diabetes mellitus. The strength of this association is 
further increased when abdominal obesity is considered. 
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2.2. INTRODUCTION 
 
Studies have identified diabetes as a major determinant of all-cause and cardiovascular 
mortality 
3
. Substantial evidence supports the notion that too much abdominal fat promotes 
the development of diabetes by increasing insulin resistance and hyperglycaemia 
76-78
. In 
addition, abdominal adiposity appears to amplify the impact of other cardiovascular risk 
factors, including high blood pressure and dyslipidaemia 
79
. According to the National 
Cholesterol Education Programme-Adult Treatment Panel III (NCEP-ATP III) 
80
 abdominal 
obesity, as measured by waist circumference, and not general obesity, determined by BMI, is 
recognised as the most prevalent form within the constellation of risk factors that constitute 
the metabolic syndrome.  
Abdominal obesity is generally considered to result from caloric imbalance and 
reduced physical activity, which in the Global Burden of Disease study was among the top 
ten risk factors for health 
81
. Although physical activity may ameliorate physical fitness, the 
strength of association between both is limited, and is likely the result of several factors 
including difficulties in quantifying activity, or low-intensity exercise being ineffective 
toward improving fitness 
82, 83
. However, physical fitness has previously been identified as an 
important predictor of cardiovascular and non-cardiovascular mortality 
17, 84
. This effect was 
independent of physical activity in the few studies that have addressed the association 
between cardio-respiratory fitness and mortality 
17, 85
.  
 Although some studies have examined the impact of abdominal obesity and physical 
fitness with poor health outcomes, certain aspects of this literature remain less developed. For 
instance, abdominal adiposity, in particular visceral abdominal obesity, is age- and gender- as 
well as ethnicity-dependent. While some health organisations have developed ethnicity-
specific cut-points for abdominal obesity 
86
, data that form the basis of current guidelines 
according to waist circumference are limited for non-Caucasian populations. Likewise, large-
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scale studies examining physical fitness either directly or as a surrogate (e.g. RHR) is scarce 
and predominantly derived from Caucasian populations. As developing nations such as China 
begin to increase their rate of modernisation similar to post-industrial societies, the 
prevalence of associated poor health conditions, including type 2 diabetes mellitus and the 
MetS, are likely to become more apparent, suggesting a large proportion of its 1.2 billion 
population may be at risk for adverse health consequences due to these conditions. Data 
highlighting such associations can be used as the foundation of health promotion initiatives 
that may offset this burden. 
Given the impact of abdominal obesity and physical fitness on long-term health and 
the dearth of this information in non-Caucasian populations outside the developed world, the 
current study aimed to examine the independent and combined associations of abdominal 
obesity and seated RHR, as a measure of physical fitness 
24, 87
, on the presence of diabetes 
among 30,519 older residents of China. 
 
2.3. METHODS 
 
2.3.1. Subjects 
The GBCS is a prospective population-based study aiming to examine determinants of health 
in an older Chinese population, and has been described previously 
88
. Briefly, participants 
were drawn from the membership of a city-wide community social and welfare association in 
Guangzhou city, ‘the Guangzhou Health and Happiness Association for Respectable Elders’ 
(GHHARE). Baseline examinations were performed between 2003-2006, which included a 
detailed structured interview on lifestyle habits and medical history, as well as measurements 
of anthropometric, metabolic and biological indices. The Medical Ethics Committee of the 
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Guangzhou Medical Association approved the study, and written, informed consent was 
obtained from all participants. 
 
2.3.2. Demographic and lifestyle data 
Demographic data (e.g., age and gender), details of health and lifestyle (e.g., smoking, 
alcohol consumption and physical activity) and socio-economic variables (e.g. longest held 
occupation, education level and personal income) were obtained by qualified staff belonging 
to the Guangzhou study team. Participants were defined as current smokers if they answered 
yes to the question: “Do you currently smoke?”  Also, participants were defined as current 
drinkers by answering yes to the question: “Have you consumed any alcohol in the past 12 
months?” Level of physical activity was quantified using the short version of the 
International Physical Activity Questionnaire (IPAQ), validated in the Chinese population 
89
. 
The formula for the computation of metabolic equivalent (MET)-minutes/week was; MET 
level x minutes of physical activity x events per week. In the current study, MET-
minutes/week was presented as a continuous trait. For the socio-economic measures, 
participants were categorized based on manual (indicative of a “blue collar” working 
environment) or non-manual employment according to longest held occupation. Education 
level consisted of three categories; attended primary school, secondary school or college. 
Personal income was defined as net monthly income (in Yuan) according to the following 
categories; <10,000, ≥10,000-<15,000 and ≥15,000.      
 
2.3.3. Experimental procedures 
Waist circumference was measured in cm, horizontally around the smallest circumference 
between the ribs and iliac crest, or at the navel if no natural waistline was observed. Using 
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Asian criteria, abdominal obesity was present if waist circumference was ≥90 cm in men or 
≥80 cm in women 90. Seated RHR was measured three times (Omron 705CP); one minute 
apart, following a three minute rest. Subjects were classified as having a high seated RHR if 
their rate was ≥83 bpm, determined by the 75th percentile cut point. Blood samples were 
drawn to measure fasting plasma glucose, which was determined by nurses belonging to the 
Guangzhou study team. Diabetes was defined within each group if the fasting glucose level 
was ≥7.0 mmol/L or if the participant was receiving hypoglycaemic medication and impaired 
fasting glucose was identified if fasting glucose levels were ≥5.6 and <7.0 mmol/L or 
receiving hypoglycaemic medication. All pre- and diabetic states were based solely in 
accordance with the International Diabetes Federation criteria 
91
.   
 
2.3.4. Statistical methods 
Participants were stratified into four groups based on the presence of abdominal obesity and 
the 75% cut-off point for seated RHR; 1) non-obese/low RHR; 2) non-obese/high RHR; 3) 
obese/low RHR and; 4) obese/high RHR. Overall and gender comparisons between groups 
were performed by analysis of variance (ANOVA), with a Bonferroni post-hoc test for 
continuous parameters and χ2 test with P for linear-by-linear test for categorical variables. 
MET-minutes/week, glucose and triglyceride levels were non-normally distributed and 
therefore logarithmically transformed with their geometric means and 95% CIs presented. 
Otherwise data are shown as Mean±SD for continuous parameters or prevalence for 
categorical variables.  
Multivariable logistic regression was built to assess the independent and combined 
effects of abdominal obesity and seated RHR in determining the presence of diabetes. The 
first model adjusted for age and sex. The second model additionally adjusted for lifestyle 
factors including; smoking, alcohol, physical activity, socio-economic measures including; 
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longest held occupation, education level and personal income, and finally, chronic diseases 
such as; arterial hypertension, cardiovascular disease history and dyslipidaemia.  
Additionally, we restricted the analyses to those who reported good health as a means 
of addressing potential reverse causality. We also excluded volunteers with potential sinus 
bradycardia (<50 bpm) and those on medication for blood pressure and heart disease, given 
that such medication including β-blockers and calcium channel blockers artificially reduce 
pulse rate. All data analyses were performed using SPSS 18.0 statistical package (SPSS Inc., 
Chicago, IL). 
 
2.4. RESULTS 
     
Of the 30,519 men and women who volunteered for the study, 684 (2.2%) were excluded due 
to missing data on a number of the variables examined, leaving a total of 29,835 (97.8%) 
available for analysis. Clinical attributes of the subjects are presented in Tables 2.1 to 2.3. 
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Table 2.1. Baseline characteristics overall 
 Non-obese/low heart rate Non-obese/high heart rate Obese/low heart rate Obese/high heart rate P value
#
 
Number of participants (%) 14,791 (49.6) 4,748 (15.9) 7,363 (24.7) 2,933 (9.8)  
Age (years) 62.2±6.7 62.2±6.7
 
63.4±6.4
*† 
63.7±6.5
*†
 < 0.001 
Heart rate (beats/minute) 70±7 91±7
*
 71±7
†
 91±7
*§
 < 0.001 
Waist circumference (cm) 74.6±6.5 74.4±6.7 87.2±5.9
*†
 87.8±6.4
*†
 < 0.001 
Body mass index (kg/m
2
) 22.2±2.5 22.0±2.5 26.4±2.6
*†
 26.6±2.8
*†
 < 0.001 
Current smoker (%) 14.8 12.2 7.2 7.1 < 0.001 
Current drinker (%) 33.4 29.4 25.2 23.5 < 0.001 
MET-score (minutes/week) 2,550 2,312
*
 2,627
†
 2,336
*§
 < 0.001 
  (2,492-2,608) (2,224-2,403) (2,545-2,712) (2,216-2,463)  
Manual occupation (%) 57.9 59.4 66.2 67.7 < 0.001 
Education (%)      
   Primary 36.5 39.0 53.6 54.6 < 0.001 
   Secondary 53.3 51.7 39.3 39.1  
   University 10.2 9.4 7.1 6.3  
Personal income - Yuan (%)      
   <10,000 6.7 6.7 9.1 9.6 < 0.001 
   ≥10,000-<15,000 40.9 41.1 45.1 45.6  
   ≥15,000 52.4 52.3 45.8 44.9  
Fasting glucose (mmol/L) 5.35 (5.33, 5.37) 5.65 (5.60, 5.70)
*
 5.79 (5.75, 5.82)
*†
 6.25 (6.17, 6.33)
*†§
 < 0.001 
Impaired fasting glucose (%) 22.3 25.9 33.0 33.1 < 0.001 
Type 2 diabetes mellitus (%) 8.4 14.8 16.6 26.8 < 0.001 
IFG/Type 2 diabetes (%) 30.7 40.7 49.6 59.9 < 0.001 
Systolic blood pressure (mm/Hg) 127±22 131±21
*
 135±22
*†
 139±22
*†§
 < 0.001 
Diastolic blood pressure (mm/Hg) 72±11 75±11
*
 75±11
*
 78±11
*†§
 < 0.001 
Arterial hypertension (%)  34.3 40.6 52.7 60.1 < 0.001 
Cardiovascular disease history (%) 35.8 37.8 50.3 53.4 < 0.001 
Triglyceride (mmol/L) 1.23 (1.22, 1.24) 1.36 (1.34, 1.39)
*
 1.60 (1.57, 1.62)
*†
 1.79 (1.75, 1.84)
*†§
 < 0.001 
Total cholesterol (mmol/L)
 
5.85±1.13 6.02±1.19
*
 5.94±1.14
*†
 6.10±1.21
*§
 < 0.001 
LDL-cholesterol (mmol/L)
 
3.13±0.68 3.25±0.71
*
 3.16±0.68
†
 3.27±0.72
*§
 < 0.001 
HDL-cholesterol (mmol/L)
 
1.68±0.41 1.69±0.42 1.63±0.37
*†
 1.63±0.39
*†
 < 0.001 
Dyslipidaemia (%) 46.1 52.7 56.1 65.0 < 0.001 
Data are presented as Mean±SD, Geometric mean (95% confidence interval) or percentage values. 
#
P value was obtained by ANOVA or χ
2
 test. 
*
P < 0.05 when compared to Non obese/Low heart rate group; 
†
P < 0.05 when compared to Non obese/high heart rate group; 
§
P < 0.05 when 
compared to obese/low heart rate group. Abbreviations: MET = metabolic equivalent, IFG = impaired fasting glucose, LDL = low density 
lipoprotein, HDL = High density lipoprotein. 
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 Overall, those with a low RHR undertook the most physical activity according to total 
MET-minutes/week (Tables 2.1 to 2.3). Of the total population, the highest proportion of 
current smokers and drinkers tended to be non-obese with a low RHR (Table 2.1). These 
observations were similar in the gender-specific analyses (Tables 2.2 and 2.3). Subjects who 
were obese with a high RHR were more likely to be manual employees who had received less 
education and were earning a lower income (Table 2.1). In addition, female subjects who 
were obese with a high RHR also reported earning a lower income, probably as a result of 
being less educated and having worked more years in manual occupation (Table 2.3).     
A total of 3,777 (12.7%) subjects were diagnosed as having type 2 diabetes mellitus, 
7,850 (26.3%) as having impaired fasting glucose and 11,627 (39.0%) had either of these 
hyperglycaemic states. The prevalence of type 2 diabetes mellitus increased across the 
abdominal obesity/RHR groups. The obese/high RHR group had the greatest prevalence of 
type 2 diabetes mellitus (26.8% overall, 38.8% for males and 36.9% for females). Similarly, 
this group also contained more subjects with impaired fasting glucose (33.1% overall, 46.7 
for males and 42.7% for females) and the combined hyperglycaemic state (59.9% overall, 
60.2% for males and 57.1% for females [Tables 2.1 to 2.3]). 
Of the metabolic parameters, between-group differences were observed across the 
overall and gender stratified abdominal obesity/RHR groups for blood pressure (systolic and 
diastolic), lipids (total, high-density lipoprotein [HDL]- and low-density lipoprotein [LDL]-
cholesterol and triglyceride levels) and glucose levels (P < 0.001). That is, the obese/high 
RHR group had the highest values for each of these parameters, although HDL-cholesterol 
was inversely associated. 
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Table 2.2. Baseline characteristics according to men 
 Non-obese/low heart rate Non-obese/high heart rate Obese/low heart rate Obese/high heart rate P value
#
 
Number of participants (%) 5,080 (60.2) 1,591 (18.8) 1,074 (12.7) 495 (5.9%)  
Age (years) 63.8±6.7 63.4±6.8 64.6±6.8
*† 
64.3±6.7
†
 < 0.001 
Heart rate (beats/minute) 70±7 91±7
* 
70±7
† 
92±7
*§ 
< 0.001 
Waist circumference (cm) 78.6±6.9 79.0±7.0 94.3±4.3
*†
 95.2±5.3
*†
 < 0.001 
Body mass index (kg/m
2
) 22.6±2.6 22.6±2.7 27.3±2.4
*†
 27.4±2.4
*†
 < 0.001 
Current smoker (%) 37.9 33.3 28.8 27.9 < 0.001 
Current drinker (%) 46.2 43.9 42.6 42.2 0.008 
MET-score (minutes/week) 2,668 2,355
*
 2,664
†
 2,477 < 0.001 
  (2,609-2,729) (2,258-2,455) (2,539-2,796) (2,308-2,658)  
Manual occupation (%) 51.4 53.4 53.4 51.3 0.40 
Education (%)      
   Primary 30.1 29.6 31.6 28.9 0.52 
   Secondary 53.4 52.6 50.7 53.3  
   University 16.5 17.8 17.8 17.8  
Personal income - Yuan (%)      
   <10,000 6.6 5.4 4.9 4.4 0.40 
   ≥10,000-<15,000 42.4 42.0 47.7 41.3  
   ≥15,000 51.0 52.6 47.3 54.3  
Fasting glucose (mmol/L) 5.43 (5.41, 5.47) 5.74 (5.67, 5.81)
* 
5.83 (5.77, 5.90)
* 
6.21 (6.07, 6.36)
*†§ 
< 0.001 
Impaired fasting glucose (%) 27.1 33.0 42.9 46.7 < 0.001 
Type 2 diabetes mellitus (%) 11.8 21.8 23.4 38.8 < 0.001 
IFG/Type 2 diabetes (%) 33.6 43.5 51.4 60.2 < 0.001 
Systolic blood pressure (mm/Hg) 130±21 134±22
*
  139±21
*† 
143±21
*†
 < 0.001 
Diastolic blood pressure (mm/Hg) 75±11 77±12
*
 80±11
*†
 82±12
*†§
 < 0.001 
Arterial hypertension (%)  39.2 46.4 62.0 68.1 < 0.001 
Cardiovascular disease history (%) 36.4 37.1 54.1 58.8 < 0.001 
Triglyceride (mmol/L) 1.77 (1.72, 1.84) 2.14 (2.02, 2.29)
*
 3,42 (3.18, 3.69)
*†
 4.59 (4.10, 5.12)
*†§
 < 0.001 
Total cholesterol (mmol/L)
 
5.54±1.05 5.68±1.11
*
 5.59±1.03 5.78±1.09
*§
 < 0.001 
LDL-cholesterol (mmol/L)
 
3.03±0.64 3.12±0.67
*
 3.07±0.66 3.17±0.67
*§
 < 0.001 
HDL-cholesterol (mmol/L)
 
1.54±0.38  1.52±0.39 1.42±0.34
*†
 1.41±0.34
*†
 < 0.001 
Dyslipidaemia (%) 38.1 46.9 52.3 66.8 < 0.001 
Data are presented as Mean±SD, Geometric mean (95% confidence interval) or percentage values. 
#
P value was obtained by ANOVA or χ
2
 test. 
*
P < 0.05 compared to Non obese/Low heart rate group; 
†
P < 0.05 compared to Non obese/high heart rate group; 
§
P < 0.05 compared to 
obese/low heart rate group. Abbreviations as in Table 2.1. 
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Table 2.3. Baseline characteristics according to women 
 Non-obese/low heart rate Non-obese/high heart rate Obese/low heart rate Obese/high heart rate P value
#
 
Number of participants (%) 9,711 (44.0) 3,157 (14.3) 6,289 (28.5) 2,438 (11.0)  
Age (years) 59.6±6.9 59.9±7.1 62.0±6.9
*†
 62.3±7.0
*†
 < 0.001 
Heart rate (beats/minute) 71±6 91±7
*
 71.0±7
†
 91±8
*§
 < 0.001 
Waist circumference (cm) 72.0±5.1 71.8±5.2 86.0±5.4
*†
 86.0±5.5
*†
 < 0.001 
Body mass index (kg/m
2
) 22.1±2.4 22.0±2.5 26.4±2.7
*†
 26.5±2.5
*†
 < 0.001 
Current smoker (%) 2.7 1.6 3.5 2.9 0.09 
Current drinker (%) 26.3 21.7 22.1 19.6 < 0.001 
MET-score (minutes/week) 2,934  2,641
*
  2,999
†
 2,734
*§
 < 0.001 
  (2,887-2984) (2,565-2,720) (2,942-3,059) (2,647-2,824)  
Manual occupation (%) 61.4 62.4 68.3 71.0 < 0.001 
Education (%)      
   Primary 39.9 43.7 57.4 59.8 < 0.001 
   Secondary 53.3 51.2 37.3 36.2  
   University 6.9 5.1 5.3 4.0  
Personal income - Yuan (%)      
   <10,000 6.8 7.3 9.9 10.7 < 0.001 
   ≥10,000-<15,000 40.0 40.6 44.6 46.5  
   ≥15,000 53.1 52.1 45.5 42.8  
Fasting glucose (mmol/L) 5.32 (5.30, 5.34) 5.66 (5.62, 5.71)
* 
5.76 (5.73, 5.79)
*†
 6.19 (6.13, 6.26)
*†§
 < 0.001 
Impaired fasting glucose (%) 21.1 29.7 37.2 42.7 < 0.001 
Type 2 diabetes mellitus (%) 8.9 18.1 22.5 36.9 < 0.001 
IFG/Type 2 diabetes (%) 26.8 39.2 46.9 57.1 < 0.001 
Systolic blood pressure (mm/Hg) 125±21 128±21
*
 134±22
*†
 138±22
*†§
 < 0.001 
Diastolic blood pressure (mm/Hg) 70±10 73±11
*
 74±11
*†
 77±11
*†§
 < 0.001 
Arterial hypertension (%)  31.8 37.6 51.1 58.5 < 0.001 
Cardiovascular disease history (%) 35.5 38.1 49.7 52.3 < 0.001 
Triglyceride (mmol/L) 1.75 (1.71, 1.79) 2.25 (2.16, 2.35)
* 
 3.09 (3.01, 3.18)
*† 
3.91 (3.73, 4.11)
*†§ 
< 0.001 
Total cholesterol (mmol/L)
 
6.03±1.12 6.10±1.15
*
 6.01±1.13
† 
6.12±1.18
*§
 < 0.001 
LDL-cholesterol (mmol/L)
 
3.32±0.70 3.37±0.73
*
 3.30±0.71
†
 3.39±0.73
*§
 < 0.001 
HDL-cholesterol (mmol/L)
 
1.76±0.41 1.76±0.42 1.63±0.35
*†
 1.64±0.38
*†
 < 0.001 
Dyslipidaemia (%) 50.2 55.6 56.8 64.7 < 0.001 
Data are presented as Mean±SD, Geometric mean (95% confidence interval) or percentage values. 
#
P value was obtained by ANOVA or χ
2
 test. 
*
P < 0.05 compared to Non obese/Low heart rate group; 
†
P < 0.05 compared to Non obese/high heart rate group; 
§
P < 0.05 compared to 
obese/low heart rate group. Abbreviations as in Table 2.1. 
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In multivariable analyses, an increased OR for type 2 diabetes mellitus was 
independently associated with the fourth (vs. first) quartile for abdominal obesity (OR [95% 
CI] = 3.51 [3.10, 3.98], P < 0.001) and RHR (OR [95% CI] = 2.59 [2.33, 2.90], P < 0.001), 
hereby indicating both contribute independently towards the prevalence of type 2 diabetes 
mellitus (Figure 2.1). Moreover, according to the obesity/RHR groups, the risk for type 2 
diabetes mellitus doubled in those who were obese with a low RHR (OR [95% CI] = 2.13 
[1.93, 2.35], P < 0.001) and in those who were non-obese with a high RHR (OR [95% CI] = 
2.05 [1.83, 2.29], P < 0.001), highlighting the importance of both (Table 2.4). The OR for 
type 2 diabetes mellitus further increased peaking in those who were obese with a high RHR 
for overall (OR [95% CI] = 3.93 [3.48, 4.43], P < 0.001), male (OR [95% CI] = 2.73 [2.09, 
3.57], P < 0.001) and female participants (OR [95% CI] = 4.31 [3.75, 4.94], P < 0.001), 
which remained robust after full adjustment (Table 2.4). Similar trends were present for 
impaired fasting glucose and the combined hyperglycaemic state with the adjusted risk 
increasing by 125% and 173% for overall, 85% and 112% for male and 136% and 189% for 
female subjects, respectively (Table 2.4). 
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Table 2.4. Odds ratios (with 95% confidence intervals) for the presence of impaired fasting glucose, type 2 diabetes mellitus and both combined among 
29,835 older Chinese adults according to abdominal obesity and physical fitness parameters 
 Odds ratios (95% confidence intervals) 
 Overall  Men  Women 
 Model 1 Model 2  Model 1 Model 2  Model 1 Model 2 
 Impaired fasting glucose 
Non-obese/low heart rate 1 (reference) 1 (reference)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
Non-obese/high heart rate 1.48 (1.37, 1.61) 1.44 (1.33, 1.56)  1.32 (1.15, 1.51) 1.25 (1.09, 1.44)  1.58 (1.43, 1.74) 1.54 (1.39, 1.70) 
Obese/low heart rate 2.04
 
(1.91, 2.19) 1.89 (1.76, 2.03)  1.99 (1.72, 2.31) 1.75 (1.51, 2.04)  2.07 (1.92, 2.24) 1.94 (1.79, 2.10) 
Obese/high heart rate 2.52 (2.29, 2.90) 2.25 (2.04, 2.48)  2.21 (1.78, 2.75) 1.86 (1.49, 2.33)  2.61 (2.34, 2.91) 2.36 (2.11, 2.64) 
P for trend <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
 Type 2 diabetes mellitus 
Non-obese/low heart rate 1 (reference) 1 (reference)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
Non-obese/high heart rate 2.24 (2.02, 2.50) 2.05 (1.83, 2.29)  2.14 (1.80, 2.56) 1.88 (1.56, 2.26)  2.30 (2.01, 2.63) 2.14 (1.86, 2.46) 
Obese/low heart rate 2.59 (2.36, 2.85) 2.13 (1.93, 2.35)  2.28 (1.81, 2.74) 1.61 (1.29, 2.00)  2.70 (2.42, 3.02) 2.29 (2.04, 2.56) 
Obese/high heart rate 5.27 (4.70, 5.91) 3.93 (3.48, 4.43)  4.47 (3.47, 5.74) 2.73 (2.09, 3.57)  5.52 (4.84, 6.29) 4.31 (3.75, 4.94) 
P for trend <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
 Impaired fasting glucose/Type 2 diabetes mellitus combined 
Non-obese/low heart rate 1 (reference) 1 (reference)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
Non-obese/high heart rate 1.68 (1.57, 1.81) 1.60
 
(1.49, 1.72)  1.54 (1.36, 1.73) 1.42 (1.25, 1.60)  1.76 (1.62, 1.93) 1.69 (1.55, 1.85) 
Obese/low heart rate 2.20
 
(2.07, 2.33) 1.96
 
(1.84, 2.10)  2.06 (1.80, 2.36) 1.72 (1.49, 1.98)  2.24 (2.09, 2.40) 2.03 (1.89, 2.18) 
Obese/high heart rate 3.26
 
(3.00, 3.55) 2.73
 
(2.50, 2.98)  2.81 (2.31, 3.41) 2.12 (1.74, 2.58)  3.39 (3.08, 3.73) 2.89 (2.63, 3.20) 
P for trend <0.001 <0.001  <0.001 <0.001  <0.001 <0.001 
Model 1 adjusted for age and sex. Model 2 also adjusted for smoking, drinking, physical activity, longest held occupation, education, personal income, 
arterial hypertension, cardiovascular disease history and dyslipidaemia. 
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Figure 2.1. Odds Ratios (fourth vs. first quartile) for the independent 
associations of abdominal obesity and heart rate with impaired fasting 
glucose (IFG), type 2 diabetes mellitus (T2DM) and the combined 
hyperglycaemic state. Values are derived from multivariable analysis 
which adjusted for age, sex, smoking, drinking, physical activity, longest 
held occupation, education, personal income, arterial hypertension, 
cardiovascular disease history and dyslipidaemia. 
 
In light of these findings, we tentatively explored whether the risk of type 2 diabetes 
mellitus in the presence of a high RHR differed among the non-obese and obese participants. 
A raised RHR appeared to double the risk of diabetes among the non-obese (Table 2.4). 
Likewise, in the obese subjects, the presence of a high RHR also almost doubled the risk for 
diabetes among the obese (OR [95% CI] = 1.89 [1.66, 2.12], P < 0.001).   
We also addressed the potential issue of reverse causality by restricting to subjects 
who reported good or very good health (n = 24,346), and therefore were less likely to have 
poor physical fitness as a consequence of underlying chronic conditions. We found the risk of 
type 2 diabetes mellitus increased slightly from 3.93 (95% CI = 3.48, 4.43) to 4.10 (95% CI = 
3.57, 4.71), which remained robust even after adjusting for several possible confounders 
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(fourth vs. first quartile). Further exclusion of those with potential sinus bradycardia (n = 
115) or those receiving medication for blood pressure or heart disease (n = 815) did not affect 
these observations (data not shown).  We additionally explored the data using the median 
heart rate of 75 bpm. The outcome risk of diabetes was similar whether we used the median 
(75 bpm) or 75% cut-off point (83 bpm) to stratify groups based on heart rate. 
 
2.5. DISCUSSION 
 
Our findings indicate, poor physical fitness determined by a raised RHR 
24, 87
 and abdominal 
obesity independently doubled the risk of type 2 diabetes mellitus. In addition, we observed 
those with a combination of both conditions may require more aggressive treatment, as the 
risk of diabetes was found to be two-fold higher. For instance, the strength of the association 
with type 2 diabetes mellitus was additionally increased on the background of abdominal 
obesity and a raised RHR by almost 300%, even after adjusting for potential confounding 
factors. Collectively, these data confirm earlier studies in Caucasians, showing that obese and 
physically less fit individuals are at a greater risk of metabolic complications such as type 2 
diabetes mellitus 
84
.  
We found a raised RHR may exacerbate the development of diabetes in addition to 
abdominal obesity, possibly contributing to the increased risk of mortality among those 
subjects 
55
. However, the small differences in the anthropometric measures observed in the 
present study, although reaching significance in the latter groups, suggests these observations 
are further mediated through alternative mechanisms.  
For example, other studies have reported an association between a raised RHR and 
increased sympathetic activity 
3, 24
, which has been implicated in the development of 
hyperglycaemia, including type 2 diabetes mellitus 
3, 24
. Increased sympathetic tone both 
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amplifies insulin resistance and is further increased in response to insulin, potentially 
exacerbating hyperglycaemia 
27, 92
 and other metabolic abnormalities 
93
. Laakso and 
colleagues 
94
 reported that insulin resistant subjects had an attenuated rise in the postprandial 
elevation in blood flow to skeletal muscles when compared to control subjects. Thus, 
sympathetic vasoconstriction may reduce blood flow leading to acute insulin resistance 
within peripheral tissue, further negatively impacting on the maintenance of glucose 
homeostasis 
95
.  
There has also been renewed interest in other factors which mediate adipose tissue 
distribution and function, such as abnormal activity of the hypothalamic-pituitary-adrenal 
axis 
96
. For instance, overweight populations may have a mild form of hypercortisolaemia 
97, 
98
, and it is thought that cortisol counter-regulates the actions of insulin whereby the 
association between cortisol and type 2 diabetes mellitus is likely due to increased insulin 
resistance which is evident in the hypercortisolaemic condition 
99
. Both clinical and 
experimental investigations show excess cortisol is related to insulin resistance 
100
 and may 
be a contributory cause of obesity 
101
. However, studies representative of the general 
population, examining cortisol and its relative contribution to obesity, insulin resistance and 
type 2 diabetes mellitus are sparse and warrant further investigation.    
As the rate of modernisation continues to rise in China, it seems unsurprising that the 
prevalence of type 2 diabetes mellitus continues to approach the figures observed in more 
developed societies. The changes that have occurred in the present study are likely to increase 
the burden of adverse health consequences associated with this condition. Thus, public health 
interventions are urgently required to delay or prevent the potential medical or societal 
ramifications that may occur in Chinas 1.2 billion population. In general, physical activity 
interventions have shown that exercise not only reduces basal sympathetic activity but also 
improves the metabolic profile overall. Improvements in physical fitness can also induce 
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these beneficial effects even in the absence of changes in body weight 
102
, supporting the 
impact of fitness independent of obesity levels as observed in the current study.  
Our older Chinese sample were randomly drawn from the membership of a city-wide 
community social and welfare association in Guangzhou city which represents 7% of the 
city's older permanent population of that age strata. After limiting the analysis to those with 
good or very good self-rated health, the association between physical fitness and type 2 
diabetes mellitus remained essentially unchanged, suggesting that our findings are unlikely to 
be affected by reverse causality. Likewise, further exclusion of those who may have 
artificially reduced RHR resulting from treatment or sinus bradycardia did not affect the 
observations. Sensitivity analyses also showed that the observations were not sensitive to the 
choice of cut-off for the classification of a high RHR with both the median (75 bpm) and 
75% cut-off point (83 bpm) giving similar results. However, given the cross-sectional nature 
of the present study, confirmation using a longitudinal design to detect the causative role of 
physical fitness on the incidence of type 2 diabetes mellitus is required.  
 
To our knowledge, the present study is the first to address the independent and 
combined effects of abdominal obesity and physical fitness as measured by RHR on the 
prevalence of type 2 diabetes mellitus in an older Chinese population. RHR is only a crude 
measure of physical fitness, but has shown to be an independent predictor of fitness as 
measured by maximal treadmill exercise test 
103
. We demonstrate that a high RHR as 
mediated by poor physical fitness may lead to an increased prevalence of glucose intolerance 
in both non-obese and obese community dwelling older subjects. Although biologically 
plausible, further research is warranted as it remains equivocal whether elevated RHR in 
individuals with poor physical fitness is causal, consequential, or epiphenomenal. However, 
should these observations be confirmed, RHR may provide a cheap and simple means of risk 
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stratification in such populations for which targeted interventions, including lifestyle 
modification, should be implemented. 
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CHAPTER THREE 
 
3.0. INFLUENCE OF HEART RATE AT REST FOR PREDICTING THE 
METABOLIC SYNDROME IN OLDER CHINESE ADULTS 
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3.1. ABSTRACT 
  
The aim of this study was to examine the relationship between seated resting heart rate and 
the metabolic syndrome among older residents of Guangzhou, South China. 30,519 older 
participants (≥50 years) from the Guangzhou Biobank Cohort Study were stratified into 
quartiles based on seated resting heart rate. The associations between each quartile and the 
metabolic syndrome were assessed using multivariable logistic regression. 6,907 (22.8%) 
individuals were diagnosed as having the metabolic syndrome, which was significantly 
associated with increasing heart rate quartiles (P <0.001). Participants in the upper-most 
quartile (mean resting heart rate 91±8 bpm) of this cardiovascular proxy had an almost two-
fold increased adjusted risk (odds ratio [95% CI] = 1.94 [1.79, 2.11], P <0.001) for the 
metabolic syndrome, as compared to those in the lowest quartile (mean resting heart rate 63±4 
bpm). Heart rate, which is an inexpensive and simple clinical measure, was independently 
associated with the metabolic syndrome in older Chinese adults. We hope these observations 
will spur further studies to examine the usefulness of resting heart rate as a means of risk 
stratification in such populations, for which targeted interventions should be implemented. 
 
  
41 
 
3.2. INTRODUCTION 
 
The MetS represents a constellation of closely associated cardiovascular risk factors including 
central adiposity, hyperglycaemia, hypertension, and hyperlipidaemia 
90, 104
. The clustering of 
these factors has been known for over 80 years 
105
, and since that time, the concept of the 
MetS has evolved considerably 
106
. Multiple lines of evidence suggest that RHR is associated 
with the presence of the MetS 
107, 108
, and in this regard, data highlighting such relationships 
may raise awareness for health promotion initiatives.  
In three different populations, Palatini and co-workers 
107
 observed that men with 
elevated RHR also presented higher values of cholesterol, triglycerides, fasting insulin, and 2 
h post-load glucose concentrations, all of which are indicative of the MetS. Results from the 
TAMCIS project reported a four-fold increase in the risk of the MetS among men and women 
with a RHR ≥80 bpm 43. In a population-based study of healthy adults, Panzer and colleagues 
109
 found fasting plasma glucose was positively associated with RHR following an exercise 
test. In hypertensive patients, RHR was independently associated with obesity, waist girth, 
blood pressure and serum glucose 
110
. Moreover, on several occasions RHR has been 
described as an independent predictor of cardiovascular morbidity and mortality 
3l, 53-56, 59, 111, 
112
.  
In light of this data however, these findings were mostly derived from Black and 
Caucasian populations, and large scale studies examining RHR with the MetS, particularly 
among Asian cohorts are largely unavailable. As developing nations such as China continue 
to increase their rapid rate of modernisation, the prevalence of cardiovascular-associated 
health conditions such as the MetS will likely become more apparent 
113-115
, possibly leading 
to overwhelming public health ramifications. Therefore, the purpose of our investigation was 
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to increase the recognition of RHR as an independent marker of the MetS, among older 
residents of Guangzhou, in South China. 
  
3.3. METHODS 
 
3.3.1. Participants and setting 
The GBCS is a prospective population based study aiming to examine determinants of health 
in an older Chinese population, and has been described previously 
88, 116
. Briefly, participants 
were drawn from the membership of a city-wide community social and welfare association 
(GHHARE) for older people in Guangzhou, China. Baseline assessment included a detailed 
structured interview on lifestyle habits and medical history, as well as measurements of 
anthropometric indices, blood pressure, and fasting plasma markers. The Medical Ethics 
Committee of the Guangzhou Medical Association approved the study, and written, informed 
consent was obtained from all participants. For the present study, data from 30,519 
participants recruited from 2003-2006 were analysed. 
 
3.3.2. Demographic and lifestyle data 
Demographic data (e.g., age and gender), details of health and lifestyle (e.g., smoking, alcohol 
consumption and physical activity) and socio-economic variables (e.g. occupational status, 
personal income and education level) were obtained by qualified staff. Participants were 
defined as current smokers if they answered yes to the question: “Do you currently smoke?” 
Also, participants were defined as current alcohol drinkers by answering yes to the question: 
“Have you consumed any alcohol in the past 12 months?” Level of physical activity was 
quantified using the short version of IPAQ, validated in the Chinese population 
89
. The 
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formula for the computation of MET-minutes/week was: MET level x minutes of physical 
activity x events per week. In the current study, MET-minutes/week was presented as a 
continuous variable. For socio-economic measures, participants were categorized based on 
manual (indicative of a “blue collar” working environment) or non-manual employment 
according to occupational status. Education level consisted of three categories; attended 
primary school, secondary school or college. Personal income was defined as net monthly 
income in Yuan (6.40 Yuan = 1.00 USD) according to the following categories; <10,000, 
≥10,000-<15,000 and ≥15,000.   
 
3.3.3. Experimental procedures 
Seated RHR was measured three times (Omron 705CP), 1 minute apart, following a 3 minute 
rest, with the average calculated from the second and third measurements. For the purpose of 
this study, participants were stratified into quartiles based on seated RHR. The presence of 
three out of five factors from the following MetS guidelines were used to identify participants 
with the MetS: (a) waist circumference ≥90 cm in men and ≥80 cm in women (Asian central 
obesity criteria); (b) raised blood pressure (≥130/85 mm Hg) or receiving treatment for 
hypertension; (c) raised fasting plasma glucose (≥5.6 mmol/L) or previously diagnosed type 2 
diabetes; (d) raised plasma triglycerides (≥1.7 mmol/L); and (e) reduced HDL-cholesterol 
(<1.00 mmol/L in men and <1.30 mmol/L in women) 
90
.  
 
3.3.4. Statistical methods  
MET-minutes/week, glucose and triglyceride concentrations were non-normally distributed 
and therefore logarithmically transformed with their geometric means and 95% CIs presented. 
Otherwise data are shown as Mean±SD for continuous parameters or prevalence for 
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categorical variables. Comparisons between groups were performed by ANOVA, with a 
Bonferroni post-hoc test for continuous parameters and χ2 test with P for linear-by-linear test 
for categorical variables.  
The associations between seated RHR and the MetS were determined using 
hierarchical multivariable logistic regression models. In these analyses, model 1 describes the 
unadjusted association; model 2 adjusted for age (continuous variable) and sex; and model 3 
further adjusted for smoking, alcohol, physical activity, occupational status, personal income 
and education. To better understand the relationship between RHR and the MetS, the latter 
analyses were performed examining RHR as a categorical and continuous parameter. We 
conducted a sensitivity test on the above models including only those who reported good or 
very good health as a means of addressing underlying illnesses that may have otherwise 
influenced our analyses. We further removed participants with potential sinus bradycardia 
(<50 bpm) and those on medication for blood pressure and heart disease, given that such 
medication including β-blockers and calcium channel blockers artificially reduce pulse rate. 
All statistical tests were 2-sided, and statistical significance was defined as P <0.05. All data 
were analyzed using SPSS (SPSS 18.0; SPSS Inc, Chicago, Illinois). 
 
3.4. RESULTS 
 
Of the 30,519 older Chinese subjects recruited, we obtained full information regarding heart 
rate and other relevant fasting biochemical, physiological, and metabolic parameters on 
30,328, thus 99.4% of subjects recruited are included in this study. Logistic regression 
analysis revealed no significant interaction effect between gender and RHR with the MetS (P 
=0.14), therefore the two sexes were combined.  
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As shown in Table 3.1, a total of 6,907 (22.8%) individuals were diagnosed with 
having the MetS. Subjects in the highest quartile for RHR had a higher BMI and waist 
circumference, but reported less physical activity, as compared to those in the lowest quartile. 
Likewise, these participants had higher concentrations of fasting glucose, total and LDL-
cholesterol, triglycerides and higher systolic and diastolic blood pressures, reflecting the 
increased prevalence of type 2 diabetes, dyslipidaemia and arterial hypertension. Of the other 
parameters, those in the upper-most quartile for RHR were more likely to be manual 
employees, perhaps as a result of being less well educated. Further, these participants reported 
greater use of cardiovascular treatment including anti-hypertensives, lipid-lowering agents 
and anti-hyperglycaemic medication. In contrast, a greater proportion of participants in the 
lowest quartile tended to be current smokers and/or drinkers (Table 3.1). 
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Table 3.1. Participant characteristics according to quartiles of resting heart rate   
 Resting heart rate quartiles  
 Q1 Q2 Q3 Q4 P-value
*
 
No. (%) 7,628 (25.2) 7,709 (25.4) 7,427 (24.5) 7,564 (24.9)  
Age (years) 61.9±7.1 61.1±7.1 61.2±7.1 61.7±7.1 <0.001 
Male (%) 32.2 25.4 25.2 27.8 <0.001 
Heart rate (beats/minute) 63±4 72±1 78±2 91±8 <0.001 
Body mass index (kg/m
2
) 23.6±3.2 23.7±3.2 23.8±3.3 23.9±3.4 <0.001 
Waist circumference (cm) 78.4±8.8 78.4±8.8 78.7±8.9 79.5±9.4 <0.001 
Current smoker (%) 14.8 11.4 10.2 10.4 <0.001 
Current alcohol drinker (%) 32.0 30.2 29.5 27.3 <0.001 
Metabolic equivalent score 2,690 2,509 2,529 2,307 0.46 
(min/week)  (2,610-2,773) (2,428-2,592) (2,454-2,607) (2,236-2,381)  
Metabolic syndrome (%) 17.8 20.5 23.5 29.5 <0.001 
Fasting glucose (mmol/L)
 
5.41 (5.39, 5.43) 5.49 (5.46, 5.51) 5.59 (5.57, 5.62) 5.88 (5.84, 5.91) <0.001 
Type 2 diabetes (%) 11.0 13.8 17.0 26.0 <0.001 
Systolic blood pressure (mm/Hg) 130±23 129±22 129±21 134±22 <0.001 
Diastolic blood pressure 72±10 73±11 74±11 76±11 <0.001 
Arterial hypertension (%) 42.6 39.5 39.5 48.0 <0.001 
Total cholesterol (mmol/L) 5.83±1.13 5.90±1.12 5.94±1.12 6.01±1.16 <0.001 
HDL-cholesterol (mmol/L)
ǂ 
1.65±0.39 1.66±0.40 1.65±0.40 1.65±0.41 0.22 
LDL-cholesterol (mmol/L)
ǂ 
3.20±0.70 3.24±0.69 3.28±0.71 3.31±0.71 <0.001 
Triglyceride (mmol/L)
 
1.32 (1.30, 1.33) 1.39 (1.37, 1.40) 1.46 (1.44, 1.48) 1.56 (1.54, 1.58) <0.001 
Dyslipidaemia (%) 46.1 49.9 52.8 57.4 <0.001 
Occupational status (% manual) 59.6 61.2 61.4 62.6 0.001 
Personal income – Yuan (%)      
   <10,000 7.9 7.1 7.6 7.6 0.26 
   ≥10,000-<15,000 41.6 42.3 42.5 43.0  
   ≥15,000 50.6 50.6 49.9 49.4  
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Table 3.1. continued      
 Resting heart rate quartiles  
 Q1 Q2 Q3 Q4 P-value
*
 
Education (%)      
   Attended primary 42.4 42.4 42.1 45.0 <0.001 
   Secondary 47.4 49.0 49.5 46.8  
   College 10.2 8.8 8.4 8.2  
Cardiovascular treatment (%)      
   Anti-hypertensive medication 27.6 24.6 25.0 29.2 0.02 
   Lipid-lowering agents 6.2 6.8 6.5 7.6 0.003 
   Anti-hyperglycaemic medication 5.7 6.8 8.1 11.7 <0.001 
Mean±SD, Geometric mean (95% confidence intervals) or percentage values are reported. 
*
P-value was obtained by ANOVA or χ
2
 test. HDL = high-
density lipoprotein; LDL = low-density lipoprotein. 
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Figure 3.1 describes the relationship between RHR measured continuously with the 
MetS and its individual components. A 10 bpm increment in RHR was associated with a 16% 
increase in the risk of having the MetS (P <0.001). Likewise, a 10 bpm increase in RHR was 
most strongly associated with elevated fasting glucose as compared to the other individual 
components; surprisingly presenting a similar risk in comparison to the overall MetS score 
(see Figure 3.1). In Table 3.2, the relationship between each RHR quartile and the MetS is 
shown. In model 3, the adjusted risk associated with the MetS was almost two-fold greater for 
seated RHR among individuals in the highest quartile (OR [95% CI] = 1.94 [1.79-2.11], P 
<0.001), as compared to subjects in the lowest quartile. 
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Figure 3.1. Fully adjusted odds ratios for the metabolic syndrome and the 
individual components according to seated resting heart rate (per 10 
beats/minute increment). MetS = metabolic syndrome; HDL = high-density 
lipoprotein. Model adjusted as abbreviated in Table 3.2. 
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Table 3.2. Odds ratios for the metabolic syndrome according to quartiles of seated resting heart rate  
 Resting heart rate quartiles 
 Q1 Q2 Q3 Q4 Ptrend 
No. MetS/without 1355/6273 1577/6132 1746/5681 2229/5335  
Unadjusted      
OR 1 1.22 1.41 1.97 <0.001 
95% CI ··· 1.12 – 1.33 1.30 – 1.54 1.82 – 2.14  
P value ··· <0.001 <0.001 <0.001  
Age and sex adjusted      
OR 1 1.22 1.41 1.96 <0.001 
95% CI ··· 1.11 – 1.32 1.29 – 1.54 1.80 – 2.13  
P value ··· <0.001 <0.001 <0.001  
Fully adjusted      
OR 1 1.21 1.41 1.94 <0.001 
95% CI ··· 1.11 – 1.32 1.29 – 1.53 1.79 – 2.11  
P value ··· <0.001 <0.001 <0.001  
Fully adjusted model included age, sex, smoking, alcohol, physical activity, occupational status, 
personal income and education. MetS = metabolic syndrome; OR = odds ratio; CI = confidence 
interval. 
 
Lastly, we conducted a sensitivity test including only subjects who reported good or 
very good health (n = 24,286), and who were therefore less likely to have influenced the 
present analyses as a consequence of underlying chronic conditions. We found the risk for the 
MetS remained virtually unchanged (OR [95% CI] = 1.93 [1.76, 2.12], P <0.001) after 
adjusting for potential confounders. In a separate sensitivity check, exclusion of individuals 
with potential sinus bradycardia (<50 bpm) or those receiving medication for blood pressure 
or heart disease (n = 8,224) did not affect these results (OR [95% CI] = 2.12 [1.89, 2.38], P 
<0.001).  
 
3.5. DISCUSSION 
 
In this study, an elevated RHR was independently associated with the MetS in older Chinese 
adults. Participants in the upper-most quartile (≥91 bpm) of this cardiovascular proxy had an 
almost two-fold increased adjusted risk for the MetS, after correcting for a range of potential 
confounding factors. Our data confirm earlier investigations among non-Asian populations, 
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indicating that those with an elevated RHR were at greater risk of cardio-metabolic 
complications 
43, 107, 110
. Though the prevalence of the MetS has become commonplace among 
affluent nations 
117, 118
, its implications within developing countries are of great concern 
106
. 
As the rate of modernisation increases in China, the prevalence of the MetS will continue to 
rise, and may amplify the burden of adverse health outcomes associated with this condition. 
Thus, public health interventions are urgently needed. The results from this study suggest that 
RHR, which is an inexpensive and simple clinical measure, may be used as an indicator for 
the possible presence of the MetS in older Chinese adults.  
Indeed, epidemiological studies have consistently shown that elevated RHR is a 
predictive factor for the MetS. For example, Singh et al. 
30
 observed that, apart from genetic 
factors, RHR was associated with several environmental causes including BMI, systolic, and 
diastolic blood pressure. Martin and co-workers 
119
 found individuals who presented with a 
higher RHR had substantially elevated levels of insulin and glucose, waist circumference, 
BMI, diastolic blood pressure and suggestively elevated triglycerides and systolic blood 
pressure. Given the potential clinical impact of RHR, the mechanisms on how it interacts with 
other cardiovascular risk factors are of significant biomedical interest. To this end, ANS 
activity is considered to play a central role in regulating pulse rate. Previous literature has 
implicated dysfunctional ANS activity with a number of deleterious health consequences 
pertaining to CVD 
107, 120, 121
. This is often afforded to a sympatho-vagal imbalance, usually in 
favour of sympathetic over-activity 
121
. Here, predominant sympathetic activity provokes 
numerous negative sequelae including abnormal heart-rate control, impaired central and 
peripheral vascular dynamics 
122
, as well as sustained insulin resistance and blood pressure 
elevation 
123
. Moreover, due to the unwanted shift in ANS activity, lower parasympathetic 
outflow (i.e. reduced vagal tone) has been suggested to exacerbate a faster RHR and diastolic 
dysfunction 
122, 124
. 
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We may add that resting tachycardia is perhaps attributable to the consequent actions 
of leptin on cardiovascular control; a faster RHR may be influenced by a decline in vagal 
drive to the heart by leptin 
125
. Indeed, high leptin has been shown to be a strong independent 
predictor of cerebrovascular disease 
126
 as well as acute MI 
127
. Further, Narkiewicz et al. 
125
 
observed that RHR in men with high leptin concentrations was faster in comparison to men 
with lower plasma leptin levels. Thus, if confirmed by additional studies, the link between 
leptin and RHR may well extend our understanding of the pathophysiological processes 
underlying cardiovascular function. 
Recent studies have also highlighted that a defect in nitric oxide (NO) bioavailability 
may contribute to the pathophysiology of the MetS 
128
. In particular, a defect in the production 
of NO impairs oxidative metabolism by diminishing mitochondrial biogenesis, resulting in 
lipid accumulation in skeletal muscle, liver and pancreas, which may ultimately impede 
insulin signalling, glycaemic control, and NO-mediated vasodilation 
120, 129, 130
. Interventions 
to improve mitochondrial function have been shown to correct insulin signalling as well as 
other metabolic and vascular abnormalities 
130
. Interestingly, NO also modulates autonomic 
control of pulse rate by participating in parasympathetic vasodilation within the coronary 
arteries while inhibiting sympathetic vasoconstriction 
111
. Further, experimental studies have 
shown NO augments cardiac vagal control in healthy adults, as well as patients suffering from 
heart failure 
131, 132
. In summary, the relationship between RHR and the cluster of risk factors 
that form the MetS is well validated, and it seems plausible that RHR may well represent a 
member of this family, for which NO could be the missing link 
111
; though clearly, further 
longitudinal and interventional studies are needed to help establish this notion.         
To our knowledge, no other studies have examined the association between RHR and 
the MetS among older Chinese. The present large-scale sample was randomly drawn from the 
membership of a city-wide community social and welfare association in Guangzhou city, 
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representing 7% of the city's older permanent population of that age strata. In this regard, our 
sample may not be representative of all older Chinese in Guangzhou, although, we have 
previously shown that our sample has similar levels of metabolic disorders including type 2 
diabetes and hypertension as compared to nationally representative samples of urban Chinese 
133, 134, suggesting reasonable external validity. We cannot rule out the possibility of “healthy 
volunteer bias” among people who have chosen to join GHHARE, and by extension, in 
common with all cohorts in developing countries, our subjects are with increasing age 
selected survivors. In particular, our subjects survived childhood infections in a pre-antibiotic 
environment, and lived through significant periodic social turmoil up until the 1970s. 
However, if survivorship were an issue, we would expect different relationships in the older 
compared with the younger subjects, which we check for routinely.  
After limiting the analysis to individuals with good or very good self-rated health, the 
association between RHR and the MetS remained essentially unchanged, suggesting that our 
findings are unlikely to be affected by other underlying illnesses. Further exclusion of 
participants who may have artificially lowered RHR resulting from treatment or sinus 
bradycardia did not affect these observations. However, given the cross-sectional nature of the 
present investigation, confirmation using a longitudinal design to study the prediction of RHR 
on the incidence of the MetS is necessary.  
In conclusion, seated RHR was found to be significantly associated with the MetS in 
older Chinese adults. Our data highlights the importance of RHR as a distinct marker of 
health status, independent of other major risk factors. In light of these findings, RHR may 
provide a cheap and simple means of risk stratification in such populations for which targeted 
interventions should be implemented. 
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CHAPTER FOUR 
 
4.0. USEFULNESS OF RESTING HEART RATE AND THE METABOLIC 
SYNDROME TO PREDICT VASCULAR DISEASE RISK IN OLDER CHINESE: 
FROM THE GUANGZHOU BIOBANK COHORT STUDY-CARDIOVASCULAR 
DISEASE SUB-COHORT 
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4.1. ABSTRACT 
 
Physical fitness may independently lower the risk of cardiovascular disease. We explored the 
independent and combined associations of physical fitness measured by seated resting heart 
rate, and the metabolic syndrome, with cardiovascular disease risk, as described by elevated 
pulse wave velocity in older Chinese. Data from 1,996 participants were drawn from the 
Guangzhou Biobank Cohort Study-Cardiovascular Disease Sub-cohort. Analysis of Variance 
and logistic regression were employed to establish the independent and combined 
associations of resting heart rate and the metabolic syndrome with pulse wave velocity. 
Resting heart rate was independently associated with elevated pulse wave velocity; odds ratio 
(95% CI) = 1.63 (1.22, 2.18), as was the metabolic syndrome; odds ratio (95% CI) = 2.36 
(1.76, 3.17). Participants with a high resting heart rate, but without the metabolic syndrome 
had an adjusted odds ratio (95% CI) of 1.63 (1.15, 2.30) for the presence of the 
cardiovascular proxy. Those with a low resting heart rate and the metabolic syndrome had an 
adjusted odds ratio (95% CI) of 2.35 (1.66, 3.33). The risk of an elevated pulse wave velocity 
increased almost four-fold on the background of both a high resting heart rate and diagnosis 
of the metabolic syndrome; odds ratio (95% CI) 3.87 (2.39, 6.28) (P = 0.52 for interaction). 
In conclusion, physical fitness, measured by seated resting heart rate and the metabolic 
syndrome are independently associated with elevated pulse wave velocity, a surrogate marker 
for cardiovascular disease. The strength of this association is further increased on the 
background of both. These findings confirm the beneficial effects of physical fitness on 
attenuating the risk of vascular disease among older Chinese. 
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4.2. INTRODUCTION 
 
Risk factors for CVD attribute to a number of medical disorders and their clustering is known 
as the MetS. The MetS is largely the result of altered modifiable lifestyle factors, for instance 
physical fitness. Several studies have indicated poor physical fitness is associated with the 
MetS, exacerbating an unhealthy CVD risk profile and promoting all-cause mortality 
16, 135
. 
However, the current contributions of RHR and the MetS toward the risk of CVD remain 
underexplored, particularly among Chinese populations. Therefore, in the present study we 
evaluated the independent and combined associations of physical fitness as measured by 
seated RHR, and the MetS, with CVD risk, as described by pulse wave velocity (PWV) in 
older Chinese residents of Guangzhou, China. We specifically hypothesized that poor 
physical fitness; 1) would be coupled with a higher prevalence of CVD risk and; 2) the risk of 
CVD would additionally increase on the background of the MetS, thus forewarning of a 
major developing health burden in a rapidly modernizing and burgeoning older Chinese 
population.   
 
4.3. METHODS 
 
4.3.1. Participants and setting 
Data were drawn from 1,996 older Chinese volunteers (>50 years) as part of the Guangzhou 
Biobank Cohort Study-Cardiovascular Disease Sub-cohort (GBCS-CVD). This sub-cohort 
enables a thorough evaluation of volunteers’ current CVD status through the measurement of 
a range of surrogate markers of vascular disease/risk, thus allowing for the development of 
testable hypotheses. Our older volunteers were permanent residents of Guangzhou, belonging 
to a community and welfare association (GHHARE), which represents a homogeneous 
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Cantonese group who has retained many traditional and cultural norms, despite previous 
turmoil and extensive economic transition. This population forms part of an ideal setting to 
assess, both cross-sectionally and longitudinally, the impact of rapid economic development 
on health outcomes. A more comprehensive description of this sub-cohort and its 
multidisciplinary measures is detailed by Jiang et al. 
136
. The Medical Ethics Committee of 
the Guangzhou Medical Association approved the study, and written, informed consent was 
obtained from all volunteers. 
 
4.3.2. Experimental procedures 
Volunteers were classified according to physical fitness status as indicated by seated RHR 
and diagnosis of the MetS. Seated RHR was measured three times (Omron 705CP); 1 minute 
apart, following a 3 minute rest, with the average calculated from the second and third 
measurements. Volunteers were classified as having a high seated RHR, if their heart rate 
was ≥83 bpm, determined by the 75th percentile cut-point. The presence of three out of five 
factors from the following criteria were used to identify those with the MetS: (a) waist 
circumference ≥90 cm in men and ≥80 cm in women; (b) raised blood pressure (≥130/85 mm 
Hg) or receiving treatment for hypertension; (c) raised fasting plasma glucose (≥5.6 mmol/L 
or ≥100 mg/dL) or previously diagnosed type 2 diabetes; (d) raised plasma triglycerides (≥1.7 
mmol/L or ≥150 mg/dL); and (e) reduced HDL-cholesterol (<1.00 mmol/L or <40 mg/dL in 
men and <1.30 mmol/L or <50 mg/dL in women) 
90
. Volunteers with CRP levels ≥11mg/L 
(4.8%) were excluded due to a suspected inflammatory or infectious condition, leaving 1,902 
participants available for analyses.  
 PWV was measured using a volume-plethysmographic apparatus with an automatic 
waveform analyzer (Colin VP1000; Colin Medical Technology, Komaki, Japan). 
Measurements were taken with volunteers lying in a supine position after 5 minutes of rest. 
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Occlusion and monitoring cuffs were placed around both sites of the lower legs and upper 
arms. Pressure waveforms of the brachial and tibial arteries were then recorded 
simultaneously using semiconductor plethysmographic and oscillometric pressure sensors. 
These waveforms allow the determination of the time interval between the initial rise in the 
brachial and tibial pressure waveforms (T). The path length from the suprasternal notch to the 
elbow (La) and also from the suprasternal notch to the ankle (Lb) were automatically 
statistically determined from the patient’s height. PWV was calculated using the formula 
PWV ¼(Lb-La)/T. Measurements of the left and right brachial-to-ankle PWV were obtained 
for an average of 10 seconds. The method validity has been reported previously, with an 
inter-observer coefficient of variation of 8.4% and intra-observer coefficient of variation of 
10.0% 
137
. The average of the left and right brachial-to-ankle PWV was used for subsequent 
analyses. 
 
4.3.3. Statistical methods 
The independent effects of seated RHR and the MetS on CVD status were first examined. 
Subsequently these parameters were used to stratify the participants into four groups 1: Low 
RHR/no-MetS, 2: High RHR/no-MetS, 3: Low RHR/MetS and 4: High RHR/MetS. 
Comparisons between groups were performed by ANOVA with a Bonferroni post-hoc test 
for continuous parameters, and χ2 test with P for linear-by-linear test for categorical 
variables. All variables following a non-normal distribution were logarithmically transformed 
and their geometric means and 95% CIs presented. Otherwise data are presented as Mean±SD 
for continuous parameters or prevalence for categorical variables.  
 Associations were tested using three hierarchical models derived from multivariate 
logistic regression. Model 1 included age (continuous) and sex as covariates. Model 2 further 
adjusted for lifestyle factors including; smoking (never, ever), alcohol (never, ever), physical 
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activity (MET-minutes/week), and personal history of CVD (yes, no), which volunteers 
reported if a physician had ever told them they had experienced; hypertension, dyslipidaemia, 
valvular heart disease, CHD, stroke, angina pectoris, MI, peripheral heart disease, rheumatic 
heart disease or any other CVD-related events. Finally, model 3 additionally adjusted for 
socio-economic measures including; education level (primary or below, middle, or college or 
above) and personal income (<10,000, ≥10,000-<15,000 and ≥15,000 Yuan). For the purpose 
of our analyses, PWV was dichotomized into low and high risk groups based on the 75% cut-
point (16.98 m/s). For comparison, we additionally explored the relationship across each of 
the stratified groups using the median cut-point for PWV (14.80 m/s). All statistical tests 
were 2-tailed, and statistical significance was defined as P <0.05. Analyses were conducted 
using Statistical Software for Social Sciences, version 18 (SPSS, Chicago, Illinois, USA).  
 
4.4. RESULTS 
 
Demographic characteristics are presented in Table 4.1. The prevalence of those with a high 
RHR was 24.9% (n = 473), while 21.2% (n = 403) were classed as having the MetS. Of these 
MetS participants, 114 (28.3%) had a high RHR while the remaining 289 (71.2%) volunteers 
had a low RHR (Table 4.1). Physical activity levels were greatest in those who had a low 
RHR without the presence of the MetS (P = 0.006). Between-group differences were 
observed for waist circumference and BMI (P <0.001). Several parameters including PWV 
(Figure 4.1), blood pressure, fasting glucose, glycosylated haemoglobin, lipids and CRP were 
significantly higher in those with a high RHR and the MetS whilst HDL-cholesterol was 
significantly lower (Table 4.1). No interaction effect was observed between RHR and the 
MetS (P = 0.52).    
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Table 4.1. Baseline characteristics  
 
Low RHR/no-MetS 
(n=1,140) 
High RHR/no-MetS 
(n=359) 
Low RHR/MetS 
(n=289) 
High RHR/MetS 
(n=114) P value
# 
Age (Years) 59.0±6.8 58.5±6.9 60.8±6.9
*†
 60.6±7.0 <0.001 
Male 48.8% 51.0% 53.6% 43.9% 0.689 
Heart Rate (beats/minute) 71±7 91±7
*
 72±7
†
 92±7
*§
 <0.001 
Pulse Wave Velocity (m/s) 14.8±2.8 15.6±2.7
*
 16.6±3.0
*†
 17.4±3.1
*†
 <0.001 
Waist Circumference (cm) 76.2±7.9 76.8±7.8 86.0±8.0
*†
 86.2±9.0
*†
 <0.001 
Body mass index (kg/m
2
) 23.0±2.7 23.0±2.7 26.1±2.6
*†
 25.9±2.9
*†
 <0.001 
Fasting glucose (mg/dL) 94.22 (93.67, 94.93) 97.82 (95.83, 99.62)
*
 108.44 (106.10, 110.97)
*†
 116.91 (110.79, 123.40)
*†§
 <0.001 
Glycosylated haemoglobin (%) 5.9 6.0 6.3
*†
 6.7
*†§
 <0.001 
Impaired fasting glucose 16.6% 27.3% 59.5% 61.4% <0.001 
Type 2 diabetes mellitus 2.1% 3.6% 12.5% 16.7% <0.001 
Total cholesterol (mg/dL) 223.89±40.60 224.28±41.37 231.24±43.31
*
 234.72±45.63
*
 0.006 
LDL-cholesterol (mg/dL) 129.15±25.52 129.54±26.29 133.02±25.90 136.89±28.61
*
 0.003 
HDL-cholesterol (mg/dL) 64.19 ± 14.69 62.64±15.08 51.43±12.37
*†
 50.65±12.37
*†
 <0.001 
Triglyceride (mg/dL) 116.03 (113.37, 119.57) 129.88 (103.87, 130.20) 221.43 (208.14, 235.60)
*†
 237.37 (214.34, 263.06)
*†
 <0.001 
Dyslipidaemia 41.8% 44.6% 70.2% 73.7% <0.001 
Systolic blood pressure (mm/Hg) 123±20 126±18 142±20
*†
 142±19
*†
 <0.001 
Diastolic blood pressure (mm/Hg) 72±10 75±10
*
 81±10
*†
 81±10
*†
 <0.001 
Arterial hypertension 27.0% 31.5% 74.7% 69.3% <0.001 
CVD history 35.2% 34.0% 58.2% 50.9% <0.001 
C-reactive protein (mg/L) 1.13 (1.06, 1.19) 1.34 (1.20, 1.50)
*
 1.92 (1.72, 2.15)
*†
 2.09 (1.75, 2.49)
*†
 <0.001 
Current smoker 39.8% 42.3% 43.7% 38.1% 0.518 
Current alcohol user 59.4% 52.9% 58.5% 60.2% 0.635 
Physical activity (MET-minutes/week) 3,167 (2,973-3,373) 2,741 (2,224-2,886)
*
 2,784 (2,455-3,157) 3,128 (2,643-3,702) 0.006 
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Table 4.1. Continued      
 
Low RHR/no-MetS 
(n=1,140) 
High RHR/no-MetS 
(n=359) 
Low RHR/MetS 
(n=289) 
High RHR/MetS 
(n=114) P value
# 
Education      
   College or above 12.9% 10.6% 14.9% 14.0% 0.059 
   Middle 61.4% 61.8% 54.9% 46.5%  
   Primary or below 25.7% 27.6% 30.2% 39.5%  
Personal income (Yuan/USD)      
   ≥15,000/2,292  14.7% 16.6% 14.3% 14.7% 0.088 
  ≥10,000-<15,000/≥1,528-<2,292 63.6% 62.7% 60.5% 51.4%  
   <10,000/<1,528 21.7% 20.7% 25.2% 33.9%  
Data are presented as mean±SD, geometric mean (95% confidence interval) or percentage values. 
#
ANOVA with Bonferroni for continuous data or χ
2
 test for 
categorical data was used. 
*
P <0.05 when compared to Low RHR/no-MetS; 
†
P <0.05 when compared to High RHR/no-MetS; 
§
P <0.05 when compared to 
Low RHR/MetS. Dyslipidaemia was defined as total cholesterol ≥200 mg/dL, triglycerides ≥150 mg/dL or lipid lowering agents. Abbreviations; LDL = Low-
density lipoprotein, HDL = High-density lipoprotein, CVD = cardiovascular disease, MET = metabolic equivalent, USD = United States Dollar. 
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Figure 4.1. Brachial-to-ankle-pulse wave velocity according to seated resting heart rate 
(RHR) and the metabolic syndrome (MetS) groups. Values presented are geometric 
means with 95% CIs in meters per second (m/s). 
*
P <0.05 when compared to the Low 
RHR/no-MetS group; 
**
P <0.05 when compared to the High RHR/no-MetS group; 
***
P 
<0.05 when compared to the Low RHR/MetS group. 
 
  
 In Figure 4.2, mutually adjusted logistic regression revealed a high RHR and the MetS 
were independently associated with PWV (P <0.001, respectively), indicating both contribute 
separately towards increasing the risk of this cardiovascular proxy. Further, in Table 4.2 we 
observed those with a high RHR, the MetS, or both, had a greater adjusted OR for increased 
PWV (Ptrend <0.001 respectively). Through additional exploratory analysis using the median 
as the cut-point for PWV, we found a raised RHR, diagnosis of the MetS, and both combined, 
were similarly linked to an elevated PWV following adjustment; OR [95 % CI] = 2.18 [1.64, 
2.89], 2.73 [1.97, 3.80] and 5.28 [3.10, 9.00], Ptrend <0.001 respectively. To address the 
potential issue of reverse causality, we examined only those who had reported good or very 
good health (n = 1,594), and found the ORs were virtually the same. Further exclusion of 
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volunteers with potential bradycardia (RHR <50 bpm), or those on blood pressure-lowering 
medications did not affect these findings (data not shown). 
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Figure 4.2 Independent associations of seated resting heart 
rate (RHR) and the metabolic syndrome (MetS) with pulse wave 
velocity. Values are dichotomous, and derived from mutually 
adjusted multivariate analyses which included age, sex, 
smoking, drinking, and physical activity, prior history of 
cardiovascular disease, education and personal income. 
 
 
 
Table 4.2 Odds ratios (95% CI) for the risk of elevated pulse wave velocity among 1,902 older Chinese 
subjects according to seated resting heart rate and the metabolic syndrome 
 Model
1
 Model
2
 Model
3
 
Low RHR/no-MetS 1 (Reference) 1 (Reference) 1 (Reference) 
High RHR/no-MetS 1.64 (1.17, 2.30) 1.61 (1.14, 2.27) 1.63 (1.15, 2.30) 
Low RHR/MetS 2.66 (1.90, 3.73) 2.40 (1.70, 3.38) 2.35 (1.66, 3.33) 
High RHR/MetS 4.26 (2.65, 6.84) 4.02 (2.49, 6.49) 3.87 (2.39, 6.28) 
Ptrend <0.001 <0.001 <0.001 
Model
1
 adjusted for age and sex. Model
2 
additionally adjusted for smoking, drinking, physical activity and 
prior history of cardiovascular disease. Model
3
 further adjusted for education and personal income. 
Abbreviations; CI = confidence interval; RHR = resting heart rate; MetS = metabolic syndrome. 
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4.5. DISCUSSION 
 
In the present study, we described the independent and combined effects of physical fitness 
as measured by RHR, and the MetS on a surrogate marker of CVD in older Chinese. We 
found the risk of a high PWV was independently associated with RHR and the MetS. These 
data confirm previous studies derived from Caucasians, whereby physical fitness was 
identified as an important predictor of cardiovascular mortality 
17, 84
, while the MetS was 
associated with an approximately two-fold increase in CVD risk 
138, 139
. Further, participants 
who presented with both a raised RHR and the MetS had an increased risk for high PWV by 
almost 400%, which remained robust after controlling for a range of potential confounders.   
Several epidemiological studies have addressed the importance of RHR as a predictor 
for CVD. Mounting evidence shows that RHR >80-85 bpm is directly associated with the risk 
of developing hypertension and atherosclerosis, and is a strong predictor of cardiovascular 
morbidity and mortality 
140
. For instance, in the HARVEST study, RHR was found to be a 
significant marker for the development of hypertension, even after many clinical variables 
including physical activity were taken into consideration 
29
. In the CASS investigation, RHR 
emerged as a significant predictor for CVD mortality independent of other risk factors 
67
. 
Also, RHR was found to be strongly correlated with the severity of atherosclerosis among 
men who had developed MI at a young age 
141
. Data from several other studies examined in a 
recent review provide additional evidence linking RHR to a greater risk of all-cause and CVD 
mortality, which pertains to both the general population and in those already at-risk for CVD 
142
. In light of this evidence, recent reviews have recommended that improving physical 
fitness (i.e. reducing pulse rate) may have important benefits towards cardiovascular health 
143, 144
. Several clinical and experimental studies have also suggested that a reduced RHR may 
increase coronary endothelial function while attenuating atheroprogression 
112, 145
. These data 
along with our own support the relevance of examining the impact of reducing RHR, perhaps 
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lowering the risk associated with CVD morbidity and mortality. Subsequently, a potential 
role for RHR and its modulation should be included in prospective cardiovascular guidance 
documents 
142
. 
Previous research has indicated physical fitness is influenced by dysfunctional ANS 
activity 
146
, suggesting that progressive autonomic damage may be involved in elevating 
RHR 
147
. Autonomic dysfunction is characterized by a sympathetic-parasympathetic 
imbalance which may also, in part, be attributable to the individual components of the MetS 
109, 148
. For instance, patients with a faster RHR tend to have an abnormal metabolic profile 
147, 149
. This was shown in a population-based study of healthy adults 
109
, whereby fasting 
plasma glucose was associated with poor HRR following an exercise test. This association 
was particularly evident among volunteers whose RHR was ≥80 bpm 109. Likewise, 
Shishehbor et al. 
148
 found individuals in the highest quartile of the triglyceride-to-HDL-
cholesterol ratio, a strong correlate of insulin resistance 
150
, had a significantly poor HRR 
post-exercise. In the present study, we observed the risk of a high PWV doubled in those with 
a fast RHR even in the absence of the MetS, suggesting the risk of experiencing a 
cardiovascular event extends below those with a fast RHR and the MetS, and not just the 
MetS. The current findings may well reflect subtle changes of sympathetic and 
parasympathetic imbalance that occur as a consequence of minimal abnormalities to the 
metabolic profile. It seems those unfit individuals who might otherwise appear healthy may 
actually be at an increased risk for CVD.  
Lack of consideration of fitness in studies examining CVD risk suggests their healthy 
control groups may have included participants with poorer physical health as determined by a 
high RHR, resulting in underestimation of CVD risk. We therefore recommend future studies 
addressing the risk of CVD in those with the MetS should consider physical fitness when 
determining a reference group, which is achievable in most studies if pulse rate is used as a 
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surrogate. The present study carries its inherent limitations. Given its cross-sectional nature, 
confirmation using a longitudinal design to detect the causative role of physical fitness on the 
incidence of CVD is required. Nonetheless, our study adds value to the existing literature 
highlighting RHR as a simple, easy-to-measure marker with implications towards the 
prediction of CVD risk. The study’s large sample size allowed for us to establish the 
independent effects of physical fitness and the MetS in subgroups. Even after adjusting for 
several confounding factors, our findings remained robust. In addition, we controlled for 
acute inflammatory or infectious conditions and further controlled for reverse causality by 
excluding those with poor self-reported health, strengthening our findings. 
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CHAPTER FIVE 
 
5.0. SUSTAINED ELEVATED HEART RATE PREDICTS INCIDENT 
CARDIOVASCULAR MORTALITY IN APPARENTLY HEALTHY MIDDLE-AGED 
BRITISH ADULTS: FROM THE EUROPEAN PROSPECTIVE INVESTIGATION 
INTO CANCER AND NUTRITION-NORFOLK STUDY 
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5.1. ABSTRACT 
 
Despite increasing evidence underlining the relationship between a raised heart rate and 
cardiovascular mortality, this easily measurable, inexpensive, clinical parameter continues to 
be overlooked as a potential risk factor in the general population. Thus, we aimed to promote 
the clinical value of sustained tachycardia as a predictor of death due to cardiovascular 
disease in a cohort of generally healthy middle-aged British adults. A total of 25,639 
participants (men n = 11,607 and women n = 14,032) aged between 39 and 79 years were 
followed prospectively. Risk estimates for cardiovascular mortality according to quartiles of 
resting heart rate were determined using hierarchical multivariate Cox proportional hazards 
regression. During a median follow-up time of 14.9 years, 1,734 incident cases of 
cardiovascular mortality were reported. In the upper-most quartile of resting heart rate, the 
overall adjusted risk for cardiovascular mortality was HR (95% CI) 1.19 (1.03-1.37). Sex-
specific analyses revealed the strongest associations were found among the men HR (95% 
CI) 1.37 (1.14-1.64). No association was observed in the women. In conclusion, we 
recommend elevated heart rate should no longer be neglected as a predictor of cardiovascular 
mortality, at least in the general population.       
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5.2. INTRODUCTION 
 
Over the past few decades, a number of epidemiological studies have been undertaken to 
examine the relationship of accelerating RHR with adverse cardiovascular outcome. One of 
the earliest in the series to describe this association was the Chicago Employee Study 
53
. 
Across three groups of middle-aged Caucasian males, Dyer and colleagues 
53
 documented 
that a rapid RHR predicted both total and CVD mortality. Several other observational studies 
have indeed highlighted a similar association including, but not constrained to, the 
Framingham Heart Study 
54
, the British Regional Heart Study 
57
, the MATISS Project 
63
, and 
NHANES 
55
. Despite literature emphasizing the independent contribution of sustained 
tachycardia for predicting poor cardiovascular prognosis, its current role as a modifiable 
determinant of health status remains suboptimal and lacks consideration, particularly in the 
general population. Therefore, the present investigation sought to further ascertain the 
importance of RHR as a predictor of CVD mortality in a large cohort of generally healthy 
middle-aged adults.   
 
5.3. METHODS 
 
5.3.1. Study design and population 
The EPIC-Norfolk study is a prospective cohort study designed to investigate the relationship 
between diet, nutritional status, lifestyle and environmental factors for the risk of developing 
a range of chronic diseases 
151
. A total of 25,639 participants (men n = 11,607 and women n = 
14,032) aged between 39 and 79 years, were enrolled in the EPIC-Norfolk study. Thirty five 
general practices from the city of Norwich and surrounding rural towns were chosen as the 
study area, and all individuals within the age range in each general practise database were 
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invited to participate, with the exception of those deemed unsuitable by the general 
practitioner. Those who provided signed informed consent were invited to participate in a 
health examination. The EPIC-Norfolk study was approved by the Norfolk Local Research 
Ethics Committee. 
 
5.3.2. Baseline examination 
Participant examination began in 1993 and was completed at the end of 1997. An overall 
summary of the recruitment process, study design, and population characteristics have been 
described elsewhere 
152
. In brief, participants completed a detailed health and lifestyle 
questionnaire including questions on smoking status (current, former, never), and a four-level 
(e.g., 1 = inactive, 2 = moderately inactive, 3 = moderately active, and 4 = active) physical 
activity index derived from the validated EPIC short physical activity questionnaire 
153
. 
Information regarding prevalent hypertension, dyslipidaemia, and diabetes was based on self-
reported physician diagnosis. From the baseline questionnaire, we further obtained 
information about self-reported use of anti-hypertensive and lipid-lowering therapy. At 
baseline, participants attended for a health check whereby a range of anthropometric indices 
were recorded by trained nurses using standardised procedures 
154
. Waist was measured in 
cm, horizontally around the smallest circumference between the ribs and iliac crest. When the 
minimum circumference was not possible to identify, the minimum circumference at the level 
of the navel was used instead. BMI was estimated as weight (kg) divided by height (m
2
). 
Blood pressure was determined using an Accutorr sphygmomanometer (Datascope, UK). 
Two measurements were taken 30 seconds apart after the participant had been seated for 3 
min. RHR was also obtained using an Accutorr non-invasive blood pressure monitor. 
Likewise, 2 measures were taken 30 seconds apart following a 3 min rest in the seated 
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position. For the purpose of this study, we used the mean of the 2 measures for blood 
pressure and RHR in analyses.  
 
5.3.3. Laboratory analyses 
Samples of non-fasted venous blood were collected by venepuncture into plain and citrate 
monovettes, while participants were in the supine position. Blood samples for assay were 
immediately stored at 4
o
C. Early the following morning, samples were transported to the 
department of clinical biochemistry, at the University of Cambridge for processing. All 
remaining samples were stored at -80 C for further analyses. Total-, and HDL-cholesterol, as 
well as triglycerides (mmol/L) were measured using the RA 1000 (Bayer Diagnostics, 
Basingstoke). LDL-cholesterol (mmol/L) was determined using Friedewald criteria 
155
. CRP 
(mg/L) concentrations taken from serum were measured using a full-range, high-sensitivity 
assay on an Olympus AU640 clinical chemistry analyser (Olympus, UK, Ltd). Absolute 
white blood cell enumeration (10
3
/µL) was obtained using a Coulter MD18 Haemolyser 
(Coulter Corporation, Miami, FL, USA). Fibrinogen (g/L) was measured using the Clauss 
method 
156
.          
 
5.3.4. Study endpoint 
Information on vital status was obtained at the UK Office of National Statistics. Follow-up 
time for mortality was calculated for each individual from time of entry to the study to time 
of death, or up until February 29, 2008. The primary endpoint in this study was death due to 
CVD. Qualified nosologists who were masked to any data of the study probands except for 
the information from the death certificates classified those who died from a CVD event. 
Death from CVD causes were defined using the International Classification of Diseases ninth 
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(ICD-9) and tenth (ICD-10) edition codes: CVD mortality (ICD-9 401–448, or ICD-10 I10–
I79), CHD mortality (ICD-9 410–414 or ICD-10 I20–I25), and stroke mortality (ICD-9 430–
438 or ICD-10 I60–I69). 
 
5.3.5. Statistical methods 
A total of 73 (0.3%) participants were excluded due to incomplete resting HR measurement 
at baseline. Hence the analytic sample consisted of 25,566 (99.7%) men and women. All 
continuous covariates were checked for normality and those which visually deviated on 
inspection of the frequency distribution were transformed onto the natural log (base e) scale. 
The study sample was summarised by comparing participants according to RHR quartiles, 
reporting the mean±SD (or median and inter quartile ranges [IQR] for those variables which 
were skewed) for continuous measures, and proportions for categorical variables. 
Comparisons between quartiles were performed by ANOVA with a Bonferroni post-hoc test 
for continuous parameters, and two-way tables of frequency counts with Pearson’s χ2 test for 
categorical variables. Kaplan-Meier survival function with Log rank test for equality was 
used to evaluate the predictive ability of RHR quartiles with CVD mortality. Due to funding, 
some covariates measured in the present analyses were restricted to approximately 71-86% of 
the entire cohort. Thus, we employed multiple imputation procedures permitting the 
substitution of each missing data point with an imputed value drawn from a distribution of 
the present study’s complete data. Details of the variables which underwent multiple 
imputations are outlined in Table 5.1. 
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Table 5.1. Reporting multiple imputation according to missing data 
 Observations per m
† 
 
Variable Complete Incomplete Imputed Total
ǂ 
Glucose 18,639 7,000 6,949 25,639 
C-reactive protein 18,586 7,053 7,002 25,639 
Total white blood cells 18,195 7,444 7,396 25,639 
Fibrinogen 22,171 3,468 3,425 25,639 
†
Reported imputed datasets created were m=5. 
ǂ
Complete + Incomplete = Total number of observations.  
 
Time-to-event analyses were then performed using stepwise multivariate Cox 
proportional hazards regression, reporting HRs with 95% CIs. Two models were fitted for 
analyses; Model 1 adjusted for age and sex, and Model 2 additionally corrected for smoking, 
physical activity, BMI, waist circumference, total-, LDL-, and HDL-cholesterol, 
triglycerides, dyslipidaemia, lipid-lowering therapy, glucose, type 2 diabetes, systolic and 
diastolic blood pressure, hypertension, anti-hypertensive treatment, CRP, fibrinogen, and 
total white blood count. To better understand the relationship between RHR and CVD 
mortality, the latter analyses were performed examining RHR as a categorical (quartiles) and 
continuous (10 bpm increment) parameter, respectively. As anti-hypertensive therapy may 
influence RHR, participants who reported the use of these agents were excluded from 
secondary analyses in order to explore whether the initial findings would be affected. Lastly, 
to minimise potential bias due to subclinical and undetected pre-existing disease at baseline, 
we also carried out the analyses removing those who died within 2 years of enrolment. The 
above analyses were considered significant at a P-value of <0.05 (two-tailed). All 
calculations were performed using STATA version 11.2 (StataCorp, Texas). 
 
5.4. RESULTS 
During a median follow-up time of 14.9 years, 1,734 (6.8%) deaths occurred due to CVD 
(incidence, 4.4 per 1,000 person-years). Overall, there was a greater incidence of CVD 
mortality in the highest quartile of RHR as compared to the others (Table 5.2 and Figure 5.1). 
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Table 5.2. Population characteristics at baseline according to quartiles of resting heart rate 
 Resting heart rate quartiles 
 Q1 Q2 Q3 Q4 P value
# 
Patients (n) 6,659 6,451 6,300 6,156  
All-cardiovascular mortality (%) 7.2 6.1 6.0 7.8 <0.0001 
Age (years) 59.6±9.3 58.6±9.3 58.9±9.3 59.7±9.4 <0.0001 
Male sex (%) 59.1 44.9 39.3 36.9 <0.0001 
Resting heart rate (beats/minute) 57±4 66±2 74±2 87±8 <0.0001 
Waist circumference (cm) 89.3±11.9 87.6±12.3 87.6±12.4 88.9±13.0 <0.0001 
Body mass index (kg/m
2
) 26.1±3.5 26.2±3.8 26.3±4.0 26.8±4.4 <0.0001 
Smoking status (%)      
   Never 44.5 45.7 46.2 47.3 <0.0001 
   Former 47.0 43.5 40.5 38.0  
   Current 8.5 10.8 13.3 14.7  
Physical activity status (%)      
   Inactive 27.4 28.7 30.2 36.7 <0.0001 
   Moderately inactive 27.2 28.8 29.8 29.0  
   Moderately active 24.8 23.1 22.0 20.1  
   Active 20.6 19.4 18.0 14.2  
Glucose (mmol/L) 3.90 (3.40-4.50) 4.00 (3.40-4.60) 4.10 (3.50-4.80) 4.30 (3.60-5.20) <0.0001 
Type 2 diabetes (%) 2.0 1.8 2.3 3.1 <0.0001 
Systolic blood pressure (mmHg) 133±18 133±18 135±18 140±18 <0.0001 
Diastolic blood pressure (mmHg) 79±10 81±10 83±10 87±11 <0.0001 
Hypertension (%) 62.3 60.1 65.0 75.4 <0.0001 
Blood pressure lowering therapy (%) 25.4 15.4 15.1 18.7 <0.0001 
Lipids (mmol/L)      
   Total cholesterol 6.00 (5.30-6.80) 6.00 (5.40-6.80) 6.10 (5.40-6.90) 6.20 (5.50-7.00) <0.0001 
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Table 5.2. continued 
 Resting heart rate quartiles  
 Q1 Q2 Q3 Q4 P value
# 
   LDL-cholesterol 3.87 (3.23-4.57) 3.85 (3.23-4.54) 3.90 (3.25-4.59) 3.91 (3.29-4.67) 0.004 
   HDL-cholesterol 1.29 (1.09-1.59) 1.40 (1.10-1.70) 1.40 (1.10-1.70) 1.41 (1.09-1.71) <0.0001 
   Triglycerides 1.49 (1.00-2.09) 1.52 (1.10-2.20) 1.57 (1.18-2.20) 1.72 (1.20-2.50) <0.0001 
Dyslipidaemia (%) 67.8 69.0 71.0 76.3 <0.0001 
Lipid lowering therapy (%)  1.8 1.4 1.3 1.4 0.10 
Markers of inflammation      
   C-reactive protein (mg/L) 1.30 (0.70-2.70) 1.50 (0.70-3.10) 1.60 (0.80-3.40) 1.90 (0.90-4.00) <0.0001 
   Total white blood cells (10
3
/µL) 6.09 (5.19-7.09) 6.19 (5.29-7.29) 6.39 (5.39-7.50) 6.60 (5.60-7.89) <0.0001 
   Fibrinogen (g/L) 2.80 (2.37-3.27) 2.85 (2.40-3.35) 2.90 (2.46-3.40) 3.00 (2.50-3.50) <0.0001 
Categorical variables are shown as percentages, and continuous data are presented as mean±SD, or median (IQR) for skewed data. 
#
One-
way ANOVA was conducted for continuous parameters, and χ
2
 test for categorical variables. LDL = low-density lipoprotein; HDL = high-
density lipoprotein. 
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Figure 5.1. Kaplan-Meier curve for cardiovascular mortality according to resting heart 
rate quartiles. The log-rank test indicated significant differences between quartiles (P 
<0.0001). 
 
  Likewise, those in the highest quartile were older, had a higher BMI, consumed more 
tobacco and tended to be less physically active. Similar observations were observed in sex-
specific analyses (Tables 5.3 and 5.4). Of the lipids, there were higher concentrations of total-
, LDL-, and HDL-cholesterol, as well as triglycerides and glucose for participants in the 
upper-most quartile of RHR (Table 5.2). In men, no relationship was found for RHR with 
both LDL- and HDL-cholesterol (Table 5.3). Overall and sex-specific analyses also revealed 
both systolic and diastolic blood pressures were higher among participants in the fourth 
quartile of RHR as compared to those in the lower quartiles (Tables 5.2 to 5.4). As expected, 
the proportion of type 2 diabetes, arterial hypertension and dyslipidaemia were all 
significantly higher among those in the top quartile of RHR (Tables 5.2 to 5.4). Conversely, 
self-reported use of anti-hypertensive therapy was greater among participants in the lowest 
quartile of RHR. The inflammatory markers CRP, total white cell count, and fibrinogen were 
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all higher among individuals belonging to the fourth quartile of RHR (Table 5.2). Similar 
findings for the inflammatory markers based on gender-specific analyses are reported in 
Tables 5.3 and 5.4. 
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Table 5.3. Sex-specific characteristics at baseline according to quartiles of resting heart rate 
 Resting heart rate quartiles (Men) 
 Q1 Q2 Q3 Q4 P value
# 
Patients (n) 3,936 2,898 2,473 2,269  
All-cardiovascular mortality (%) 8.7 8.0 8.1 11.2 <0.0001 
Age (years) 60.1±9.3 59.0±9.3 59.0±9.3 60.1±9.2 <0.0001 
Resting heart rate (beats/minute) 57±5 67±2 74±2 87±8 <0.0001 
Waist circumference (cm) 95.1±9.2 95.3±9.6 96.0±9.8 98.0±10.7 <0.0001 
Body mass index (kg/m
2
) 26.3±3.1 26.4±3.2 26.5±3.4 27.0±3.7 <0.0001 
Smoking status (%)      
   Never 36.1 33.2 31.8 30.0 <0.0001 
   Former 55.6 55.0 53.3 53.4  
   Current 8.3 11.8 14.9 16.6  
Physical activity status (%)      
   Inactive 26.9 30.4 31.1 38.0 <0.0001 
   Moderately inactive 24.3 24.6 25.2 24.6  
   Moderately active 25.7 22.4 22.0 19.9  
   Active 23.1 22.6 21.7 17.5  
Glucose (mmol/L) 3.90 (3.40-4.50) 4.00 (3.50-4.70) 4.10 (3.50-4.90) 4.30 (3.70-5.30) <0.0001 
Type 2 diabetes (%) 2.5 2.8 3.4 4.4 <0.0001 
Systolic blood pressure (mmHg) 135±17 136±17 138±17 142±18 <0.0001 
Diastolic blood pressure (mmHg) 81±10 84±11 86±11 90±12 <0.0001 
Hypertension (%) 67.2 67.3 72.3 80.8 <0.0001 
Blood pressure lowering therapy (%) 23.8 14.8 15.0 18.8 <0.0001 
Lipids (mmol/L)      
   Total cholesterol 5.89 (5.19-6.59) 5.90 (5.30-6.60) 6.00 (5.29-6.70) 6.10 (5.30-6.90) <0.0001 
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Table 5.3. continued 
 Resting heart rate quartiles (Men)  
 Q1 Q2 Q3 Q4 P value
# 
   LDL-cholesterol 3.88 (3.28-4.53) 3.84 (3.26-4.46) 3.90 (3.30-4.52) 3.86 (3.26-4.59) 0.46 
   HDL-cholesterol 1.20 (1.00-1.40) 1.20 (1.00-1.40) 1.20 (1.00-1.40) 1.20 (1.00-1.40) 0.47 
   Triglycerides 1.59 (1.20-2.29) 1.70 (1.20-2.50) 1.80 (1.30-2.60) 2.00 (1.40-2.90) <0.0001 
Dyslipidaemia (%) 69.5 72.4 75.1 79.4 <0.0001 
Lipid lowering therapy (%)  2.0 1.2 1.3 1.3 0.06 
Markers of inflammation      
   C-reactive protein (mg/L) 1.30 (0.70-2.70) 1.50 (0.70-3.00) 1.60 (0.80-3.30) 1.90 (0.90-4.00) <0.0001 
   Total white blood cells (10
3
/µL) 6.19 (5.29-7.19) 6.29 (5.39-7.39) 6.39 (5.59-7.59) 6.79 (5.79-8.00) <0.0001 
   Fibrinogen (g/L) 2.73 (2.30-3.20) 2.80 (2.34-3.30) 2.90 (2.40-3.40) 2.90 (2.50-3.50) <0.0001 
Categorical variables are shown as percentages, and continuous data are presented as mean±SD, or median (IQR) for skewed data. 
#
One-
way ANOVA was conducted for continuous parameters, and χ
2
 test for categorical variables. LDL = low-density lipoprotein; HDL = high-
density lipoprotein. 
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Table 5.4. Sex-specific characteristics at baseline according to quartiles of resting heart rate 
 Resting heart rate quartiles (Women) 
 Q1 Q2 Q3 Q4 P value
# 
Patients (n) 2,723 3,553 3,827 3,887  
All-cardiovascular mortality (%) 4.9 4.5 4.7 5.8 0.06 
Age (years) 59.0±9.2 58.3±9.2 58.8±9.2 60±9.5 <0.0001 
Resting heart rate (beats/minute) 58±4 67±2 74±2 87±7 <0.0001 
Waist circumference (cm) 81.0±10.2 81.3±10.5 82.1±10.7 83.8±11.5 <0.0001 
Body mass index (kg/m
2
) 25.9±4.1 26.0±4.2 26.2±4.3 26.7±4.7 <0.0001 
Smoking status (%)      
   Never 56.7 55.8 55.7 57.4 <0.0001 
   Former 34.4 34.2 32.1 29.0  
   Current 8.9 10.0 12.2 13.6  
Physical activity status (%)      
   Inactive 28.2 27.3 29.5 35.9 <0.0001 
   Moderately inactive 31.2 32.3 32.9 31.5  
   Moderately active 23.6 23.7 22.0 20.1  
   Active 17.0 16.7 15.6 12.5  
Glucose (mmol/L) 3.90 (3.40-4.40) 3.90 (3.40-4.50) 4.00 (3.40-4.70) 4.20 (3.60-5.10) <0.0001 
Type 2 diabetes (%) 1.3 1.0 1.5 2.3 <0.0001 
Systolic blood pressure (mmHg) 130±19 131±18 133±18 139±19 <0.0001 
Diastolic blood pressure (mmHg) 76±10 79±10 81±11 86±11 <0.0001 
Hypertension (%) 55.1 54.2 60.2 72.3 <0.0001 
Blood pressure lowering therapy (%) 27.7 15.9 15.2 16.6 <0.0001 
Lipids (mmol/L)      
   Total cholesterol 6.09 (5.39-6.89) 6.14 (5.39-7.00) 6.19 (5.39-7.00) 6.29 (5.59-7.19) <0.0001 
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Table 5.4. continued 
 Resting heart rate quartiles (Women)  
 Q1 Q2 Q3 Q4 P value
# 
   LDL-cholesterol 3.87 (3.19-4.64) 3.88 (3.20-4.61) 3.90 (3.20-4.69) 3.98 (3.29-4.73) 0.0005 
   HDL-cholesterol 1.51 (1.29-1.79) 1.53 (1.31-1.78) 1.52 (1.29-1.81) 1.49 (1.28-1.77) 0.0009 
   Triglycerides 1.29 (0.89-1.79) 1.29 (0.89-1.90) 1.40 (1.00-2.00) 1.50 (1.09-2.19) <0.0001 
Dyslipidaemia (%) 65.4 66.5 68.3 74.5 <0.0001 
Lipid lowering therapy (%)  1.6 1.6 1.3 1.5 0.70 
Markers of inflammation      
   C-reactive protein (mg/L) 1.40 (0.70-2.90) 1.50 (0.70-3.20) 1.60 (0.80-3.40) 1.80 (0.80-4.00) <0.0001 
   Total white blood cells (10
3
/µL) 6.00 (5.09-7.00) 6.09 (5.19-7.19) 6.29 (5.29-7.50) 6.50 (5.50-7.79) <0.0001 
   Fibrinogen (g/L) 2.85 (2.40-3.30) 2.90 (2.41-3.40) 2.94 (2.50-3.48) 3.04 (2.60-3.57) <0.0001 
Categorical variables are shown as percentages, and continuous data are presented as mean±SD, or median (IQR) for skewed data. 
#
One-
way ANOVA was conducted for continuous parameters, and χ
2
 test for categorical variables. LDL = low-density lipoprotein; HDL = high-
density lipoprotein. 
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 Cox proportional hazard regression models for the risk of CVD mortality according to 
RHR quartiles are shown in Figure 5.2. Overall, after correcting for a range of covariates, 
those in the highest quartile of RHR had an increased risk of CVD mortality by 
approximately 20% (P =0.02). Sex-stratified analyses indicated the adjusted risk for CVD 
mortality increased further by almost 20% (P =0.001) in men. However, no association was 
observed among women. In Figure 5.3, a 10 bpm increment in RHR was associated with an 
increased adjusted risk of death due to CVD in the overall population HR (95% CI) = 1.05 
(1.01-1.10), P =0.02 and in males HR (95% CI) = 1.09 (1.03-1.15), P =0.002. Upon removal 
of those who reported the use of anti-hypertensive therapy (n = 4,408), we observed the 
initial findings did not differ materially for the entire cohort HR (95% CI) = 1.23 (1.01-1.48), 
P =0.03. On the other hand, the risk of CVD mortality slightly attenuated HR (95% CI) = 
1.28 (1.04-1.62), P =0.04 for men in the fourth quartile of RHR as compared to the first. 
Lastly, the results remained similar after excluding participants who died within 2 years of 
follow-up (n = 307) for the overall cohort HR (95% CI) = 1.16 (1.01-1.34), P =0.04 as well 
as in men HR (95% CI) = 1.33 (1.10-1.62), P =0.004. 
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Figure 5.2. Hazard ratio estimates (with 95% CIs) using multiple 
imputation methods for incident cardiovascular mortality according to 
resting heart rate quartiles. Multivariate model included age, sex 
(Overall), smoking, physical activity, body mass index, waist 
circumference, total-, LDL-, and HDL-cholesterol, triglycerides, 
dyslipidaemia, lipid-lowering therapy, glucose, type 2 diabetes, 
systolic and diastolic blood pressure, hypertension, anti-hypertensive 
treatment, high sensitivity C-reactive protein, fibrinogen, and total 
white blood count. 
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Figure 5.3. Hazard ratio estimates (with 95% CIs) using multiple imputation methods 
for incident cardiovascular mortality according to resting heart rate (per 10 
beats/minute increments). Multivariate model was adjusted as abbreviated in Figure 
5.2. 
†
Sex was included as a covariate in Overall only. 
 
 
5.5. DISCUSSION 
 
In this study, the integral relationship between elevated RHR and CVD mortality was 
consistent with a number of published data in the general population 
53, 54, 57, 60, 63
. Of 
particular note, a faster RHR was found to be a critical determinant of all-cardiovascular 
death in men, but not in women; though only a few investigations have reported a higher 
RHR as an independent predictor of CVD mortality in women 
55, 69, 110, 157
. 
 Consistently, several large population-based cohort studies with particularly lengthy 
follow-ups have emphasized the relevance of RHR as a significant predictor of 
cardiovascular risk. Across 30-years of follow-up, 894 incidents of CVD evolving from 5,070 
participants were documented in the Framingham Heart Study, of which the number of case 
fatalities increased impressively with antecedent RHR, and was most striking among men 
aged 35 to 64 years 
54
. In parallel, a study consisting of 5,713 asymptomatic working men 
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followed for a period of 23 years demonstrated the risk of sudden death due to MI increased 
in subjects with a RHR >75 bpm 
66
. Likewise, in the MATISS Project including 2,533 Italian 
middle-aged males who were followed for a combined duration of 24,457 person-years, RHR 
was found to be a robust independent predictor of total, CVD and non-CVD mortality 
63
. 
Collectively, these findings taken together with the present study observations underline the 
significance of RHR as an inexpensive, and easily measured clinical parameter for 
determining the risk of adverse CVD outcomes. 
 Moving forward, there appears little doubt that dysfunctional ANS activity plays a 
central role in the pathogenesis of a number of vascular anomalies. To this end, predominant 
sympathetic overactivity is a crucial feature in atherosclerotic plaque development via 
initiation of several haemodynamic (i.e., tachycardia, hypertension) and metabolic (i.e., 
hyperglycaemia, dyslipidaemia) alterations 
158
. In light of this conjecture, it may seem that 
RHR is merely a marker of ANS dysfunction rather than a risk factor per se. Despite this, 
ample literature supports the notion that a rapid RHR may intervene along a chain of events, 
thereby promoting CVD 
159, 160
. These mechanisms include, but are unlikely restricted to, 
disturbed haemodynamics, oxidative stress, vascular remodelling, endothelial dysfunction 
and inflammation 
158, 159
. Moreover, elevated RHR may, in part, induce myocardial ischemia 
by amplifying myocardial oxygen demand as well as inhibiting coronary blood flow 
159, 161
. 
We may add that these actions perhaps due to the involvement of RHR may subsequently 
enhance the progression of plaque vulnerability as well as erosion and rupture 
159
. 
 Accordingly, we speculate that slowing the RHR may prove a useful adjunct for 
interrupting the risk associated with CVD mortality. In the BEAUTIFUL study 
162
, the novel 
specific pulse rate-lowering agent ivabradine, afforded an opportunity to evaluate the efficacy 
of selectively slowing the RHR without altering other aspects of cardiac function. Here, the 
usefulness of ivabradine for lowering the primary endpoint was not achieved. However, 
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ivabradine did reduce a number of secondary outcomes including admission to hospital for 
fatal and non-fatal MI (36%), as well as coronary revascularization (30%). The Systolic Heart 
failure treatment with the If inhibitor ivabradine Trial (SHIFT) 
163
 further confirmed the 
importance of RHR reduction by ivabradine. Here, patients who received ivabradine 
treatment had fewer serious adverse cardiovascular events (n = 3,388 events) as compared to 
patients who received placebo (n = 3,847 events). Significantly, in the latter trial, intervention 
to modulate RHR successfully resulted in parallel modulation of CVD risk. In this respect, it 
may well be postulated that a raised RHR should be considered a risk factor for CVD. 
Undeniably, these reports provide a compelling basis to develop similar, well-designed, 
randomized controlled trials aimed at exclusively slowing the RHR, as a means of addressing 
the risk associated with vascular disorders. 
 Though the present study was prospective in nature, RHR was only measured 
at a single momentary time point. Further, there is significant diurnal variation in RHR, and 
thus, may not reflect sustained chronic tachycardia. It therefore remains to be confirmed in 
our cohort whether rapid RHR is itself a cause, or is purely associated with mortality. Almost 
7% less patients reported the use of anti-hypertensive treatment in the highest compared to 
the lowest quartile of RHR. Such agents are generally administered for the management of 
cardiac arrhythmias, which in part, slow the RHR. Therefore, this may have inflated the risk 
estimates observed in the present investigation. Nonetheless, we counter that after removing 
individuals who reported the use of anti-hypertensive medication, the results did not 
materially change. 
Though the relationship between RHR and CVD is well documented, it has remained 
neglected as a potential risk factor for some time. Only recently have current guidelines 
begun to recognize RHR as an important parameter with prognostic implications for 
cardiovascular health. The European Society of Cardiology and the European Society of 
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Hypertension 
164
 along with the Global Registry of Acute Coronary Events score 
165
 have 
since included RHR as a risk factor because of the growing body of evidence describing its 
relationship with CVD morbidity and mortality. Our data support the contention that RHR as 
an inexpensive, easily measured and modifiable risk factor should no longer be overlooked, 
especially among the general population. 
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CHAPTER SIX 
 
6.0. INFLUENCE OF RESTING HEART RATE ON MORTALITY IN PATIENTS 
UNDERGOING CORONARY ANGIOGRAPHY (FROM THE LUDWIGSHAFEN 
RISK AND CARDIOVASCULAR HEALTH STUDY) 
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6.1. ABSTRACT 
 
Several epidemiological studies have reported an association between elevated resting heart 
rate and reduced survival. The usefulness of resting heart rate in predicting endpoints in high-
risk patients is yet to be definitively established. The purpose of this study was to clarify the 
relation between resting heart rate with total and cardiovascular mortality in patients who had 
undergone coronary angiography. A total of 3,316 Caucasian individuals with availability of 
a coronary angiogram were prospectively followed from 2001-2011 (median 9.9 years). We 
explored the effect of resting heart rate on total and cardiovascular mortality, while correcting 
for a number of confounders. Patients in the highest quartile (resting heart rate ≥84 bpm) had 
a survival time reduced by 1.2 and 1.4 years for overall and cardiovascular mortality, 
respectively. Likewise, these patients had a significantly elevated adjusted risk for total (HR 
[95% CI] = 1.39 [1.17, 1.67], Ptrend <0.001) and cardiovascular mortality (HR [95% CI] = 
1.38 [1.08, 1.78], Ptrend =0.004). In conclusion, resting heart rate is an inexpensive, easily 
measured and modifiable predictor of mortality. 
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6.2. INTRODUCTION 
 
Numerous epidemiological studies have linked resting tachycardia to increased risk of 
morbidity and mortality 
53-55, 111, 112
. One of the first to describe this association was the 
Chicago People’s Gas Company Study 53. Here, mortality from CVD and non-CVD causes 
generally increased with accelerating RHR. Despite these studies having identified an 
association between RHR and CVD outcome in a general population, few have explored this 
question in populations at intermediate-to-high risk. Examining the prognostic value of RHR 
in patients with stable CAD, Diaz and colleagues 
67
 found that high RHR independently 
predicted overall and CVD mortality. Likewise, admission RHR was considered to be the 
best predictor for in-hospital and 1 year post-discharge mortality in patients hospitalized for 
acute MI 
58
. In light of these observations, however, resting tachycardia as a modifiable CVD 
risk factor is often overlooked 
111, 112
, especially among high-risk patients. Therefore, the 
present investigation sought to determine the role of RHR as an important predictor of 
mortality in patients who have undergone coronary angiography.  
          
6.3. METHODS 
 
6.3.1. Patients and setting 
The LURIC study is an ongoing prospective cohort study of patients referred for coronary 
angiography, and is designed to evaluate determinants of cardiovascular health 
166
. In total, 
3,316 subjects (2,309 men and 1,007 women) between the ages of 18-95 years were recruited 
from July 1997 to January 2000, at the Herzzentrum (Cardiac Center) Ludwigshafen in 
southwest Germany. In order to reliably classify the cardiovascular disease phenotype at 
study entry and to minimise misclassification of silent CAD as non-CAD, inclusion criteria 
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for LURIC demanded the availability of a coronary angiogram in all participants. Other 
inclusion and exclusion criteria such as restriction to Caucasians of German ancestry and to 
stable clinical disease, with the exception of acute coronary syndromes (ACS) were 
established in order to limit the genetic and the clinical heterogeneity of the sample. An ACS 
was diagnosed if patients presented within 7 days of onset of symptoms of unstable angina 
pectoris or acute MI, comprising non-ST-elevation MI (troponin T > 0.1 µg/L) and ST-
elevation MI (troponin T > 0.1 µg/L). Participants with a history of malignancy within the 
past five years, or any predominant non-cardiac disease were excluded from the study. 
Written, informed consent was obtained from each participant, and the study was approved 
by the institutional review board at the Ärztekammer Rheinland-Pfalz (Medical Association 
of Rheinland-Pfalz).  
 
6.3.2. Baseline examination  
Detailed descriptions of the LURIC baseline examination are described elsewhere 
166
. 
Briefly, all variables included in the present investigation were selected on the background of 
previous literature, data availability, and the possibility of confounding. Between the hours of 
06:00-09:00am, RHR was obtained by trained nurses using electrocardiography. Five 
measures were taken 30 seconds apart, following a 10 minute rest in the supine position away 
in a quiet room, with the average derived from the last 2 measures. Death certificates 
obtained from local person registries were reviewed to classify those who died from 
cardiovascular and non-cardiovascular events. Death from cardiovascular causes included 
sudden cardiac death (SCD), fatal MI, death due to heart failure, death after intervention to 
treat CAD, stroke and other deaths due to heart disease. Two experienced physicians masked 
to any data of the study probands except for the information from the death certificates 
independently classified the causes of death.  
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6.3.3. Statistical methods  
Continuous parameters following a non-normal distribution underwent natural logarithmic 
transformation. Baseline characteristics according to quartiles of RHR are given as 
percentages for categorical data, and depending on their distribution, continuous data are 
presented as means±SD values (normal distribution) or as geometric means with 95% CIs 
(skewed distribution). Comparisons between groups were performed by ANOVA for 
continuous parameters, and by Pearson’s χ2 test for categorical variables. Kaplan-Meier 
survival function with Log rank test for equality was used to evaluate the predictive ability of 
RHR quartiles with overall and CVD mortality. We also fitted a fractional polynomial model 
in order to evaluate the non-linear pattern of baseline RHR as a continuous parameter with 
all-cause and CVD mortality.  
Time-to-event analyses were performed using multivariable Cox proportional hazards 
regression. Three models were fitted for analyses; Model 1 was unadjusted, Model 2 adjusted 
for age and sex, and Model 3 also corrected for a range of conventional risk factors including 
smoking, alcohol, exercise, obesity, CRP, hypertension, diabetes mellitus, dyslipidaemia, and 
angina pectoris, symptoms of heart failure, CAD severity, family history and medical 
therapy. As anti-hypertensive therapy (i.e., ACE-inhibitors, β-blockers, and statins) may 
influence RHR, patients who reported the use of these agents were removed from secondary 
analyses in order to examine whether the initial findings would be affected. Further, to 
minimise potential bias due to subclinical and undetected pre-existing disease at baseline, we 
also carried out the analyses excluding those who died within 2 years since the time of 
enrolment. The above analyses were considered significant at a P-value of <0.05 (two-tailed). 
All calculations were performed using STATA version 11.2 (StataCorp, Texas). 
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6.4. RESULTS 
 
The median duration of follow-up was 9.9 years. There were 995 (30%) deaths, of which 558 
(56%) occurred due to CVD. A higher incidence of all-cause and CVD mortality was 
observed with increasing quartiles of RHR (Table 6.1). Patients in the upper quartile (RHR 
≥84 bpm) had a higher waist circumference, BMI, systolic and diastolic blood pressure, total, 
LDL- and LDL-to-HDL-cholesterol ratio, glucose, glycosylated haemoglobin A1c, 
interleukin-6 (IL-6), CRP, and symptoms of heart failure (Table 6.1). A greater proportion of 
MetS, hypertensive, diabetic, and less physically active patients were found among higher 
quartiles (Table 6.1). In contrast, there was a greater prevalence of angina pectoris in the 
lowest (RHR <64 bpm) compared to the highest quartile of RHR. Likewise, β-blockers and 
statins were more prevalent in the lowest quartile compared to the others (Table 6.1). Figure 
6.1 presents Kaplan-Meier survival plots for total and CVD mortality according to quartiles 
of RHR. Patients in the highest quartile for RHR showed a greater risk for all-cause and CVD 
mortality. Log rank test for equality revealed a significant difference between quartiles (P 
<0.001). 
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Table 6.1. Baseline characteristics of the LURIC study population according to quartiles of resting heart rate 
 Resting heart rate quartiles 
 Q1 Q2 Q3 Q4 P value 
 (n=829) (n=815) (n=843) (n=829)  
All-cause mortality 221 (26.6%)      225 (27.6%)       248 (29.4%)       301 (36.3%) <0.001 
Cardiovascular disease mortality 123 (14.8%)       126 (15.4%)      138 (16.3%)       171 (20.6%)                          0.007 
Age (years) 62.7±10.5              62.9±10.7 62.8±10.3 62.2±10.7 0.49 
Men 616 (74.3%)       566 (69.4%)       558 (66.1%)       570 (68.7%) 0.003 
Waist (cm) 98.4±10.4          98.2±11.7 99.5±12.4 99.5±12.6 0.04 
Body mass index (kg/m
2
) 27.2±3.6 27.3±3.8 27.6±4.2 27.8±4.5 0.03 
Metabolic syndrome 429 (51.7%)       415 (50.9%)       495 (58.7%)       512 (61.7%) <0.001 
Heart rate (beats/minute)     55±4                       64±2 71±2 84±8 <0.001 
Systolic blood pressure (mm Hg) 140±24 139±23 140±23 144±23 <0.001 
Diastolic blood pressure (mm Hg) 78±11 79±11 81±10 84±11 <0.001 
Prevalence of hypertension 421 (50.7%)       393 (48.2%)       450 (53.3%)      500 (60.3%) <0.001 
Triglycerides (mg/dl) 147.92 (142.60, 152.34) 148.80 (143.49, 154.11) 152.34 (147.92, 157.66) 155.00 (149.69, 160.32) 0.16 
Total cholesterol (mg/dl) 185.23 (182.91, 187.55) 186.77 (184.06, 189.01) 189.48 (187.16, 192.19) 191.80 (189.01, 194.51) 0.002 
Low density lipoprotein cholesterol (mg/dl) 108.66 (106.34, 110.10) 110.21 (107.90, 112.53) 111.76 (109.44, 114.11) 112.92 (111.37, 116.41) 0.02 
High density lipoprotein cholesterol (mg/dl) 37.51 (36.74, 38.28) 37.12 (36.35, 37.90) 36.74 (36.10, 37.51) 37.12 (36.35, 37.90) 0.59 
Low/high density lipoprotein cholesterol ratio 2.89 (2.82, 2.96) 2.96 (2.88, 3.03) 3.02 (2.95, 3.10) 3.06 (2.97, 3.14) 0.008 
Prevalence of dyslipidaemia 557 (67.1%)       557 (68.3%)       596 (70.7%)       577 (69.6%)                         0.43 
Glucose (mg/dl) 93.67 (91.33, 94.21) 94.39 (92.77, 96.01) 96.73 (94.93, 98.36) 103.40 (101.24, 105.74) <0.001 
Glycosylated haemoglobin A1c (%) 6.1 6.2 6.3 6.5 <0.001 
Diabetes mellitus 91 (10.9%)      134 (16.4%)       155 (18.3%)     210 (25.3%) <0.001 
Interleukin-6 (ng/L) 2.95 (2.79, 3.13) 3.22 (3.03, 3.42) 3.50 (3.29, 3.71) 4.03 (3.78, 4.30) <0.001 
C-reactive protein (mg/L) 2.59 (2.37, 2.82) 3.20 (2.93, 3.49) 3.85 (3.52, 4.21) 4.85 (4.41, 5.32) <0.001 
Smoking status                                                       
   Never 274 (33.0%)      303 (37.1%)       319 (37.8%)       298 (35.9%) 0.23 
   Former 396 (47.7%)                         354 (43.3%) 348 (41.2%) 370 (44.6%)  
   Current 159 (19.1%) 158 (19.3%) 176 (20.8%) 161 (19.4%)  
Current alcohol drinker 443 (53.4%) 386 (47.3%) 410 (48.6%) 414 (49.9%) 0.08 
Exercise
†
      
   Low 189 (22.8%) 199 (24.4%) 202 (23.9%) 261 (31.4%) 0.003 
   Average 448 (54.0%) 423 (51.9%) 460 (54.5%) 420 (50.6%)  
   High 173 (20.8%) 175 (21.4%) 165 (19.5%) 133 (16.0%)  
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Table 6.1. Continued 
 Resting heart rate quartiles 
 Q1 Q2 Q3 Q4 P value 
 (n=829) (n=815) (n=843) (n=829)  
Family history of cardiovascular disease 442 (53.3%) 427 (52.3%) 440 (52.1%) 420 (50.6%) 0.75 
Angina status      
   Stable 257 (31.4%) 272 (34.2%) 269 (32.9%) 219 (27.0%) 0.04 
   Unstable 321 (39.2%) 292 (36.7%) 303 (37.0%) 316 (39.0%)  
New York Heart Association functional class      
    1 471 (56.8%) 410 (50.3%) 460 (54.5%) 381 (45.9%) <0.001 
    2 223 (26.9%) 248 (30.4%) 256 (30.3%) 240 (28.9%)  
    3 113 (13.6%) 130 (15.9%) 110 (13.0%) 175 (21.1%)  
    4 22 (2.6%) 27 (3.3%) 17 (2.0%) 33 (3.9%)  
Coronary Artery Disease severity      
    0 241 (29.3%) 239 (29.6%) 269 (32.5%) 286 (35.1%) 0.01 
    1 154 (18.7%) 151 (18.7%) 146 (17.6%) 169 (20.7%)  
    2 182 (22.1%) 158 (19.6%) 144 (17.4%) 139 (17.0%)  
    3 244 (29.7%) 257 (31.9%) 268 (32.4%) 220 (27.0%)  
Cardiovascular medication use      
   Angiotensin converting enzyme-inhibitors 444 (53.5%) 428 (52.5%) 438 (51.9%) 459 (55.3%) 0.52 
   β-blockers 600 (72.3%) 553 (67.8%) 519 (61.5%) 427 (51.5%) <0.001 
   Statins 423 (51.0%) 397 (48.7%) 399 (47.3%) 336 (40.5%) <0.001 
Data are expressed as n (%), mean±SD, or geometric mean (95% confidence interval).
 †
Exercise was recorded using an 11-point scale ranging from bedridden to 
extremely active, and categorised into “low” (not very active), “average” (usual office work) and “high” (heavy work or sports).  
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Figure 6.1. Kaplan-Meier plots for all-cause and cardiovascular mortality according to resting heart rate quartiles. Log-rank tests revealed significant 
differences between resting heart rate quartiles (P <0.001). CVD = cardiovascular disease.
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Interestingly, after correction for covariates, fractional polynomial models revealed a 
J-shaped curve for RHR with overall and CVD mortality (Figure 6.2). That is, in addition to 
those with a high RHR, patients with a very low RHR also appear to be at risk of 
experiencing either endpoint. Cox proportional hazard regression models for overall and 
CVD mortality are presented in Table 6.2. There was a survival reduction of 1.2 and 1.4 years 
for those in the highest compared to those in the lowest quartile for overall and CVD 
mortality, respectively. Patients in the highest quartile had an increased risk for overall 
mortality by almost 40% after adjusting for a range of potential confounders (Table 6.2). 
Likewise, these patients had a significantly greater risk for CVD mortality by around 40% 
(Table 6.2). In Figure 6.3, a 10 bpm increase in RHR was significantly associated with 
overall (HR [95% CI] = 1.12 [1.06, 1.19], P <0.001) and CVD mortality (HR [95% CI] = 
1.13 [1.05, 1.22], P =0.001) following adjustment. 
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Figure 6.2. Fractional polynomial models present the non-linear pattern for baseline resting heart rate (continuous) according to overall (A) and 
cardiovascular mortality (B). Models adjusted for covariates as seen in Table 2. Grey regions are 95% confidence intervals. 
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Table 6.2. Crude and adjusted hazard ratios (with 95% CIs) for all-cause and cardiovascular mortality according to resting 
heart rate quartiles 
 Resting heart rate quartiles 
 Q1 Q2 Q3 Q4 Ptrend 
All-cause mortality      
Median follow-up time (yrs) 5.5 5.4 5.0 4.3  
No. alive/deaths 608/221 590/225 595/248 528/301  
Model 1, HR (95% CI) 1 (reference) 1.06 (0.88, 1.28) 1.16 (0.96, 1.39) 1.54 (1.29, 1.84) <0.001 
Model 2, HR (95% CI) 1 1.05 (0.87, 1.27) 1.26 (1.05, 1.52) 1.70 (1.42, 2.03) <0.001 
Model 3, HR (95% CI) 1 0.94 (0.78, 1.14) 1.19 (0.98, 1.43) 1.39 (1.17, 1.67) <0.001 
Cardiovascular mortality      
Median follow-up time (yrs) 4.9 4.7 4.6 3.5  
No. alive/deaths 706/123 689/126 705/138 658/171  
Model 1, HR (95% CI) 1 (reference) 1.10 (0.86, 1.42) 1.14 (0.89, 1.47) 1.56 (1.24, 1.98) <0.001 
Model 2, HR (95% CI) 1 1.10 (0.85, 1.41) 1.25 (0.97, 1.60) 1.72 (1.36, 2.18) <0.001 
Model 3, HR (95% CI) 1 0.97 (0.75, 1.26) 1.15 (0.89, 1.48) 1.38 (1.08, 1.78) 0.004 
Model 1 was unadjusted. Model 2 adjusted for age and sex. Model 3 also adjusted for smoking, alcohol, exercise, obesity, high 
sensitivity C-reactive protein, hypertension, diabetes mellitus, dyslipidaemia, un/stable angina, family history of stroke or 
myocardial infarction, New York Heart Association functional class, number of diseased vessels, and cardiovascular 
medication. HR = hazard ratio; CI = confidence interval. 
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Figure 6.3 Hazard ratio estimates for resting heart rate (per 10 beats/minute 
increments) according to all-cause and cardiovascular mortality. Models 
were adjusted as abbreviated in Table 6.2. 
 
The analyses were also carried out after excluding those who reported the use of 
ACE-inhibitors, β-blockers and/or statins (n = 758). For the highest quartile, the association 
between RHR with total (HR [95% CI] = 1.38 [1.12, 1.70], Ptrend <0.001) and CVD mortality 
(HR [95% CI] = 1.30 [0.99, 1.73], Ptrend =0.02) remained essentially unchanged. Lastly, we 
removed patients who died within 2 years (n = 224) since the time of enrolment, likely the 
result of a pre-existing chronic illness. We found RHR continued to remain a strong 
independent predictor of overall (HR [95% CI] = 1.32 [1.07, 1.62], Ptrend =0.002) and CVD 
mortality (HR [95% CI] = 1.26 [0.94, 1.67], Ptrend =0.04). 
 
6.5. DISCUSSION 
 
In the present study, RHR, a familiar and easily accessible clinical parameter was found to be 
an independent risk predictor for total and CVD mortality. Though these findings apply to 
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persons at intermediate-to-high cardiovascular risk, they are nonetheless consistent with 
published data from a number of epidemiological studies in general populations 
53-55, 69, 70
.  
Among the few studies that examined these associations in high risk patients, one 
investigation retrospectively examined data from 106 patients who underwent coronary 
angiography, and observed a positive association between plaque rupture and RHR >80 bpm 
167
. Similarly, in the oral glycoprotein IIb/IIIa inhibition with Orofiban in Patients with 
Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction trial, Kovar and 
colleagues 
168
 showed mortality at 30 days and 10 months increased progressively according 
to higher RHR strata. Likewise, in the Asymptomatic Cardiac Ischemic Pilot Study, Pratt and 
co-workers 
169
 demonstrated that the incidence rate of ischemic events in patients with stable 
CAD was associated with their mean RHR, and those who had a RHR >80 bpm presented an 
almost two-fold increase in signs/symptoms of ischemia compared to those with a RHR <70 
bpm. 
 Though the pathophysiologic mechanisms underlying the development of CAD are, 
in general, well recognized 
170, 171
, it is possible in theory that an elevated RHR is influential 
in identifying the risk of plaque instability. For example, sympathetic over-activity plays a 
vital role in the pathogenesis of atherosclerosis, most often through stimulation of several 
hemodynamic (i.e. tachycardia) and metabolic changes 
158
. In this regard, resting tachycardia 
likely reflects an imbalance between sympathetic and parasympathetic tone 
172
. A higher 
RHR may well be an indicator of dysregulated hemodynamic and ANS function, encouraging 
CVD morbidity and mortality by inducing atherosclerotic plaque disruption 
173
. 
Indeed, resting tachycardia directly affects vascular risk by contributing to an 
imbalance between demand and supply of myocardial oxygen consumption 
112
. An elevated 
RHR causes both an increase in myocardial oxygen demand, and a decline in coronary blood 
supply (the latter occurring via a shorter diastolic period) 
67, 112
, inducing fatigue and fracture 
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of elastic fibres within the arterial wall 
172
. Any increase in RHR would therefore be 
deleterious, as it further decreases diastolic perfusion, augments stealing from the ischemic 
zone and impairs blood supply at the ischemic obstruction, further compromising coronary 
flow 
174
. Seemingly, these functional alterations would likely provoke the onset of 
atherosclerotic plaque formation, and precipitate the later stages of atherosclerosis that lead to 
plaque rupture and coronary thrombosis 
112
.  
There are several limitations to the present data that bear mention. Inclusion of only 
Caucasian subjects limits the generalisability of our findings which are therefore not 
applicable to other ethnic populations with CAD. That said it is unlikely that the 
pathophysiology differs significantly between ethnicities as supported by similar associations 
observed in other ethnic groups 
55, 114, 175
. Although prospective in patient enrollment, RHR 
was only determined at a single time point, making it observational in nature. Thus, it cannot 
be confirmed from the present data whether rapid RHR is itself a cause, or is merely 
associated with mortality. Nevertheless, through multivariable analyses, we did however, take 
into account several risk factors that are most often associated with pulse rate, and which may 
have confounded the relationship between resting tachycardia and mortality. Moreover, two 
recent epidemiological studies with particularly lengthy follow-ups support a possible link. In 
the first study 
66
 RHR was determined in 5,713 middle-aged asymptomatic men, with a mean 
follow-up duration of 23 years. Here, the risk of death from total mortality and MI increased 
incrementally with RHR, which remained significant after correction for a number of known 
risk factors including age, diabetes, arterial hypertension, obesity and physical activity. 
Second, in the CASS investigation 
67
 involving 24,913 patients with suspected or proven 
CAD followed for a median of 14.9 years, RHR was also a robust independent predictor of 
overall and CVD mortality. On the background of this data, a faster RHR presents as a 
significant cardiovascular parameter, playing an integral role in predicting adverse 
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complications at different stages of the cardiovascular continuum. Interestingly, fractional 
polynomial models revealed that patients with a very low RHR also presented with greater 
risk in respect to both endpoints. To this end, our results may, in part, provide additional 
insight into the relative prognostic contribution of RHR as a risk factor for mortality. 
However, because the number of our patients with a very low RHR was minimal, and 
perhaps underpowered, we did not subsequently assess its significance with the risk of 
mortality. Nonetheless, we encourage forthcoming studies to consider the usefulness of a 
very low RHR as a potential hazard, rather than simply focussing on the effects of a high 
RHR, as here, its relationship with mortality seems non-linear. 
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CHAPTER SEVEN 
 
7.0. EVIDENCE OF A SYNERGISTIC ASSOCIATION BETWEEN RESTING 
HEART RATE, INFLAMMATION, AND CARDIOVASCULAR MORTALITY IN 
PATIENTS UNDERGOING CORONARY ANGIOGRAPHY 
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7.1. ABSTRACT 
 
Both elevated inflammatory activity and sustained tachycardia reflects unfavourable 
cardiovascular risk profiles, and there is evidence to suggest the deleterious effects of 
inflammation are amplified by increased heart rate. The purpose of this study was to assess 
the interaction between resting heart rate and inflammation in cardiovascular mortality. 3,267 
patients (2,283 men), aged 18-95 years, scheduled for coronary angiography, were followed 
prospectively. By principle component analysis, we developed an overall multi-marker index 
of inflammation weighting the respective coefficients of five inflammatory markers 
including: interleukin-6, C-reactive protein, serum amyloid A, neutrophils, and fibrinogen. 
Cox proportional hazard models were employed to evaluate the relationship between 
inflammation and resting heart rate with cardiovascular mortality. Across 29,940 person 
years of follow-up, there were 546 (17%) deaths due to cardiovascular disease. Significantly, 
we observed a strong synergistic effect of inflammatory activity and concurrent elevated 
heart rate. For cardiovascular disease mortality, patients in the highest quartile of 
inflammation had an adjusted HR (95% CI) of 1.84 (1.31-2.57), P <0.0001 if their resting 
heart rate was <75 beats/minute. Substantially, patients had a greater adjusted HR of 7.50 
(3.21-17.50), P <0.0001 if their resting heart rate was ≥75 beats/minute. The present analyses 
underline elevated inflammation as a risk factor for cardiovascular mortality. The effects of 
inflammation were strongly amplified by a faster resting heart rate. If confirmed by additional 
studies, this association may prove a useful adjunct for therapeutic approaches to alleviate 
symptoms and prolong survival.  
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7.2. INTRODUCTION 
 
CAD represents an important public health burden. In particular, lifetime risk of CHD is 
around one in two for men and one in three for women over the age of 40 
176
. Aside from the 
more recognised parameters of CAD risk such as smoking, diabetes, hypertension, and 
dyslipidaemia, compelling evidence has now accumulated in support of chronic inflammation 
as another risk factor, contributing towards all stages of atherosclerosis from endothelial 
dysfunction and plaque formation to plaque disruption and thrombosis 
48, 177
.  
 Recent evidence indicates that inflammation and sustained tachycardia interact at 
several levels of the cardiovascular continuum 
159
, and may hereby exert a synergistic effect 
on cardiovascular morbidity and mortality. For example, elevated RHR increases tensile 
stress which apart from inducing endothelial injury also increases endothelial permeability to 
circulating inflammatory mediators 
158
. In addition, dysfunctional ANS activity may underlie 
both progression of inflammation as well as elevated RHR 
7
. Stimulation of efferent vagus 
nerve activity has been associated classically with normalizing tachycardia, whereas 
experimental evidence has shown that this process also inhibits inflammation via stimulation 
of the cholinergic anti-inflammatory pathway 
178, 179
. Similarly there is ample evidence that 
elevated sympathetic activity modifies the inflammatory process and thereby promotes 
endothelial dysfunction and subsequent atheroprogression 
160, 180
. Though, clearly, further 
studies are required to test the notion that a high RHR will exacerbate the effects of 
inflammation on CVD.           
In light of the preceding discussion, this study was undertaken to evaluate the inter-
relationship between RHR and inflammation with CVD mortality in a large cohort of German 
patients enrolled in the LURIC study. 
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7.3. METHODS 
 
7.3.1. Study population 
 The LURIC study is a prospective cohort study designed to investigate environmental and 
genetic risk factors for CVD 
166
. A total of 3,316 patients (2,309 men and 1,007 women), 
aged 18 to 95 years were enrolled in the LURIC study. A baseline examination was 
performed between July 1997 and January 2000 in a single tertiary care medical centre in 
South-West Germany (Herzzentrum, Ludwigshafen). Inclusion criteria were availability of a 
coronary angiogram, Caucasians of German ancestry to limit genetic heterogeneity, and 
clinical stability, with the exception of ACS. An ACS was diagnosed if patients presented 
within 7 days of onset of symptoms of unstable angina pectoris or acute MI, comprising non-
ST-elevation MI (troponin T > 0.1 µg/L) and ST-elevation MI (troponin T > 0.1 µg/L). 
Participants with a history of malignancy within the past five years, or any predominant non-
cardiac disease were excluded from the study. The LURIC study was approved by the 
institutional review board of the ethics committee at the “Landesärztekammer Rheinland-
Pfalz” (Mainz, Germany) and written informed consent was obtained from all study 
participants. 
 
7.3.2. Patient examination 
An overall summary of the LURIC study objectives and baseline examination procedures 
have been published elsewhere 
166
. Briefly, all body measures were recorded by trained study 
nurses on the same day, during early morning, between the hours of 06:00-09:00am. RHR 
was obtained by electrocardiography. Five measures were taken 30 seconds apart, following a 
10 minute rest in the supine position in a quiet room, with the average derived from the last 2 
measures. Other variables included in the study were selected on the basis of previous 
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literature, data availability, and the possibility of confounding. Details of these variables are 
provided in Table 7.1. 
 
Table 7.1. Description of variables measured in the present study 
Variable Definition  
Age Taken at time of enrolment 
Sex Male/female 
Waist Measured in cm, horizontally around the smallest 
circumference between the ribs and iliac crest 
Body mass index weight (kg) divided by height (m
2
) 
Smoking Never/ever smoker 
Physical activity Recorded using an 11-point scale ranging from bedridden to 
extremely active, and categorised into “below average” (not 
very active), “average” (usual office work) and “above 
average” (heavy work or sports) 
Arterial hypertension Systolic ≥140 and/or diastolic ≥90 mmHg, or anti-
hypertensive medication – confirmed by a physician 
Diabetes mellitus Fasting glucose ≥7.0 mmol/L, or patients receiving anti-
diabetic medication – confirmed by a physician  
Dyslipidaemia Total cholesterol ≥6.2 mmol/L, HDL-cholesterol <1.03/1.29 
mmol/L (male/female), triglycerides ≥1.7 mmol/L, or use of 
lipid-lowering medication – confirmed by a physician  
Angina pectoris Stable (graded severity classes I to IV described by the 
Canadian Cardiovascular Society); Unstable (subdivided 
into different classes by subjective assessment of clinical 
symptoms using Braunwald’s classification) 
Family history Family questionnaire regarding the history of cardiovascular 
disease in first and second degree relatives  
Cardiovascular medication use Use of ACE-inhibitors, β-blockers or Statins   
HDL = high density lipoprotein; ACE = angiotensin converting enzyme. 
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7.3.3. Laboratory analyses 
Samples of fasted venous blood were collected during baseline examination, with patients in 
the supine position. Routine laboratory parameters were immediately measured on a daily 
basis as previously mentioned 
166
. Remaining blood samples were snap-frozen and stored in -
80 C for further analyses. All markers were processed at the Institute of Haemostaseology 
and Transfusion Medicine of the Ludwigshafen General Hospital. IL-6 was measured using a 
high sensitivity enzyme immunoassay (R&D Systems, Wiesbaden, Germany). CRP 
concentrations were measured by high sensitivity immunoturbidimetric assay (Roche 
Mannheim, Germany). Serum amyloid A was determined by immunonephelometry (Dade 
Behring, Marburg, Germany). Fibrinogen was measured using the Clauss method (Roche 
Mannheim, Germany). Neutrophil count was determined using EDTA whole blood and was 
later quantified using an automated analyser (Technicon H-1, Bad Vilbel, Germany until Dec 
1998; Advia 120, Siemens Healthcare Diagnostics, Eschborn, Germany since Jan 1999).  
 
7.3.4. Outcome measure  
The primary endpoint was death due to CVD. Information on vital status was obtained from 
local community registries. Death certificates were reviewed to classify the deceased into 
those who died from CVD and non-CVD causes. Death from CVD causes included SCD, 
fatal MI, and death due to heart failure, death after intervention to treat CAD, stroke and 
other deaths due to heart disease. Two experienced physicians who were masked to any of the 
study data independently classified the causes of death. In the case of a disagreement 
concerning the classification, it was discussed and the final decision was made by one of the 
principal investigators of LURIC (W.M.), who was also masked to the key study variables. 
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7.3.5. Statistical methods 
For the purpose of this investigation RHR was dichotomised into low (<75 bpm, n = 2,391) 
and high (≥75 bpm, n = 876) according to the 75 percentile. The study sample was then 
summarised by comparing those with a low and a high RHR, reporting the mean±SD (or 
median and IQRs for those variables which were skewed), or by numbers and percentages for 
categorical variables. The two groups were compared using t-tests for continuous data, and 
the Mann-Whitney U test for those continuous variables which were skewed, as well as χ2 
tests for categorical variables. All inflammatory markers and continuous covariates were 
checked for normality and those which visually deviated on inspections of the frequency 
distribution were transformed onto the natural (base e) log scale. In this study, only the single 
markers of inflammation required logarithmic transformation. Inflammatory activity can be 
assessed by a number of correlated markers, such as IL-6, CRP, serum amyloid A, 
fibrinogen, and the neutrophil count (Table 7.2).  We employed a principle component 
analysis to extract from the individual markers of inflammation a single weighted multi-
marker index of inflammation. In this study, the first principle component accounted for 
61.3% of the explained variance and no additional significant principal components were 
identified. Accordingly, we developed the overall multi-marker index of inflammation by 
weighting the respective coefficients of each of the five inflammatory markers that 
contributed towards the primary underlying factor (i.e. inflammation). Kaplan-Meier survival 
curves with the log rank test for equality were used to illustrate the predictive ability of 
inflammation (quartiles) with CVD mortality, stratified by low and high RHR. 
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Table 7.2. Pairwise Pearson correlation coefficients between the individual markers of inflammation 
 Interleukin-6 C-reactive protein Serum amyloid A Fibrinogen Neutrophils 
Interleukin-6 1.00     
C-reactive protein 0.58
*** 
1.00    
Serum amyloid A 0.52
***
 0.79
***
 1.00   
Fibrinogen 0.50
***
 0.73
***
 0.62
***
 1.00  
Neutrophils 0.33
***
 0.33
***
 0.30
***
 0.33
***
 1.00 
For the single markers of inflammation, natural log transformations were applied to normalize 
distributions. 
***
P <0.0001. 
 
The association between inflammation quartiles and CVD mortality for those with a 
low and a high RHR was further tested using Cox proportional hazard survival models, 
reporting HRs with 95% CIs and P for trend. Three models were employed to test these 
relationships. The first model was unadjusted; the second model corrected for age and sex; 
the final model additionally controlled for BMI, smoking, physical activity, arterial 
hypertension, type 2 diabetes, dyslipidaemia, angina pectoris, family history of CVD, and 
cardiovascular medications. To further understand the relationship between inflammation and 
CVD mortality, the latter analyses were also performed examining the single markers of 
inflammation in those with a low and a high RHR, respectively. Due to the large 
heterogeneity of LURIC patients, we re-performed the survival models according to a 
number of separate sensitivity checks. First, we examined the initial findings among those 
who were clinically stable at baseline. Second, patients with signs of heart failure were 
removed in order to examine whether the initial findings would be affected. In the current 
study, heart failure was determined according to a classification developed by the New York 
Heart Association (i.e., whereby/in whom slight physical activity caused symptoms; inability 
to carry on any physical activity without discomfort; symptoms of cardiac insufficiency 
present even at rest) 
181
. Third, patients accompanied with an ongoing infection who may 
have spuriously contributed towards elevated inflammation were excluded. Fourth, to 
minimise potential bias due to subclinical and undetected pre-existing disease at baseline 
which is associated with increased mortality, we also carried out the analyses after removing 
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patients who died within 12 months from the time of enrolment. Fifth, we excluded those 
who reported the use of β-blockers, as these agents are known to artificially lower pulse rate, 
which may have biased our initial assignment of patients to the RHR categories. We then 
assessed the discriminatory value of the multi-marker index of inflammation by computing 
the c-statistic and integrated discrimination improvement (IDI), as well as the net 
reclassification improvement (NRI). For the latter, we chose a priori meaningful risk 
category of <6, 6–20, and >20 per cent 10-year risk of CHD based on the Third Adult 
Treatment Panel risk classification 
80
. Model calibration was evaluated using the Hosmer-
Lemeshow goodness-of-fit test according to 10 risk categories. All calculations were 
performed using STATA version 11.2 (StataCorp, Texas).     
 
7.4. RESULTS 
 
Of the 3,316 patients enrolled in the LURIC study, 49 (1.5%) were excluded due to missing 
data on a number of parameters examined. Hence, the analytic sample included a total of 
3,267 patients (2,283 men and 984 women). Preliminary analyses revealed that there were no 
sex-specific differences present. Baseline characteristics of the overall population are 
reported in Table 7.3. The median duration of follow-up was 9.9 years. Across the 29,940 
person years of follow-up, there were 546 (17%) deaths due to CVD. There was a trend 
towards higher BMI, lower physical activity, arterial hypertension, and type 2 diabetes 
mellitus in patients with a high RHR. In contrast, there was a higher incidence of unstable 
angina pectoris in patients with a low RHR. Similarly, use of β-blockers and statins was 
significantly higher among patients with a low RHR (Table 7.3). Of the individual 
inflammatory markers, IL-6, CRP, serum amyloid A, fibrinogen and neutrophils were all 
significantly higher in patients with a high RHR. 
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Table 7.3. Baseline characteristics of patients according to low and high resting heart rate 
 Low RHR (<75 
beats/minute) 
High RHR (≥75 
beats/minute) 
P value 
No. (n=2,391) (n=876)  
Cardiovascular mortality, n (%) 366 (15.3) 180 (21.0) <0.0001 
Age, mean±SD, y 62.7±10.5 62.3±10.7 0.32 
Male sex, n (%) 1,682 (70.4) 601 (68.6) 0.34 
Waist circumference, mean±SD, cm 98.8±11.6 99.5±12.6 0.11 
Body mass index, mean±SD, kg/m
2 
27.4±3.9 27.7±4.5 0.04 
Resting heart rate, mean±SD  63±7 83±8 <0.0001 
Smoking status, n (%)    
   Never 858 (35.9) 312 (35.6) 0.89 
   Ever 1,533 (64.1) 564 (64.4)  
Physical activity, n (%)    
   Low 564 (23.6) 278 (31.7) <0.0001 
   Average 1,277 (53.4) 443 (50.6)  
   High 550 (23.0) 155 (17.7)  
Arterial hypertension, n (%) 1,208 (50.5) 528 (60.3) <0.0001 
Type 2 diabetes mellitus, n (%) 363 (15.2) 217 (24.8) <0.0001 
Dyslipidaemia, n (%) 1,642 (68.7) 612 (69.9) 0.52 
Angina pectoris, n (%)    
   Stable 893 (37.7) 339 (38.9) 0.01 
   Unstable 776 (32.8) 241 (27.7)  
Family history of CVD, n (%) 1,266 (53.0) 440 (50.2) 0.17 
Cardiovascular medication use, n (%)    
   ACE-inhibitors 1,268 (53.0) 483 (55.0) 0.29 
   β-blockers 1,617 (67.6) 465 (53.1) <0.0001 
   Statins 1,189 (49.7) 354 (40.4) <0.0001 
Inflammatory markers    
   Interleukin-6, median (IQR), pg/mL
ǂ 
 3.00 (1.74-5.69) 3.89 (2.11-7.29) <0.0001 
   C-reactive protein, median (IQR), mg/L
ǂ
  3.02 (1.21-7.69) 4.69 (1.63-10.7) <0.0001 
   Serum amyloid A, median (IQR), mg/L
ǂ
  4.80 (2.70-10.80) 6.15 (3.30-18.60) <0.0001 
   Neutrophils, median (IQR), 10
3
/µL
ǂ
 3.94 (3.11-4.88) 4.39 (3.52-5.76) <0.0001 
   Fibrinogen, median (IQR), g/L
ǂ 
 3.71 (3.16-4.43) 3.96 (3.34-4.76) <0.0001 
Categorical variables are shown as percentages, and continuous data are presented as mean±SD, or 
median (IQR). t test was computed for continuous parameters (with Mann-Whitney U test for skewed 
data)
ǂ
, and χ
2
 test for categorical variables. Abbreviations; RHR = resting heart rate; CVD = 
cardiovascular disease; ACE = angiotensin converting enzyme; IQR = interquartile range.  
 
Patients with a low RHR and who were in the highest quartile on the inflammation 
index had an increased risk of CVD mortality compared to those with lower levels of 
inflammation (Figure 7.1A).  For those with a high RHR there was an even stronger increase 
in CVD mortality with increasing levels of inflammation. That is, patients in the highest 
quartile of inflammation had a greater risk of CVD mortality when RHR was ≥75 bpm 
(Figure 7.1B). Log rank test for equality revealed that there was a significant difference 
between quartiles (P <0.001). 
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Figure 7.1. Kaplan Meier plots indicating the proportion of cardiovascular deaths according to quartiles of inflammation by (A) low (<75 beats/minute) 
and (B) high (≥75 beats/minute) resting heart rate. Log rank test for equality found quartiles of inflammation were significantly different in both models 
(P <0.0001, respectively). 
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 Cox proportional hazard regression reported a significant interaction effect between 
heart rate and inflammatory activity for the primary endpoint (P = 0.04). Separate Cox 
proportional hazard regression models for those with a low and a high RHR are presented in 
Table 7.4. There was a survival reduction of 1.4 and 2.7 years due to the primary endpoint in 
those with a low and a high RHR, respectively, when the highest quartile of inflammation 
was compared with the lowest quartile. For those with a low resting RHR, the fully adjusted 
HR (95% CI) for CVD mortality among patients in the upper quartile of inflammation was 
1.84 (1.31-2.57), Ptrend <0.0001. However, for patients with a high RHR, the fully adjusted 
risk increased by more than seven-fold, HR (95% CI) = 7.50 (3.21-17.50), Ptrend <0.0001, for 
those in the highest inflammatory quartile (Table 7.4).  
Since patients involved in this study were scheduled for coronary angiography, we 
subsequently explored if the degree of CAD severity could explain, in part, the interaction 
between RHR and inflammatory status in predicting risk of CVD mortality. Interestingly, we 
observed that the adjusted risk of death due to CVD increased further depending on the 
magnitude of CAD severity (Figure 7.2). Patients with ≥20% stenosis of at least one main 
luminal vessel and who were in the upper-most quartile of inflammation with a high RHR 
had a comparable risk, [HR (95% CI) = 6.68 (2.66-16.78)], Ptrend <0.0001 for CVD mortality 
compared to the overall cohort (see Table 7.4). On the other hand, the magnitude of 
cardiovascular risk increased further to approximately ten-fold HR [(95% CI) = 9.83 (3.05-
31.65), Ptrend <0.0001] among those with ≥50% narrowing of at least one main coronary 
artery, who were in the highest quartile of inflammation on the background of a high RHR. 
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Table 7.4. Relationship between inflammation and cardiovascular mortality by low and high resting heart rate 
 Inflammation quartiles  
 Q1 Q2 Q3 Q4 Ptrend 
Resting heart rate (<75 bpm)      
   No. alive/CVD event 603/65 546/89 474/111 411/110  
   Median follow-up time, y 9.7 9.1 8.8 8.3  
   Model 1, HR (95% CI) 1 (reference) 1.49 (1.07-2.06) 2.13 (1.56-2.90) 2.52 (1.85-3.44) <0.0001 
   Model 2, HR (95% CI) 1 (reference) 1.39 (1.01-1.93) 1.95 (1.43-2.66) 2.09 (1.53-2.86) <0.0001 
   Model 3, HR (95% CI) 1 (reference) 1.28 (0.91-1.79) 1.69 (1.22-2.34) 1.84 (1.31-2.57) <0.0001 
Resting heart rate (≥75 bpm)      
   No. alive/CVD event 150/6 164/25 193/46 199/104  
   Median follow-up time, y 9.7 9.0 8.5 7.0  
   Model 1, HR (95% CI) 1 (reference) 3.49 (1.43-8.53) 5.61 (2.40-13.13) 11.72 (5.15-26.72) <0.0001 
   Model 2, HR (95% CI) 1 (reference) 3.09 (1.26-7.57) 4.67 (1.99-10.96) 9.21 (4.03-21.03) <0.0001 
   Model 3, HR (95% CI) 1 (reference) 2.40 (0.97-5.92) 4.08 (1.72-9.64) 7.50 (3.21-17.50) <0.0001 
Values were obtained from Cox proportional hazard models. Model 1 was unadjusted. Model 2 corrected for age and sex. Model 3 additionally 
corrected for body mass index, smoking, physical activity, arterial hypertension, type 2 diabetes, dyslipidaemia, angina pectoris, family history 
of cardiovascular disease and cardiovascular medication. Inflammation index included: interleukin-6, high sensitivity C-reactive protein, serum 
amyloid A, neutrophil numbers, and fibrinogen. Abbreviations; bpm = beats/minute; HR = hazard ratio; CI = confidence interval.   
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Figure 7.2. Hazard ratios for incident cardiovascular mortality according to 
quartiles (Q) of inflammation by low (<75 bpm) and high (≥75 bpm) resting 
heart rate (RHR) with either ≥20% or ≥50% stenosis of at least one main 
coronary artery. Model fully adjusted as outlined in Table 7.4. 
 
 In Figure 7.3, the fully adjusted HR estimates for the single markers of inflammation 
are presented. For each marker, we compared the upper-most quartile to the lowest and found 
the risk of CVD mortality was greater among patients who had a high RHR (Figure 7.3). Of 
all these markers, the greatest prediction was provided by fibrinogen, HR (95% CI) = 3.68 
(2.02-6.70), P <0.0001). Though each individual marker was predictive of CVD mortality 
among those with a high RHR, the strongest prediction for CVD mortality was afforded by 
the overall marker of inflammation (Figure 7.3). 
To better understand the relationship between inflammation and CVD mortality, we 
repeated the latter analyses including only patients with clinical stability (n = 2,234) at 
baseline. After comparing the upper-most quartile to the lowest, we found the relationship 
between inflammation and CVD mortality increased HR (95% CI) = 2.37 (1.56-3.60), P 
<0.0001 in patients with a low RHR, as well as for those HR (95% CI) = 9.18 (3.23-26.00), P 
<0.0001 with a high RHR. The analyses were then carried out after excluding patients with 
suspected heart failure (n = 619). The fully adjusted association between inflammation and 
CVD mortality remained unchanged, HR (95% CI) = 1.87 (1.26-2.78), P =0.001 for those 
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with a low RHR. However, there was a slight attenuation in the risk HR (95% CI) = 6.81 
(2.63-17.63), P <0.0001 for those with a high RHR. We also removed patients accompanied 
by an ongoing infection (n = 315) which may have contributed towards a heightened 
inflammatory status at baseline. Likewise, we found the adjusted association between 
inflammation and CVD mortality for the highest compared to the lowest quartile did not 
materially change HR (95% CI) = 1.86 (1.31-2.64), P <0.0001 in patients with a low RHR, 
while again, there was a slight attenuation for individuals HR (95% CI) = 6.19 (2.63-14.60), 
P <0.0001 with a high RHR. To minimise potential bias due to subclinical and undetected 
pre-existing disease at baseline which is associated with increased mortality, we removed 
patients who died within 12 months (n = 130) of enrolment. The results were virtually 
identical, HR (95% CI) = 1.85 (1.29-2.65), P =0.001 for those with a low RHR, and HR 
(95% CI) = 6.23 (2.64-14.72), P <0.0001) for patients with a high RHR. Finally, after 
excluding those who reported the use of β-blockers, the adjusted association between 
inflammation and CVD death among those with a low RHR was somewhat attenuated HR 
(95% CI) = 1.78 (1.03-3.08), P =0.04, albeit the association remained significant. 
Conversely, the strong independent relationship between inflammation and CVD mortality 
HR (95% CI) = 5.35 (2.05-14.00), P =0.001 persisted among patients with a high RHR, even 
after removing those who reported the use of these agents. Further exploration of the data, 
using instead, the median cut-off value (median = 68 bpm) for RHR revealed similar findings 
(data not shown). 
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Figure 7.3. Hazard ratios (quartile 4 versus quartile 1) for incident cardiovascular mortality 
according to the individual markers of inflammation and the composite score, by low (<75 
beats/minute) and high (≥75 beats/minute) resting heart rate. Model was fully adjusted as 
abbreviated in Table 7.4. 
 
We assessed the discriminatory value of the multi-marker index of inflammation by 
computing the c-statistic and area under the receiver operating characteristic (AUC) curve; 
comparing a model including the conventional risk factors with a model based on a 
combination of these risk factors and the multi-marker index. Initially, the conventional risk 
factor model achieved reasonable discrimination, obtaining a c-statistic of 0.751 (Figure 7.4). 
After including the multi-marker index of inflammation, the discriminatory value marginally 
improved by 0.010 (0.761, P =0.015) (Figure 7.4). In addition, we employed the 
reclassification statistics of the IDI and NRI. According to the IDI, inclusion of the multi-
marker index significantly improved model discrimination by 0.010 (P <0.0001). Moreover, 
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the addition of the multi-marker index to the conventional risk factors significantly improved 
reclassification of patients to a different risk category by 6% (P =0.002) (Table 7.5). Model 
calibration using the Hosmer-Lemeshow goodness-of-fit test also yielded a chi-square of 6.29 
(P =0.61), indicating no significant deviation between observed and predicted risk (Figure 
7.5). 
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Figure 7.4. C-statistic estimates for the prediction of cardiovascular mortality according 
to the baseline conventional risk factors and multi-marker index of inflammation. 
Baseline model (grey) included age, sex, waist circumference, smoking, physical 
activity, arterial hypertension, Type 2 diabetes, dyslipidaemia, family history of 
cardiovascular disease, angina pectoris, and cardiovascular therapy. 
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Table 7.5. Reclassification of intermediate (defined as 6%-20%) risk patients with and without the 
cardiovascular endpoint  
 Reclassification accounting for multi-
marker 
 
Classification according to conventional risk factors 
 
Low 
 
Intermediate 
 
High 
Total 
no. 
Patients with CVD endpoint     
      Low <6% in 10 yrs 16 6 0 22 
      Intermediate 6%-20% in 10 yrs 5 157 34 196 
      High >20% in 10 yrs 0 17 301 318 
      Total no. with event 21 180 335 536 
Patients without CVD endpoint     
      Low <6% in 10 yrs  587 58 0 645 
      Intermediate 6%-20% in 10 yrs 95 1,165 79 1,339 
      High >20% in 10 yrs 0 88 571 659 
      Total no. without event 682 1,311 650 2,643 
Net reclassification improvement 6.0% (P =0.002) 
Conventional risk factor model included age, sex, body mass index, smoking, physical activity, arterial 
hypertension, type 2 diabetes, dyslipidaemia, angina pectoris, family history of cardiovascular disease 
and cardiovascular medication.    
 
 
 
Figure 7.5. Proportion of observed and predicted cases according to the 
risk model that included the multi-marker index of inflammation. Hosmer-
Lemeshow goodness of fit test yielded no significant deviation between 
observed and predicted risk (P =0.61). 
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7.5. DISCUSSION 
 
The present study assessed the inter-relationship between inflammation and RHR with CVD 
mortality. We found the risk associated with elevated inflammation was amplified four-fold 
in patients with a high RHR (≥75 bpm), compared to those with a low RHR (HR 7.50 versus 
1.84). This synergistic effect remained unaltered after adjusting for an extensive number of 
established risk factors. Further, these observations appeared somewhat dependent on the 
degree of CAD, since in the current investigation the risk of experiencing the study endpoint 
increased by almost ten-fold among those with severe CAD (≥50% luminal stenosis of at 
least one major coronary artery). Our study adds to the current literature because, it is, to our 
knowledge, the only investigation to address RHR as an effect-modifier of inflammation for 
predicting future CVD outcome.  
The European Society of Hypertension/European Society of Cardiology guidelines 
recently proposed the inclusion of elevated RHR when evaluating the cardiovascular risk 
profile of an individual 
164
. The present results indicate that the predictive utility of RHR may 
be substantially enhanced when considered alongside other risk factors, specifically 
inflammation. Consequently, we may speculate that slowing the RHR may prove a useful 
adjunct for interrupting the patho-physiological process initiated by inflammation within the 
local pro-atherosclerotic vascular environment. If this conjecture is correct, then it may be 
anticipated that the protective effects of selective heart rate-lowering agents (i.e., β-blockers, 
calcium antagonists, and the more novel specific heart rate-lowering agent ivabradine) may 
differ as a function of  lower and higher inflammatory activity.  
At this point the exact mechanisms by which resting tachycardia modulates the effects 
of inflammation remain to be elucidated, although the extant literature provides compelling 
evidence for several candidate processes. Among these is ANS damage. Sympathetic 
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overactivity plays a key role in atheroprogression by inducing tachycardia 
158
 as well as by 
causing immune dysregulation. For example, the sympathetic mediators adrenaline and 
noradrenaline have potent effects on cytokine release by activated T cells and macrophages 
and also regulate the migratory behaviour of these cells. Likewise, stimulation of 
parasympathetic outflow, which normalizes tachycardia, also short circuits the inflammatory 
cascade via the cholinergic anti-inflammatory pathway 
7, 10, 178, 179
, which involves down 
regulation of macrophage activity via direct neural stimulation of macrophage cholinergic 
receptors.  
Following this above logic, a raised RHR could be considered a marker of ANS 
dysfunction, rather than a risk factor per se 
112, 158, 182, 183
. Nonetheless, several lines of 
research provide evidence to suggest that RHR is also a primary risk factor for CVD 
160, 163, 
184
, and therefore other interactive mechanisms could be considered as well. For instance, 
disturbed flow-generated shear stress as a consequence of increased pulse rate stimulates 
specific mechanosensors located on the surface of endothelial cells 
158, 159
, subsequently 
upregulating pro-atherogenic genes and downregulating athero-protective genes 
158, 185, 186
. 
Many of these genes also control inflammatory processes. These include, but are unlikely 
limited to, reduced NO activity, which has potent immunomodulatory properties, increased 
vascular permeability, which is a hallmark of the inflammatory process, as well as increased 
expression of inflammatory components such as adhesion molecules (e.g., vascular cell 
adhesion molecule-1, intercellular adhesion molecule-1), chemoattractants (monocyte 
chemoattractant protein-1), and cytokines (IL-6, tumour necrosis factor-α) 158, 160, 187. Thus, an 
elevated RHR may enhance the magnitude of an unfavourable cardiovascular risk profile by 
amplifying the effects of ongoing inflammatory processes.  
Of additional importance, we derived a composite marker of inflammation from a 
principle component analysis. In doing so, we were able to combine each of the individual 
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markers into a single component, thereby reflecting a general marker of inflammation, 
permitting us to retain most of the information attributed to each marker. From a clinical 
perspective, the inclusion of a multi-marker strategy in this study based on CRP, neutrophils, 
IL-6, fibrinogen and serum amyloid A, was more informative for improving risk estimation, 
compared to single marker determination. Foremost, the clinical utility of individual 
biomarkers towards predicting subsequent cardiovascular events has recently been 
questioned. Indeed, the prognostic reliability of CRP, the most commonly measured 
inflammatory marker in cardiovascular epidemiology has been challenged by other authors 
188-190
. Thus, we postulate that simultaneous assessment of multiple markers of inflammation 
may provide additional prognostic information beyond single marker determination, at least 
among secondary care patients. 
The present study is not without limitations. Patients in the present investigation were 
Caucasian of German ancestry. Thus, caution is warranted in generalising our findings to the 
understanding of CVD in other populations. Though prospective in patient enrollment, RHR 
was only assessed at a single time point, and therefore may not reflect pulse rate over the 
longer term which would allow us to identify sustained tachycardia.  Further, heart rate shows 
significant diurnal variation which presents additional problems for a one-off measure. 
Nevertheless, we would counter that RHR was measured in a sufficiently standardised 
manner to yield reliable data, permitting comparison among patients, while minimizing 
methodological bias as much as possible 
191
. For the purpose of this investigation, resting 
heart rate was dichotomized according to the 75 percentile cut-off value. Thus, subsequent 
studies may wish to include other metrics of heart rate when evaluating its relationship with 
inflammation and adverse cardiovascular outcome. Similarly, the individual markers of 
inflammation were determined at a single time point. We also cannot exclude the possibility 
that other functionally distinct markers of inflammation may be implicated in CVD risks that 
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were not examined here. Although we performed multivariable adjustments, we cannot rule 
out that our results may be influenced by unmeasured or residual confounding. However, due 
to the large sample size and extensive range of measurements taken, we were able to adjust 
for a range of important covariates including arterial hypertension, type 2 diabetes, 
dyslipidaemia and family history of CVD. In this study, the observed association between 
resting heart rate and inflammation with CVD mortality appeared somewhat stronger with 
more severe CAD. However, due to the lack of non-fatal CVD endpoints in LURIC, we were 
unable to explore this relationship further. In light of this, we hope these findings spur future 
investigations to evaluate the putative link between resting heart rate and inflammatory 
activity with non-fatal CVD events.  
 In conclusion, the present data highlight a potential role for RHR as a risk factor for 
CVD mortality by amplifying the effect of inflammation, which may explain, in part, the 
poor cardiovascular prognosis in individuals with an elevated RHR. Should these 
observations be confirmed, slowing the heart rate may prove a useful adjunct in prolonging 
survival among CVD patients that exhibit an elevated inflammatory activity. 
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CHAPTER EIGHT 
 
8.0. DISCUSSION 
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8.1. OVERVIEW 
 
With advancing age, it has become more apparent that older individuals seem bedevilled by a 
number of adverse cardiovascular health conditions which account for considerable disability 
in later life 
5
. Of all these complications, diseases of the coronary arteries are among the most 
common of vascular disorders attributable to poor health in the aged. Moreover, CAD 
accounts for over half of all mortality among individuals beyond 65 years 
2
, and overall CVD 
tends to outrank any other cause of death in persons belonging to this age strata. For this 
reason alone, it seems justified for researchers and clinicians to identify and forestall, as early 
as possible, the multitude of CVD risk factors in an effort to enhance the quality of health 
during later years of life 
5
. 
 
8.2. SUMMARY AND INTEGRATION OF MAIN STUDY FINDINGS 
 
8.2.1. Relation between resting heart rate and cardiovascular morbidity 
Foremost, studies examining the interplay between sustained elevated RHR and 
cardiovascular risk factors beyond Caucasian populations and developed nations are, at 
present, sub-optimal. Notably, several investigations have described ethnic-specific variations 
in the number of cardio-metabolic indices including abdominal adiposity 
192
, phenotypes of 
body fat distributions 
192, 193
, ectopic fat depositions, namely, the accumulation of fat 
surrounding the liver 
194
, as well as biochemical parameters such as hyperinsulinaemia, 
hyperglycaemia, dyslipidaemia, hyperleptinaemia, low levels of adiponectin and higher levels 
of CRP 
195
. In view of these ethnic disparities, it is of prime importance to better understand 
whether the role of RHR as a predictor of CVD health among Caucasian individuals is 
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comparable in other ethnic backgrounds. Collectively, the findings derived from studies one 
to three (chapters two to four) highlight the relevance of RHR and its negative implications 
towards heightened cardio-metabolic risk within a non-western cohort. In the first study 
(chapter two), we explored the independent associations of seated RHR as well as in 
combination with abdominal obesity for the presence of type 2 diabetes among older Chinese 
residents. A novel finding of the first investigation is resting tachycardia independently 
doubled the risk of type 2 diabetes mellitus in older Chinese adults, confirming previous 
results obtained in Caucasian populations 
27, 28
. For instance, in the San Antonio Heart Study 
27
, volunteers defined as hyperdynamic (i.e., RHR and pulse pressure in the upper-most 
quartile of their respective distributions) had an almost four-fold adjusted risk for the 
prediction of future type 2 diabetes. Likewise, Carnethon et al. 
28
 reported a 12 bpm 
increment in RHR was associated with a 10% increase in the odds of having diabetes; albeit, 
this relation attenuated to non-significance following full adjustment. Nonetheless, the same 
study confirmed a raised RHR was a robust predictor (OR 1.21, 95% CI = 1.03-1.41) of death 
due to diabetes in those aged between 35-49 years, even after adjusting for BMI and post-
load glucose at baseline 
28
. To our knowledge, two other studies similarly examined the 
association between RHR and risk of diabetes in Asian-specific cohorts. In the Shanghai 
Women’s Health Study 26, the incidence rates for diabetes were 2.91, 3.31, 3.71, 4.16 and 
5.34 per 1,000 person years according to RHR categories of ≤68, 69-72, 73-76, 77-80 and 
≥80 bpm, respectively. In spite of this, the observed associations reported in the Shanghai 
Women’s Health Study 26 were limited to female participants only, and so those findings may 
not necessarily be replicated in older Chinese men. On the other hand, our investigation is 
indeed one of the first to address the independent effects of seated RHR towards the 
prevalence of type 2 diabetes mellitus in both community-dwelling older Chinese men and 
women. Second, Shigetoh and co-workers 
24
 demonstrated a high RHR predisposed older 
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Japanese subjects to the development of diabetes. We may add, however, due to the low 
incidence of obesity among Japanese individuals 
24
, the findings taken from that study are 
unlikely to be representative of other Asian cohorts.  
 Since the available literature regarding the relation between elevated RHR and the 
MetS were predominantly derived from non-Asian individuals, the purpose of the second 
study (chapter three), therefore, was to investigate the usefulness of a raised RHR as an 
independent marker of the MetS among older Chinese subjects. In this study, a rapid RHR 
was independently associated with the MetS in older Chinese men and women. Specifically, 
those in the highest quartile (≥91 bpm) of this cardiovascular proxy had an almost two-fold 
increased adjusted risk for the MetS. Related to this matter in hand, the resulting data from 
chapter three confirm earlier studies among non-Asian populations that indicated those with 
sustained elevated RHR were at greater risk for cardio-metabolic complications 
41, 43, 44
. In 
one study consisting more than 3,000 Italian individuals, Mancia et al. 
41
 compared the values 
of RHR obtained from healthy controls with those whom were identified as having the MetS. 
In that investigation, participants diagnosed as having the MetS presented with significantly 
greater office, home, and 24-h ambulatory RHR values. Rogowski and colleagues 
43
 also 
reported the OR towards risk of having the MetS according to men and women in the highest 
quintile of RHR (≥80 bpm in men and ≥82 bpm in women) increased considerably by over 
four-fold (95% CI = 3.0-5.9) and three-fold (95% CI = 2.2-6.1), respectively. Moreover, in 
the BARI 2D trial 
44
, regression analyses indicated RHR was amplified in patients with the 
MetS compared to those without (regression coefficient; 2.9, P =0.002). Notably, in the same 
trial, a persistently high RHR was related to an increasing number of components belonging 
to the MetS in patients already at-risk for CVD, suggesting the risk of elevated RHR for 
development of the MetS likely extends beyond those who appear generally healthy 
44
. 
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Although there is little understanding of the specific mechanisms as to how elevated 
RHR detrimentally affects the risk of CVD, some evidence suggests that a perturbed ANS 
function may be responsible for the rise in RHR. More precisely, as with several other 
cardiovascular risk factors such as type 2 diabetes mellitus, abdominal obesity, and 
hypertension, resting tachycardia likely reflects the same common denominator: sympathetic 
overactivity 
31, 123, 174
. Rapid RHR is perhaps a consequence of both enhanced sympathetic 
tone as well as a reduced parasympathetic outflow to the sinus node. To this end, one may 
assume a raised RHR is merely a marker of abnormal ANS activity. Though, conversely, 
RHR may likely possess some independent effects with regards to exacerbating the risk of 
CVD, since at present, the exact patho-physiological mechanisms that lead to impaired ANS 
activity are less clear, and therefore, require further investigation. 
Moving forward, the third study (chapter four) reported in this thesis attempted to 
examine high RHR as an important indicator of adverse cardiovascular health by exploring 
the utility of this simple clinical parameter with an established surrogate measure of arterial 
stiffness, namely PWV. In the same study, we separately examined the relationship of a faster 
RHR in combination with the MetS for risk of CVD as described by increased PWV. After 
correcting for numerous potential confounders, the results of chapter four indicated that 
elevated RHR and the MetS independently amplified the risk of a high PWV. On the 
background of both high RHR and the MetS, the adjusted risk increased almost four-fold. 
Recent epidemiologic evidence supports the notion that higher PWV is independently 
associated with greater risk of CVD mortality, and is dominantly influenced by advancing 
age 
196
. Thus, we may add, the results from the fourth chapter are of particular importance 
considering the significant relation between higher RHR and increased PWV among these 
older Chinese individuals. It is feasible to note that the increase in PWV observed in chapter 
four may have been mediated, in part, by a raised RHR. Indeed, the balance between 
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myocardial oxygen demand and supply is severely compromised under the presence of a high 
RHR due to its impact on shortening the fraction of cardiac cycle occupied by diastole, which 
in turn, lowers coronary blood supply, promoting greater myocardial oxygen consumption 
and oxidative stress 
174, 197
. These functional alterations induce an increased inflammatory 
response by up-regulating various circulating pro-inflammatory cytokines such as IL-6 and 
tumour necrosis factor-alpha. The latter plays a critical role in endothelial dysfunction by 
restricting the bioavailability of nitric oxide which substantially impairs endothelial-
dependent dilation 
198, 199
. This type of behaviour ultimately exposes the endothelium to a 
myriad of adverse risk factors, provoking impaired vascular tone and structural wall 
dysregulation, which may result in an increased PWV 
200
.  
   In light of the findings reported in chapter’s two to four, the data presented in this 
thesis adds to the paucity of literature among non-Caucasian subjects, confirming the strong 
independent contribution of RHR towards vascular anomalies. As developing nations such as 
China continue to increase their rapid rate of modernisation, cardio-metabolic complications 
such as type 2 diabetes mellitus as well as the MetS will likely become more apparent 
113-115
; 
possibly forewarning of a major developing health burden in a rapidly modernizing and 
burgeoning older Chinese population.                
 
8.2.2. Resting heart rate in cardiovascular mortality  
Substantial epidemiological evidence indicates that a faster RHR may well be implicated in 
the progression of cardiovascular-related death 
3, 54, 55, 60, 61, 64, 69, 71
. Yet, in the face of this 
literature, resting tachycardia as a modifiable cardiovascular risk factor continues to be 
overlooked 
111, 112
. Moreover, data based on sex-specific stratification is limited, thus it 
remains unclear whether the threat of CVD mortality according to elevated RHR is similar 
between men and women, or whether the risk differs in magnitude. Of additional importance, 
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the usefulness of RHR in predicting cardiovascular endpoints among patients who are already 
at-risk for this condition is yet to be definitively established since the vast majority of the 
existing literature consists of a general population. In this thesis, study’s four and five 
(chapters five and six) afforded an opportunity to explore these matters in hand. First, in 
chapter five, we sought to ascertain the importance of RHR as a marker of CVD mortality in 
a large cohort of apparently healthy middle-aged British men and women. In this chapter, the 
integral relation between a raised RHR and death due to CVD, according to the overall study 
sample, was fitting with a number of published data in the general population 
61, 70, 71
. Of 
particular note, however, a faster RHR was found to be a critical determinant of all-
cardiovascular death in men, but not in women. That the relationship between a high RHR 
and CVD mortality seems mainly driven by men in chapter five appears consistent with few 
other investigations that have explored this association according to sex-specific stratification 
3, 54, 60, 64
. Though, paradoxically, a handful of studies also demonstrated a high RHR to be an 
independent predictor of CVD mortality in women 
55, 69, 110, 157
. Findings from two separate 
studies reported by Gillum and colleagues 
55, 110
 show dissimilarities between elevated RHR 
and CVD mortality when age, sex, and ethnicity were accounted for. More specifically, the 
relation between high RHR and CVD death seemed particularly striking among black women 
(RR [95% CI] = 3.03 [1.46-6.28]). Further, in the Jerusalem 70-year-old Longitudinal Study, 
Perk et al. 
157
 demonstrated that the risk of CVD death increased in response to a raised RHR 
among older women only. Of particular note, however, is the latter study consisted of a 
relatively small sample size (n = 422, of which n = 193 (45%) women), and only included 
participants aged 70 years upon study entry. Unlike other ethnically homogenous cohorts, this 
study also consisted of participants born in more than 40 different countries 
157
. Collectively, 
the heterogeneous findings ascribed to the Jerusalem 70-year-old Longitudinal Study are 
perhaps due, in part, to the important distinctions observed in cohort size, age of study 
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participants at entry, as well as the large number of differences in places of birth. 
Nevertheless, the findings from these studies taken together with the observations reported in 
chapter five, clearly suggest additional investigations are required to elucidate the complex 
interactions that exist between RHR, age, gender, ethnicity and CVD complications. 
 Second, in chapter six, the usefulness of elevated RHR in predicting death due to 
CVD is described among patients who underwent coronary angiography. In this study, 
patients in the highest quartile (≥84 bpm) had an increased adjusted risk for CVD mortality 
by approximately 40%. Although the results of the sixth chapter may only apply to persons at 
intermediate-to-high cardiovascular risk, they are nonetheless consistent with published 
findings from several epidemiological studies obtained in the general population 
53-55, 69, 70
. 
Beyond this, the current data of chapter six may be of clinical importance because it provides 
specific information on patients undergoing coronary angiography, and who are otherwise of 
significant interest regarding risk assessment and therapeutic interventions; a limitation which 
currently exists in the available literature.  
Moving forward, after correcting for a number of covariates in chapter six, fractional 
polynomial models revealed a J-shaped curve for RHR with CVD mortality. In particular, 
patients with a very low RHR also appeared to be at greater risk for experiencing the study 
endpoint; proposing the observed association between elevated RHR and CVD mortality 
seems non-linear. To this end, these findings may provide additional insight into the relative 
prognostic contributions of RHR as a risk factor of CVD death. Albeit, one limitation was the 
minimal number of patients (n = 98 for RHR <50 bpm) identified as actually having a very 
low RHR, which may have underpowered any subsequent evaluation with respect to the 
relative impact of a very low RHR towards the risk of CVD outcomes. Notwithstanding, we 
hope these findings shown in chapter six will spur forthcoming studies to consider the 
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implications of a very low RHR as a potential hazard, rather than simply dismissing it and 
focussing solely on the detrimental effects of a high RHR.         
 
8.2.3.  Resting heart rate: a potential modifier of inflammatory activity 
Recent evidence indicate both inflammatory activity and sustained tachycardia interact at 
several levels of the cardiovascular continuum 
159
, and may hereby exert a synergistic effect 
reflecting an unfavourable cardiovascular risk profile. Preliminary evidence according to 
baseline characteristics reported in chapters five and six signify the deleterious effects of 
inflammation may be amplified by increasing RHR. Though, clearly, further studies are 
required to test this notion. Subsequently, in an attempt to address this question, the sixth 
study (chapter seven) was undertaken to investigate the inter-relationship between RHR and 
inflammation with CVD death in a large cohort of German patients undergoing coronary 
angiography.  
In line with the demographics shown in chapters five and six, a number of individual 
markers of inflammation including IL-6, CRP, serum amyloid A, neutrophil count and 
fibrinogen, were significantly higher among patients with a raised RHR compared to those 
with a lower RHR. In addition, inflammatory activity was also assessed by combining each of 
the single markers into an overall weighted multi-marker index of inflammation. Foremost, 
the analyses reported in chapter seven underline the robust independent effects of a 
persistently high inflammatory activity as a risk factor for CVD mortality. Second, these 
detrimental effects were substantially amplified on the background of a faster RHR. In fact, 
patients in the upper-most quartile of inflammation who had a RHR ≥75 bpm appeared to 
have more than a seven-fold increased adjusted risk of CVD death.  
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Despite the observed associations in chapter seven, the exact mechanisms by which 
resting tachycardia modulates the effects of inflammation remain to be elucidated; although 
the extant literature provides compelling evidence for several candidate processes. In 
particular, local haemodynamic forces play a critical role in predisposing a number of arterial 
areas to atherosclerotic plaque development 
158, 201-204
. These local forces generally comprise 
of flow-generated shear stress and blood pressure-derived tensile stress 
158
. Conceptually, a 
faster RHR may, in part, amplify the burden of CVD by prolonging the exposure of disturbed 
flow-generated stress imposed on the wall of the artery (Figure 8.1). In light of these 
functional alterations, a high RHR may therefore critically promote the inflammatory process 
by provoking permanent alterations to endothelial cells, as well as inducing direct endothelial 
injury by initiating increased permeability to the endothelial cell wall, perhaps, via up-
regulation of numerous inflammatory components (i.e., adhesion molecules, 
chemoattractants, and cytokines) 
158, 203, 204
. In keeping with this, it would appear feasible to 
propose that an elevated RHR may therefore enhance the magnitude of an unfavourable 
cardiovascular risk profile by amplifying the effects of ongoing inflammatory processes. 
Consequently, we may speculate, that slowing the RHR may prove a useful adjunct for 
interrupting the patho-physiological processes initiated by inflammation within the local pro-
atherosclerotic vascular environment. If this conjecture is correct, then it may be anticipated 
that the protective effects of selective heart rate-lowering agents (i.e., β-blockers, calcium 
antagonists, and the more novel specific heart rate-lowering agent ivabradine) may differ as a 
function of  lower and higher inflammatory activity. 
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Figure 8.1. A conceptual framework of pathogenetic mechanisms influenced by 
resting heart rate in coronary atherosclerosis. Adapted from Giannoglou et al. 
158
 
with permission. 
 
 
 
8.3. LIMITATIONS 
 
There are several limitations that bear mentioning in this thesis. Foremost, given the cross-
sectional nature of the GBCS, we were unable to explore the causal relation between sustained 
elevated RHR and incident CVD risk. To this end, we would counter that our large-scale 
GBCS sample are currently being followed-up at 4 year intervals. Though biologically 
plausible, the continual monitoring of the GBCS participants for morbidity and mortality will 
eventually allow us to confirm whether a raised RHR does in fact amplify the risk of poor 
cardiovascular prognosis in older, community-dwelling Asians. Our GBCS sample is 
representative of approximately 7% of all individuals greater than 50 years of age in 
Guangzhou. Thus, caution is warranted when extrapolating our findings to other individuals 
belonging to this age strata, as our study participants do not resemble all older Chinese citizens 
residing in Guangzhou City. By extension, our sample was randomly selected from GHHARE, 
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thus we cannot rule out the possibility of “healthy volunteer bias”. In spite of these limitations, 
however, our GBCS participants reflect similar levels of adverse chronic conditions observed 
in nationally representative samples of older urban Chinese adults 
26, 133, 134
, which in turn, 
enhance the external validity of the present findings. 
 In the LURIC investigation, inclusion of Caucasian patients only limits the 
generalisability of our results to other ethnic populations who are already intermediate-to-high 
risk for CAD. Although prospective in nature, the measurement of RHR was determined at a 
single momentary time-point in both LURIC and EPIC-Norfolk studies, therefore, it is difficult 
to establish whether elevated RHR is causally related, or simply an epiphenomenon of 
progressive CVD. Nevertheless, we attempted to record RHR in a standardized method, 
thereby yielding reliable data while permitting comparison between patients, as well as 
reducing the risk of methodological bias. Since the frequency of RHR illustrates significant 
diurnal variation and is easily influenced by several other confounders (i.e., psychic stimuli, 
postural position, environmental conditions etc.) one should employ strict standardized criteria 
as a means of evaluating the relationship between RHR and adverse CVD prognosis 
191
. Under 
such conditions, a standardized measurement of RHR would limit the opportunity of 
methodological bias, while enhancing the scientific value of RHR itself, yielding more accurate 
and reliable data, allowing for the comparison of RHR between studies. Lastly, across all 
cohorts, we did however, correct for a large number of potential confounders that are most 
often considered to be associated with increased pulse rate.  
 
8.4. CONCLUSION AND FUTURE DIRECTIONS 
 
For some time, a raised RHR has remained a neglected risk factor of poor health in the clinical 
setting. Despite this, we propose that RHR should no longer be overlooked since our data along 
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with others indicate that sustained elevated RHR is strongly associated with increased 
cardiovascular risk as well as mortality. In the present thesis, an accelerated RHR tended to 
amplify the risk of CVD in generally healthy individuals, as well as among patients already at 
intermediate-to-high-risk for the condition. Though we were unable to determine the relation 
between RHR and mortality in Asian participants, nevertheless, we were able to identify a 
strong association between high RHR and a number of surrogate markers of vascular risk, 
suggesting the burden of increased RHR extends beyond Caucasian subjects. In light of the 
growing literature describing the relation between resting tachycardia and adverse CVD 
prognosis, it comes as no surprise that the European Society of Cardiology and the European 
Society of Hypertension 
164
 along with the Global Registry of Acute Coronary Events score 
165
 
have recently included RHR as a risk factor for unfavourable CVD outcomes. These guidelines 
support the contention for slowing the pulse rate in an effort to attenuate the risk attributable to 
CVD. Indeed, few trials have already demonstrated the potential health benefits afforded by 
effective pharmacological therapy when slowing the RHR 
162, 163
. Albeit, a practical limitation 
is these data are mainly confined to patients already at-risk for CVD. As a departing point for 
this conclusion, I would encourage forthcoming trials to consider the potential pharmacological 
implications of manipulating pulse rate among non-cardiac patients as well. Should a beneficial 
effect be confirmed, reducing the pulse rate pharmacologically may constitute a major public 
health benefit in one of the largest areas of human disease. 
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